{"numRecords":"517","DataElementQueryResults":[{"publicId":"3652739","version":"2","preferredName":"Cancer Diagnosis Status","preferredDefinition":"A response to signify whether the cancer is new or a recurrence.","longName":"2013917v1.0:3652737v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"BA719C1D-AAD0-472A-E053-4EBD850A227D","latestVersionIndicator":"Yes","beginDate":"2021-02-03","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-02-03","modifiedBy":"KNABLEJ","dateModified":"2021-02-24","changeNote":"2/24/21 jk upd RS/WS per SME emails.  2/3/21 jk CDE txfr to CPTAC, moved UAMS Def/Question to alternates and make CPTAC question/def primary.  created for UAMS cmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6597549","version":"1","preferredName":"Distant Metastasis Clinical M Category Anatomic Site","preferredDefinition":"The named distal location(s) within the body where malignant cells have migrated associated with the M staging category criteria.","longName":"DIS_MET_CLIN_M_ANAT_SITE","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D8A873E-6AA3-3183-E053-F662850A946B","latestVersionIndicator":"Yes","beginDate":"2018-12-21","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-12-21","modifiedBy":"KNABLEJ","dateModified":"2019-07-31","changeNote":"2/4/19 jk released for quarterly review.  12/21/18 jk created for CPTAC new tumor baseline forms and Theradex.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6607654","version":"1","preferredName":"Occupational Or Chemical Exposure History CPTAC Indicator","preferredDefinition":"A response to indicate the individual's history of exposure to chemicals and/or occupational hazards individual's history of exposure to chemicals and/or occupational hazards.","longName":"6607798v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F0A1021-CE73-3AA1-E053-F662850A8A67","latestVersionIndicator":"Yes","beginDate":"2019-01-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-09","modifiedBy":"GDEEN","dateModified":"2023-11-14","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  8-14-19 edits per CPTAC NCIt terminology updates/tt.  2/4/19 jk updated to incllude PV of unknown.  1/9/19 ls created for CPTAC Med History form.","administrativeNotes":"8/3/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6607655","version":"1","preferredName":"Occupational Or Chemical Exposure History Other Specify","preferredDefinition":"The type of chemicals and/or occupational hazards other than the one(s) previously specified that an individual has been subjected.","longName":"6607798v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F0A39B2-5103-3CCA-E053-F662850AE8F4","latestVersionIndicator":"Yes","beginDate":"2019-01-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-09","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  11/7/19 jk Revised to reuse DEC 6607798 from companion CDEs.  8/14/19 edits per CPTAC NCIt terminology updates/tt. 2/4/19 jk released.  1/9/19 ls created for CPTAC Med History form.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6607872","version":"1","preferredName":"Occupational Or Chemical Exposure History CPTAC Codelist Type","preferredDefinition":"A directive to select all the relevant chemical and occupational hazardous exposures using Clinical Proteomic Tumor Analysis Consortium (CPTAC) terminology.","longName":"6607798v1.0:6607804v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F1D6CF4-BA03-2E63-E053-F662850A5BE1","latestVersionIndicator":"Yes","beginDate":"2019-01-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-10","modifiedBy":"KNABLEJ","dateModified":"2019-11-22","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  11/7/19 jk removed slash in LN.  8-14-19 edits per CPTAC NCIt terminology updates/tt. 2/4/19 jk revised for updated VD; released.  1/9/19 ls created for CPTAC Med History form.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6660900","version":"1","preferredName":"Cause of Death Reason CPTAC Name","preferredDefinition":"The circumstance or condition of greatest rank or importance that results in the death of a living being using the CPTAC permissible value set.","longName":"COD_RSN_CPTAC_NM","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8300C4ED-1892-1F03-E053-F662850A34EE","latestVersionIndicator":"Yes","beginDate":"2019-02-28","endDate":null,"createdBy":"TSESU","dateCreated":"2019-02-28","modifiedBy":"KNABLEJ","dateModified":"2021-05-19","changeNote":"5/19/21 Consider but detr new CDE (7658145) needed for Phase 3.  2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 11/23/19 jk added F/U CSI.  3/1/19 created for use by CPTAC based on COD Standard CDEs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6770749","version":"1","preferredName":"CPTAC Case Occurrence Identifier","preferredDefinition":"A character identifier assigned to a case within the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC), a national effort to understand the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.","longName":"CPTAC_CASE_ID","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"89FB24E8-898F-5263-E053-F662850AF9C6","latestVersionIndicator":"Yes","beginDate":"2019-05-28","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-05-28","modifiedBy":"COLBERTM","dateModified":"2022-09-09","changeNote":"4/15/21 jk Added CM, HNSCC, and SAR CSIs.  2020-9-8 AQT/CS/CSI added.  AK 8/27/20 jk 7/23/20 jk added Procurement CSI.  7/23/20 jk added CPTAC BLCA Pathology CSIs.  6/14/20 jk added CPTAC CESC Pathology CSIs.  6/14/20 jk added CPTAC ESCA Pathology CSIs. 4/30/20 jk added CPTAC LGG Path CSI.  4/2/20 jk added CPTAC THCA CSIs. 11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  6/11/19 jk added CSIs for 11 CPTAC Baseline CRFs.  5/28/19 jk created for CPTAC Medical History CRF","administrativeNotes":"9/9/22 Added HNSCC Local Path CSI. mr;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6770750","version":"1","preferredName":"Tumor Topology CPTAC Anatomic Site","preferredDefinition":"The named region or anatomic location of a benign or malignant tissue growth within the body.","longName":"TMR_TOPO_CPTAC_ANAT_SITE","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"89FB40B8-F761-5EE5-E053-F662850A0232","latestVersionIndicator":"Yes","beginDate":"2019-05-28","endDate":"2020-04-06","createdBy":"KNABLEJ","dateCreated":"2019-05-28","modifiedBy":"KNABLEJ","dateModified":"2022-03-31","changeNote":"3/31/22 jk chg \"Latest Version: indicator to Yes in admin.  4/15/21 jk Added CM, HNSCC, and SAR FU, BSLN CSI.  9/28/20 jk added Procurement CSIs. 2020-9-8 ak CS/CSI added.  4/20/20 jk restored prior version of CDE; per SME \"Uterus/Endometrium\" will not be split into separate values.  4/6/20 jk CDE versioned for splitting \"Uterus/Endometrium\" response into separate response values. 11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  6/11/19 jk added CSIs for 11 CPTAC Baseline CRFs.  5/28/19 jk created for CPTAC Medical History CRF","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6780670","version":"1","preferredName":"Personal Medical History Condition CPTAC Codelist Name","preferredDefinition":"Text term(s) used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on illness or circumstance which requires medical monitoring.","longName":"6780642v1.0:6780651v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B24CA40-2926-15C0-E053-F662850A5ED3","latestVersionIndicator":"Yes","beginDate":"2019-06-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-12","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  11/8/19 jk upd 17 VM Defs; added 29 PVs; chg to Application status.  6-12-19 CPTAC Medical History CRF; tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6784461","version":"1","preferredName":"Current Medication Vitamin Dietary Supplement Text","preferredDefinition":"A textual description of the current medication(s) an individual is taking.","longName":"6783961v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BA05622-5474-2E86-E053-F662850A8D72","latestVersionIndicator":"Yes","beginDate":"2019-06-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-18","modifiedBy":"COLBERTM","dateModified":"2022-07-11","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  6-18-19 tt created for CPTAC Medical History CRF.","administrativeNotes":"7/11/22 Updated def for consistency per spreadsheet from JK.  MR","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6785122","version":"1","preferredName":"Personal Medical History of Treatment CPTAC Indicator","preferredDefinition":"A response to indicate whether there is a known history of treatments.","longName":"6783932v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BA08D27-3A28-7022-E053-F662850AC777","latestVersionIndicator":"Yes","beginDate":"2019-06-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-18","modifiedBy":"JKNABLE","dateModified":"2022-08-03","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  6-18-19 tt created for CPTAC Medical History CRF.","administrativeNotes":"8/3/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6785125","version":"1","preferredName":"Personal Medical History of Cancer CPTAC Indicator","preferredDefinition":"A response to indicate whether a history of cancer exists.","longName":"6783939v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BA0E324-1084-799C-E053-F662850A6F41","latestVersionIndicator":"Yes","beginDate":"2019-06-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-18","modifiedBy":"JKNABLE","dateModified":"2022-08-03","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  6-18-19 tt created for CPTAC Medical History CRF.","administrativeNotes":"8/3/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6785207","version":"1","preferredName":"Individual Medical Record Documentation About This History of Cancer Treatment CPTAC Indicator","preferredDefinition":"A response to indicate whether there is documentation in the patient's medical record regarding this cancer and therapy.","longName":"6783956v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BACAEBE-53EF-3F06-E053-F662850A3ACA","latestVersionIndicator":"Yes","beginDate":"2019-06-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-19","modifiedBy":"JKNABLE","dateModified":"2022-07-08","changeNote":"11/10/19 jk Relased per CPTAC SME (Linda) for Medical History CRF.  6-19-19 tt created for CPTAC Medical History CRF.","administrativeNotes":"7/8/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6785213","version":"1","preferredName":"Personal Medical History Source","preferredDefinition":"The source providing the medical history.","longName":"6783936v1.0:6785209v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BAD2E01-6F41-3765-E053-F662850AFAD5","latestVersionIndicator":"Yes","beginDate":"2019-06-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-19","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  6-19-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6785267","version":"1","preferredName":"Individual Cancer History Malignant Neoplasm CPTAC Codelist Name","preferredDefinition":"The patient's medical background regarding the occurrence of cancer and cancer-related problems, using Clinical Proteomic Tumor Analysis Consortium (CPTAC) terminology.","longName":"6783941v1.0:6785216v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BAD2E01-6F6F-3765-E053-F662850AFAD5","latestVersionIndicator":"Yes","beginDate":"2019-06-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-19","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  6-19-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6785286","version":"1","preferredName":"Alcohol Use History Consumption Category","preferredDefinition":"The description of an individual's current and past experience with alcoholic beverage consumption","longName":"6783971v1.0:6785277v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BAD2E01-6FA2-3765-E053-F662850AFAD5","latestVersionIndicator":"Yes","beginDate":"2019-06-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-19","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  6-19-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6787381","version":"1","preferredName":"Individual Cancer History of Any Treatments Type","preferredDefinition":"The history of any known treatments for an individual.","longName":"6788213v1.0:5102331v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BAEE0EC-A8D4-3FAD-E053-F662850AEDC8","latestVersionIndicator":"Yes","beginDate":"2019-06-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-19","modifiedBy":"COLBERTM","dateModified":"2024-01-23","changeNote":"New version created. 11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  6-18-19 tt created for CPTAC Medical History CRF.","administrativeNotes":"1/23/24 Retired v2.0 and restored v1.0 to Latest Version bc this was initially versioned in error. We want v1.0 to be Latest Version. mr; \r\n10/17/23 Versioned this CDE bc VD 5102331 was versioned in order to delete PVs CRDC did not need. mr","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6787413","version":"1","preferredName":"Smoking History Tobacco Category","preferredDefinition":"A category which describes an individual's history of smoking tobacco.","longName":"6783977v1.0:6787391v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BB0DB4E-91CB-6FBE-E053-F662850AC5D9","latestVersionIndicator":"Yes","beginDate":"2019-06-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-19","modifiedBy":"COLBERTM","dateModified":"2023-09-21","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  11/7/19 jk modified definition.  6-19-19 tt created for CPTAC Medical History CRF.","administrativeNotes":"9/21/23 Added CCDI alts, CSI. Added 'Unknown' PV and alt VM names for PVs per JK. mr","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6788118","version":"1","preferredName":"New Tumor Event Other Site Specify","preferredDefinition":"A textual description to specify the site of the other new tumor event.","longName":"6848808v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8BC23F43-FCBA-3B29-E053-F662850A8836","latestVersionIndicator":"Yes","beginDate":"2019-06-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-20","modifiedBy":"KNABLEJ","dateModified":"2021-04-26","changeNote":"4/26/21 jk added HNSCC FU CSI.  2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 8-14-19 tt created for CPTAC F/U CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6834782","version":"1","preferredName":"Tumor Mass Bladder Anatomic Site","preferredDefinition":"The named locations of a benign or malignant pathologic structure in the bladder.","longName":"6796604v1.0:6832456v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8ED570E5-0041-2971-E053-F662850A9D28","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-07-29","modifiedBy":"KNABLEJ","dateModified":"2020-07-31","changeNote":"7/31/20 jk Released per SME (NGM) review and approval email. 7/29/19 jk created for CPTAC BLCA baseline, local and path report CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6841633","version":"1","preferredName":"Personal Medical History Height at Time of Procedure Float","preferredDefinition":"The height of an individual at the time of a procedure.","longName":"6783921v1.0:6841619v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFDAC1B-C090-1881-E053-F662850A6C75","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  7-31-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6841637","version":"1","preferredName":"Personal Medical History Weight at Time of Procedure Float","preferredDefinition":"The weight of an individual at the time of a procedure.","longName":"6783925v1.0:6841619v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFDE4DB-8BDB-0E3D-E053-F662850A134F","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  7-31-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6841640","version":"1","preferredName":"Personal Medical History Height at Time of Procedure Unit of Measure","preferredDefinition":"The unit of measure for the height of an individual at the time of a procedure.","longName":"6783921v1.0:6841639v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFE182A-D586-1719-E053-F662850A8EBE","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF  11-6-19 jk added CPTAC AQT.  7-31-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6841641","version":"1","preferredName":"Personal Medical History Weight at Time of Procedure Unit of Measure","preferredDefinition":"The unit of measure for the weight of an individual at the time of a procedure.","longName":"6783925v1.0:6851664v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFE2918-28C1-0E67-E053-F662850AB823","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  7-31-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6841644","version":"1","preferredName":"Personal Medical History Body Mass Index Finding Float","preferredDefinition":"The result of a body mass index measurement.","longName":"6783928v1.0:6841628v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFE817D-EF3D-1339-E053-F662850A9981","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF  7-31-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6841672","version":"1","preferredName":"Personal Medical History Condition Year of Onset Date","preferredDefinition":"The year when the illness or circumstance which required medical monitoring began.","longName":"6783197v1.0:6841661v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFF070F-F3ED-710D-E053-F662850AE4A2","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  7-31-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6841806","version":"1","preferredName":"Individual Cancer History Month Year Diagnosis Date","preferredDefinition":"The month/year of the diagnosis regarding cancer occurrence.","longName":"6783945v1.0:6841668v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0D81A5-FAE0-1AEB-E053-F662850AE091","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-01","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  8-1-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6841827","version":"1","preferredName":"Individual Cancer History Last Therapy Date","preferredDefinition":"The month/year of the last radiation treatment, chemotherapy, molecular targeted therapy, or immunotherapy treatment.","longName":"6783952v1.0:6841668v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F102D35-D3CB-36DF-E053-F662850AC760","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-01","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  8-1-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6841848","version":"1","preferredName":"Alcohol Use History Number of Years When Consumed More than 2 Drinks per Day for Men and More than 1 Drink per Day for Women Count","preferredDefinition":"The number of years an individual has consumed more than 2 drinks per day for men and more than 1 drink per day for women.","longName":"6783975v1.0:6841843v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F108017-2ED2-3B59-E053-F662850A2236","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-01","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  8-1-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6841850","version":"1","preferredName":"Smoking History How Old When First Smoked a Cigarette Age Value","preferredDefinition":"The age of an individual in years when they first smoked a cigarette.","longName":"6783979v1.0:2488598v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F10DD0F-AD91-1FF8-E053-F662850AA7EA","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-01","modifiedBy":"KNABLEJ","dateModified":"2019-11-22","changeNote":"11/22/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  8-1-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6841852","version":"1","preferredName":"Smoking History Age Which Participant Stopped Smoking Value","preferredDefinition":"The age of an individual in years when they stopped smoking.","longName":"6783983v1.0:2488598v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F1119DC-37FE-73A7-E053-F662850A70BE","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-01","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  8-1-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6841862","version":"1","preferredName":"Smoking History When Participant Smoked How Many Cigarettes Count","preferredDefinition":"The number of cigarettes an individual smoked on the days when he/she smoked.","longName":"6783987v1.0:6272433v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F11F6B1-73A5-3F4C-E053-F662850A97D9","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-01","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  11/7/19 jk corrected LN capitalization.  8-1-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6841869","version":"1","preferredName":"Smoking History Number of Pack Years Smoked Float","preferredDefinition":"The amount of smoking exposure an individual has had over time, which is calculated by multiplying the number of cigarettes smoked per day by the number of years smoked, and dividing the product by the number of cigarettes in a pack.","longName":"6784048v1.0:6841628v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F121B58-8D9B-12A8-E053-F662850AA156","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-01","modifiedBy":"JKNABLE","dateModified":"2024-01-15","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  8-1-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6841888","version":"1","preferredName":"Smoking History Secondhand Smoke Exposure Indicator","preferredDefinition":"The indicator response as to whether an individual has been exposed to secondhand tobacco smoke.","longName":"6784056v1.0:6841878v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F12D7E7-8D04-39A2-E053-F662850A866A","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-01","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  8-1-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6845137","version":"1","preferredName":"Current Medication Last Administration Date","preferredDefinition":"The date of the last administration of the substance of interest.","longName":"6783965v1.0:2018550v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F220DC7-B483-557E-E053-F662850AF1F2","latestVersionIndicator":"Yes","beginDate":"2019-08-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-02","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF8-2-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6845569","version":"1","preferredName":"Clinical Metastatic Diagnosis If cM1 Anatomic Site","preferredDefinition":"The named locations within the body if metastasis is categorized as cM1.","longName":"MET_DIAG_IF_cM1_ANAT_SITE","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8F28849C-812B-0CF1-E053-F662850A0ADE","latestVersionIndicator":"Yes","beginDate":"2019-08-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-08-02","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"1/2/20 jk Released per CPTAC SME (Linda) for STAD Baseline CRF.  8/2/19 jk created for CPTAC baseline CRFs for CESC, CHOL, ESCA, LIHC, STAD, THCA, UVM.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6847155","version":"1","preferredName":"Clinical Metastatic Diagnosis Distant Metastasis Anatomic Site","preferredDefinition":"The named location within the body where the presence of distant metastasis (cM) is documented.","longName":"MET_DIAG_IF_DIS_MET_ANAT_SITE","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8F748CCE-424F-1D87-E053-F662850A234F","latestVersionIndicator":"Yes","beginDate":"2019-08-06","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-08-06","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"1/2/20 jk Released per CPTAC SME (Linda). 8/6/19 jk created for PRAD baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6848011","version":"1","preferredName":"Surgical Procedure Performed Text","preferredDefinition":"A textual description of the diagnostic or treatment procedure performed by manual and/or instrumental means.","longName":"2014218v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8F896E1D-9A02-4E80-E053-F662850A4AC3","latestVersionIndicator":"Yes","beginDate":"2019-08-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-07","modifiedBy":"COLBERTM","dateModified":"2022-07-11","changeNote":"1/21/21 jk  Upd Reg Status.12/15/20 jk Released per SME (NGM) review and approval.  10/30/20 jk added Normal Tissue CSI. 8/27/20 jk added CPTAC solid tumor procurement CSI.  8/11/20 jk CDE per Mathangi, moved from deprecated surgery anesthesia form to tumor procurement form.  8-7-19 tt created for CPTAC Surg/Anesthesia CRF.","administrativeNotes":"7/11/22 Update def for consistency per spreadsheet from JK.  MR","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6848402","version":"1","preferredName":"Tumor Mass Cervical Anatomic Site","preferredDefinition":"The named locations of a benign or malignant pathologic structure that affects the cervix.","longName":"TMR_CESC_ANAT_SITE","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8F8C684C-AC9C-0472-E053-F662850A86E7","latestVersionIndicator":"Yes","beginDate":"2019-08-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-08-07","modifiedBy":"KNABLEJ","dateModified":"2020-07-28","changeNote":"7/28/20 jk Released per SME (NGM) review and approval email.  7/29/19 jk created for CPTAC CESC baseline, local and path report CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6848403","version":"1","preferredName":"Tumor Mass Cholangiocarcinoma Anatomic Site","preferredDefinition":"The named locations of a benign or malignant pathologic structure in the intrahepatic biliary tree (intrahepatic cholangiocarcinoma) or from the junction, or adjacent to the junction, of the right and left hepatic ducts (hilar cholangiocarcinoma).","longName":"TMR_CHOL_ANAT_SITE","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8F88FC77-FC97-4E7C-E053-F662850A25A5","latestVersionIndicator":"Yes","beginDate":"2019-08-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-08-07","modifiedBy":"COLBERTM","dateModified":"2022-09-19","changeNote":"7/29/19 jk created for CPTAC CHOL baseline, local and path report CRFs.","administrativeNotes":"9/19/22 Released/Qualified per jk for CPTAC CHOL baseline. mr;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6848404","version":"1","preferredName":"Tumor Mass Esophageal Anatomic Site","preferredDefinition":"The named locations of a benign or malignant pathologic structure involving the esophagus.","longName":"TMR_ESCA_ANAT_SITE","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8F8BE35C-34C6-1F4A-E053-F662850A77E8","latestVersionIndicator":"Yes","beginDate":"2019-08-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-08-07","modifiedBy":"KNABLEJ","dateModified":"2020-06-22","changeNote":"6/22/20 jk Released per SME (NGM) review and approval email. 7/29/19 jk created for CPTAC ESCA baseline, local and path report CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6848405","version":"1","preferredName":"Tumor Mass Prostate Anatomic Site","preferredDefinition":"The named locations of a benign or malignant pathologic structure that affects the prostate gland.","longName":"TMR_PRAD_ANAT_SITE","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8F8D312F-04CF-047A-E053-F662850AEBE7","latestVersionIndicator":"Yes","beginDate":"2019-08-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-08-07","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"2/13/20 jk RS chg to Qualified.   1/2/20 jk Released per CPTAC SME (Linda) for PRAD Baseline CRF.  8/7/19 jk created for CPTAC PRAD baseline, local and path report CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6848406","version":"1","preferredName":"Tumor Mass Stomach Anatomic Site","preferredDefinition":"The named locations of a benign or malignant pathologic structure involving the stomach.","longName":"TMR_STAD_ANAT_SITE","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8F88FC77-FCD1-4E7C-E053-F662850A25A5","latestVersionIndicator":"Yes","beginDate":"2019-08-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-08-07","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"1/2/20 jk Released per CPTAC SME (Linda).  11/26/19 jk correct PQT Cap to match CRFs.  8/7/19 jk created for CPTAC STAD baseline, local and path report CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6848407","version":"1","preferredName":"Tumor Mass Thyroid Anatomic Site","preferredDefinition":"The named locations of a benign or malignant pathologic structure affecting the thyroid gland.","longName":"TMR_THCA_ANAT_SITE","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F8980C8-C6E4-4E5E-E053-F662850A61C5","latestVersionIndicator":"Yes","beginDate":"2019-08-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-08-07","modifiedBy":"KNABLEJ","dateModified":"2020-04-27","changeNote":"4/27/20 jk Released per 4/8/20 SME review and post VD update.  8/7/19 jk created for CPTAC THCA baseline, local and path report CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6848409","version":"1","preferredName":"Tumor Mass Uveal Anatomic Site","preferredDefinition":"The named locations of a benign or malignant pathologic structure that affects the uvea.","longName":"TMR_UVM_ANAT_SITE","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8F8E1B74-6F79-046A-E053-F662850A1B17","latestVersionIndicator":"Yes","beginDate":"2019-08-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-08-07","modifiedBy":"KNABLEJ","dateModified":"2020-05-28","changeNote":"5/28/20 jk Re-release post db reload; released 5/20/20 per SME (LH) review and approval email.  8/7/19 jk created for CPTAC UVM baseline, local and path report CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6848410","version":"1","preferredName":"Tumor Mass Site Other Specify","preferredDefinition":"A textual description for a malignant pathologic structure which is different than the ones previously specified or mentioned.","longName":"6796604v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8F8C684C-ACD9-0472-E053-F662850A86E7","latestVersionIndicator":"Yes","beginDate":"2019-08-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-08-07","modifiedBy":"COLBERTM","dateModified":"2022-09-09","changeNote":"8/17/21 jk added Phase 3 CM Path Review CSI.  7/8/21 jk added HNSCC Path Rpt CSI.  5/14/20 jk added CPTAC GBM Baseline CSI.  4/8/20 jk added CPTAC THCA CSI. 1/2/20 jk Released per CPTAC SME (Linda) for STAD Baseline CRF.  8/7/19 jk created for CPTAC GBM, LGG, STAD baseline CRFs. 5/6/21 ls classified HBSCC and CM BSL.","administrativeNotes":"9/9/22 Added HNSCC Local Path CSI. mr;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6848540","version":"1","preferredName":"Tumor Mass Findings Laterality Category","preferredDefinition":"A qualifier that describes the position or side of the body the tumor findings assessment is performed.","longName":"TMR_FND_LAT_CAT","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8F9BED8F-6F74-5A18-E053-F662850AC6D3","latestVersionIndicator":"Yes","beginDate":"2019-08-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-08-08","modifiedBy":"JKNABLE","dateModified":"2023-07-26","changeNote":"5/10/21 jk Added Phase 3 HNSCC, SAR CSI. 7/22/20 jk removed from BLCA Baseline CSI; not on CRF.  5/14/20 jk added CPTAC GBM Baseline CSI.  5/13/20 jk replaces concatenated def.  1/2/20 jk Released per CPTAC SME (Linda) for PRAD Baseline CRF.  8/8/19 jk created for CPTAC BLCA baseline, local and path report CRFs. 4/19/21 -ls added HNSCC BSN head and Neck","administrativeNotes":"7/21/23 Added alt def. BF;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6848851","version":"1","preferredName":"Follow-Up Individual Lost to Follow-Up Indicator","preferredDefinition":"A response to indicate whether or not the individual was lost to follow-up.","longName":"6848732v1.0:3506068v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8FEF8392-B644-76D3-E053-F662850A126D","latestVersionIndicator":"Yes","beginDate":"2019-08-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-12","modifiedBy":"KNABLEJ","dateModified":"2021-04-15","changeNote":"4/15/21 jk Added CM, HNSCC, and SAR FU CSI. 2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified .12/9/19 jk reviewed and updated to Application status.  11/23/19 jk removed information from LN per concept synonym.   8-12-19 tt created for F/U CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6848852","version":"1","preferredName":"Follow-Up Last Contact Date","preferredDefinition":"The date of the last contact.","longName":"6848742v1.0:2018550v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8FEF156D-E35D-63CC-E053-F662850A2639","latestVersionIndicator":"Yes","beginDate":"2019-08-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-12","modifiedBy":"KNABLEJ","dateModified":"2021-07-29","changeNote":"7/29/21 jk Added CM FU CSI. 4/15/21 jk Added HNSCC FU CSI.  jk 12/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified ;11/23/19 jk revised LN to use concept synonyms.  8-12-19 tt created for F/U CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6848853","version":"1","preferredName":"Follow-Up Death Date","preferredDefinition":"The calendar date of subject's death.","longName":"6848761v1.0:2018550v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8FEF156D-E38B-63CC-E053-F662850A2639","latestVersionIndicator":"Yes","beginDate":"2019-08-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-12","modifiedBy":"KNABLEJ","dateModified":"2021-04-15","changeNote":"4/15/21 jk Added CM, HNSCC, and SAR FU CSI.  2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 11/23/19 jk revised LN to use concept synonyms.  8-12-19 tt created for F/U CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6848854","version":"1","preferredName":"Treatment Regimen Start Date","preferredDefinition":"The date when the treatment plan began, recorded as MM/DD/YYYY.","longName":"6848769v1.0:2018550v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8FEF8392-B672-76D3-E053-F662850A126D","latestVersionIndicator":"Yes","beginDate":"2019-08-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-12","modifiedBy":"SOKKERL","dateModified":"2020-02-13","changeNote":"2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 8-12-19 tt created for F/U CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6849030","version":"1","preferredName":"Treatment Regimen End Date","preferredDefinition":"The date when the treatment plan stopped, recorded as MM/DD/YYYY.","longName":"6848772v1.0:2018550v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FEF78AA-C306-56F3-E053-F662850ADC85","latestVersionIndicator":"Yes","beginDate":"2019-08-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-12","modifiedBy":"KNABLEJ","dateModified":"2020-01-10","changeNote":"1/10/20 jk Released for reuse by Theradex.  8-12-19 tt created for F/U CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6849032","version":"1","preferredName":"Treatment Regimen Comment Text","preferredDefinition":"A textual field for comments regarding the treatment plan.","longName":"6848774v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8FEF78AA-C334-56F3-E053-F662850ADC85","latestVersionIndicator":"Yes","beginDate":"2019-08-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-12","modifiedBy":"SOKKERL","dateModified":"2020-02-13","changeNote":"2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified.. 8-12-19 tt created for F/U CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6849041","version":"1","preferredName":"Follow-Up Period Duration","preferredDefinition":"The period of time during which the follow-up information was obtained.","longName":"6848728v1.0:6849035v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8FEF8ABE-E713-63E5-E053-F662850A6678","latestVersionIndicator":"Yes","beginDate":"2019-08-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-12","modifiedBy":"KNABLEJ","dateModified":"2021-04-15","changeNote":"4/15/21 jk Added CM, HNSCC, and SAR FU CSI. 2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified 12/9/19 jk updated semantics per follow up CRF.  11/23/19 jk removed information from LN per concept synonym.   8-12-19 tt created for F/U CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7036018","version":"1","preferredName":"Standard Or Guideline Edition Other Specify","preferredDefinition":"A textual description that describe the edition of a published document, established by consensus and approved by a recognized body, that is other than those listed.","longName":"6689548v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"MCL:Molecular and Cellular Characterization of Screened Lesions","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9637CC4E-A69A-7C2C-E053-F662850A45A0","latestVersionIndicator":"Yes","beginDate":"2019-10-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-10-31","modifiedBy":"SOKKERL","dateModified":"2021-05-11","changeNote":"5/10/21 jk added Phase 3 CSIs.  1/2/20 jk Released per CPTAC SME (Linda) for PRAD Baseline CRF.  10/31/19 jk released for reuse by CPTAC; associated CPTAC Baseline CRF CSIs.  4/10/19 jk Created for PCA-all organs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7044574","version":"1","preferredName":"Personal Medical History CDR Entry Completed By Date","preferredDefinition":"The date on which the data from a form is transcribed into the Comprehensive Data Resource (CDR).","longName":"7044573v1.0:2018550v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"96B3551B-DFB8-3B2B-E053-F662850A0442","latestVersionIndicator":"Yes","beginDate":"2019-11-06","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-06","modifiedBy":"KNABLEJ","dateModified":"2019-11-10","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  11/6/19 jk created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7044583","version":"1","preferredName":"Personal Medical History CDR Entry Completed By Text","preferredDefinition":"A textual description of the signature of the person who transcribed the data from a form into the Comprehensive Data Resource (CDR).","longName":"7044573v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"96B3C6B4-37DC-2F6E-E053-F662850A017F","latestVersionIndicator":"Yes","beginDate":"2019-11-06","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-06","modifiedBy":"COLBERTM","dateModified":"2022-07-11","changeNote":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  11/6/19 jk created for CPTAC Medical History CRF.","administrativeNotes":"7/11/22 Updated def for consistency per spreadsheet from JK.  MR","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7054994","version":"1","preferredName":"Tumor Mass Prostate Histologic Type","preferredDefinition":"The classification of benign, borderline, or malignant neoplasm that affects the prostate gland based on the type of tissue in which a tumor originated.","longName":"6796606v1.0:7055167v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9741BB2C-AD5E-50EA-E053-F662850AF536","latestVersionIndicator":"Yes","beginDate":"2019-11-13","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-13","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"2/13/20 jk RS chg to Qualified.   1/2/20 jk Released per CPTAC SME (Linda) for PRAD Baseline CRF. 11/13/19 jk created for CPTAC PRAD baseline CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7055001","version":"1","preferredName":"Tumor Mass Greatest Measured Dimension Measurement","preferredDefinition":"Numeric value in centimeters to represent the greatest measured dimension of a tumor.","longName":"7054962v1.0:7054992v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97412929-5143-3C34-E053-F662850AD199","latestVersionIndicator":"Yes","beginDate":"2019-11-13","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-13","modifiedBy":"SOKKERL","dateModified":"2021-05-11","changeNote":"5/14/20 jk added CPTAC GBM Baseline CSI. 1/2/20 jk Released per CPTAC SME (Linda) for PRAD Baseline CRF.  11/13/19 jk created for CPTAC baseline CRFs. 4/19/21 classified HNSCC  BSLN 4/20/21 ls classified CM and SAR BSLN 4/22/21ls cm bsln","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7055178","version":"1","preferredName":"Gastric Neoplasm Histologic Type WHO Classification of Tumors Category","preferredDefinition":"The classification of benign and malignant stomach tumors by World Health Organization (WHO) experts based primarily on histologic findings.","longName":"7055177v1.0:7055169v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97455D76-BE54-6363-E053-F662850A3B57","latestVersionIndicator":"Yes","beginDate":"2019-11-13","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-13","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"1/9/20 jk added CSI for STAD Path Rev and Local CRFs.   1/2/20 jk Released per CPTAC SME (Linda). 12/3/19 jk req \"Adenocarcinoma, NOS\" be added as syn for recommended PV term C4004. 11/13/19 jk created for CPTAC STAD baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7055179","version":"1","preferredName":"Gastric Neoplasm Histologic Type Lauren Classification Category","preferredDefinition":"The classification of benign and malignant stomach tumors based on the Lauren Classification system.","longName":"7055177v1.0:7055171v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97451AE9-F9B5-17B4-E053-F662850AB615","latestVersionIndicator":"Yes","beginDate":"2019-11-13","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-13","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"1/9/20 jk added CSI for STAD Path Rev and Local CRFs.   1/2/20 jk Released per CPTAC SME (Linda). 11/13/19 jk created for CPTAC STAD baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7058656","version":"1","preferredName":"Tumor Mass Focality Type","preferredDefinition":"The pathologic structure characterization of accumulated neoplastic cells based on the location.","longName":"7054966v1.0:7054981v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97508BFC-FE85-1187-E053-F662850A9536","latestVersionIndicator":"Yes","beginDate":"2019-11-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-14","modifiedBy":"SOKKERL","dateModified":"2021-05-11","changeNote":"1/2/20 jk Released per CPTAC SME (Linda) for STAD Baseline CRF.  11/13/19 jk created for CPTAC THCA and STAD baseline CRFs. 4/19/21 ls classified under HNSCC BSN. 4/20/21ls classified SARbsln 4/22/21","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7058662","version":"1","preferredName":"Tumor Mass Histologic Type Other Specify","preferredDefinition":"A textual description of the neoplasm classification based on the tissue of origin which is different than the tissue types previously specified or mentioned.","longName":"6796606v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97451AE9-FA86-17B4-E053-F662850AB615","latestVersionIndicator":"Yes","beginDate":"2019-11-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-14","modifiedBy":"COLBERTM","dateModified":"2022-09-11","changeNote":"7/12/21 jk added HNSCC Path Rpt CSI. 5/10/21 jk added Phase 3 CSIs.  7/23/20 jk added BLCA Path CSIs.   6/14/20 jk added CPTAC CESC Pathology CSIs.  6/14/20 jk added CPTAC ESCA Pathology CSI. 5/14/20 jk added CPTAC GBM Baseline CSI. 4/30/20 jk added CPTAC LGG Path CSI.  4/2/20 jk added CPTAC THCA CSIs.  1/29/20 jk added CSI for LIHC Path Rev and Local CRFs.  1/9/20 jk added CSI for STAD Path Rev and Local CRFs. 1/2/20 jk Released per CPTAC SME (Linda) for PRAD Baseline CRF. 11/14/19 jk created for CPTAC PRAD baseline CRFs.  Other tumor type CSIs added.","administrativeNotes":"7/7/22 Added CSI CHOL Local Path. MR","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7058740","version":"1","preferredName":"Clinical Metastatic Diagnosis Sites if cM1b Anatomic Site","preferredDefinition":"The named locations within the body if metastasis is categorized as cM1b.","longName":"MET_DIAG_IF_cM1b_ANAT_SITE","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97531D5B-8435-2F4B-E053-F662850A8809","latestVersionIndicator":"Yes","beginDate":"2019-11-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-14","modifiedBy":"KNABLEJ","dateModified":"2020-08-01","changeNote":"7/31/20 jk Released per SME (NGM) review and approval email. 7/20/20 jk created for CPTAC BLCA baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7060336","version":"1","preferredName":"Tumor Mass Number of Lymph Nodes Examined Count","preferredDefinition":"The quantity of lymph nodes that were examined in a malignant pathologic structure.","longName":"7060320v1.0:2182209v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97686D0A-59CA-190D-E053-F662850A780D","latestVersionIndicator":"Yes","beginDate":"2019-11-15","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-15","modifiedBy":"COLBERTM","dateModified":"2021-09-14","changeNote":"9/14/21 mr Added alt name, AQT, alt def, ref doc, and CSI. Per MCL DD. 7/27/21 jk added Phase 3 CM Baseline CSI. 1/2/20 jk Released per CPTAC SME (Linda) for PRAD Baseline CRF.  11/15/19 jk created for CPTAC baseline CRFs (BLCA, CESC, CHOL, ESCA,  LIHC, PRAD, STAD, THCA, UVM). 4/19/21 ls classified HNSCC BSNL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7060348","version":"1","preferredName":"Tumor Mass Number of Lymph Nodes Positive for Tumor by IHC Staining Only Count","preferredDefinition":"The quantity of lymph nodes that were positive for a neoplastic lesion with immunohistochemical (IHC) staining procedures.","longName":"7060324v1.0:2182209v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"976A1093-36B9-4475-E053-F662850A4622","latestVersionIndicator":"Yes","beginDate":"2019-11-15","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-15","modifiedBy":"KNABLEJ","dateModified":"2021-07-27","changeNote":"7/27/21 jk added Phase 3 CM Baseline CSI.  5/10/21 jk added Phase 3 BSLN CSI.  1/2/20 jk Released per CPTAC SME (Linda) for PRAD Baseline CRF. 11/15/19 jk created for CPTAC baseline CRFs (BLCA, CESC, CHOL, ESCA,  LIHC, PRAD, STAD, THCA, UVM).","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7060349","version":"1","preferredName":"Tumor Mass Number of Lymph Nodes Positive for Tumor by H&E Count","preferredDefinition":"The quantity of lymph nodes that were positive for a neoplastic lesion with hematoxylin and eosin (H&E) procedures.","longName":"7060332v1.0:2182209v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9766BCAE-105E-448C-E053-F662850A1913","latestVersionIndicator":"Yes","beginDate":"2019-11-15","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-15","modifiedBy":"KNABLEJ","dateModified":"2021-07-27","changeNote":"7/27/21 jk added Phase 3 CM Baseline CSI.  1/2/20 jk Released per CPTAC SME (Linda) for PRAD Baseline CRF.  11/15/19 jk created for CPTAC baseline CRFs (BLCA, CESC, CHOL, ESCA,  LIHC, PRAD, STAD, THCA, UVM). 4/19/21 ls classified HNSCC BSLN","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7060356","version":"1","preferredName":"Tumor Mass IHC Staining Not Done Checkbox Indicator","preferredDefinition":"A checkbox indicator to designate that immunohistochemical (IHC) staining was not performed.","longName":"7060328v1.0:2185839v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"976A1093-3741-4475-E053-F662850A4622","latestVersionIndicator":"Yes","beginDate":"2019-11-15","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-15","modifiedBy":"KNABLEJ","dateModified":"2021-07-27","changeNote":"7/27/21 jk created for Phase 3 CM Baseline CRF.  5/10/21 jk added Phase 3 CSIs.  1/2/20 jk Released per CPTAC SME (Linda) for PRAD Baseline CRF.  11/15/19 jk created for CPTAC baseline CRFs (BLCA, CESC, CHOL, ESCA,  LIHC, PRAD, STAD, THCA, UVM).","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7060420","version":"1","preferredName":"Metastatic Diagnosis Serum CA 19-9 Measurement Status","preferredDefinition":"The determination of the amount of cancer antigen 19-9 present in a serum sample.","longName":"7052717v1.0:7051620v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"979F2932-13E5-216C-E053-F662850A8443","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-18","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"1/2/20 jk Released per CPTAC SME (Linda). 11/18/19 jk created for CPTAC CHOL and STAD baseline CRFs; definition per Linda's email.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7060421","version":"1","preferredName":"Metastatic Diagnosis Serum CEA Measurement Status","preferredDefinition":"The determination of the amount of carcinoembryonic antigen (CEA) present in a serum sample.","longName":"7052720v1.0:7051635v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"979F499F-C777-5281-E053-F662850A0250","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-18","modifiedBy":"KNABLEJ","dateModified":"2020-04-02","changeNote":"1/2/20 jk Released per CPTAC SME (Linda) for STAD Baseline CRF. 11/20/19 jk added THCA CSI.  11/18/19 jk created for CPTAC STAD baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7062934","version":"1","preferredName":"Performance Status Preoperative Assessment ECOG Score","preferredDefinition":"Score based on the Eastern Cooperative Oncology Group (ECOG) scale representing the functional capabilities of a person immediately before a surgical operation.","longName":"7062933v1.0:7062878v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97C6021C-AEE5-3781-E053-F662850A2C91","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"KNABLEJ","dateModified":"2021-06-20","changeNote":"5/14/20 jk added CPTAC GBM Baseline CSI.  1/2/20 jk Released per CPTAC SME (Linda) for PRAD Baseline CRF.  11/20/19 jk created for CPTAC baseline CRFs. 4/20/21 ls classified HNSCC Bsln. 4/22/21ls classified cm bsln.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7062935","version":"1","preferredName":"Performance Status Preoperative Assessment Karnofsky Score","preferredDefinition":"Score based on the Karnofsky Performance status scale representing the functional capabilities of a person immediately before a surgical operation.","longName":"7062933v1.0:7062868v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97C615B8-2274-316D-E053-F662850ABEAF","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"SOKKERL","dateModified":"2021-06-03","changeNote":"5/14/20 jk added CPTAC GBM Baseline CSI. 1/2/20 jk Released per CPTAC SME (Linda) for PRAD Baseline CRF. 11/20/19 jk created for CPTAC baseline CRFs. 4/20/21 ls classified HNSCC BSLN. 4/22/21 cm bsln. ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7062936","version":"1","preferredName":"Performance Status Comment Text","preferredDefinition":"A free text field documenting performance status notes.","longName":"7062867v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97C62443-6476-2E05-E053-F662850A878B","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"SOKKERL","dateModified":"2021-06-08","changeNote":"5/10/21 jk added Phase 3 CSI. 5/14/20 jk added CPTAC GBM Baseline CSI. 1/2/20 jk Released per CPTAC SME (Linda) for PRAD Baseline CRF.  11/20/19 jk created for CPTAC baseline CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7062937","version":"1","preferredName":"Ancillary Study CDH1 Mutation Analysis Finding Outcome","preferredDefinition":"A finding following an examination or observation looking for the presence of mutations in the CDH1 gene.","longName":"7052725v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97C6BBE6-0458-3773-E053-F662850AE127","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"1/2/20 jk Released per CPTAC SME (Linda) for STAD Baseline CRF.  11/20/19 jk created for CPTAC STAD baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7062938","version":"1","preferredName":"Ancillary Study Epstein-Barr Viral Status Finding Outcome","preferredDefinition":"A finding based on the viral load assay of the Epstein-Barr virus which may be an indicator of disease status.","longName":"7052729v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97C59D74-9972-376A-E053-F662850A2391","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"SOKKERL","dateModified":"2021-05-07","changeNote":"1/2/20 jk Released per CPTAC SME (Linda). 11/20/19 jk created for CPTAC STAD baseline CRF. 5/7/21 ls classified HNSCC BSN.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7062939","version":"1","preferredName":"Ancillary Study Helicobacter pylori Status Finding Outcome","preferredDefinition":"A finding based on whether an individual is infected with the Helicobacter pylori bacteria.","longName":"7052737v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97C6E940-9A9D-377D-E053-F662850AB650","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"1/9/20 jk added CSI for STAD Path Rev and Local CRFs.  1/2/20 jk Released per CPTAC SME (Linda). 11/20/19 jk created for CPTAC STAD baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7062940","version":"1","preferredName":"Ancillary Study PD-L1 Immunohistochemistry Status Finding Outcome","preferredDefinition":"A finding following an examination or observation looking for the overexpression or lack of expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.","longName":"7054869v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97C6BBE6-0484-3773-E053-F662850AE127","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"KNABLEJ","dateModified":"2020-07-20","changeNote":"7/20/20 jk added BLCA Baseline CSI.  1/2/20 jk Released per CPTAC SME (Linda). 11/20/19 jk created for CPTAC STAD baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7062941","version":"1","preferredName":"Ancillary Study MET Amplification Status Finding Outcome","preferredDefinition":"A finding following an examination or observation looking for amplifications involving all or part of the MET gene.","longName":"7052733v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97C52E39-0F99-3787-E053-F662850AA09E","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"1/2/20 jk Released per CPTAC SME (Linda). 11/20/19 jk created for CPTAC STAD baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7062942","version":"1","preferredName":"Ancillary Study Androgen Receptor Status Finding Outcome","preferredDefinition":"A finding following an examination or observation looking for the presence or absence of androgen receptor molecules on the surface of a cells in a specimen.","longName":"7054874v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97C72052-3C9F-668D-E053-F662850A61CE","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"1/2/20 jk Released per CPTAC SME (Linda). 11/20/19 jk created for CPTAC PRAD baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7062943","version":"1","preferredName":"Ancillary Study ERG Rearrangement Status Finding Outcome","preferredDefinition":"A finding following an examination or observation looking for rearrangements involving the ERG gene.","longName":"7054878v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97C4E421-424B-3763-E053-F662850A7C88","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"1/2/20 jk Released per CPTAC SME (Linda). 11/20/19 jk created for CPTAC PRAD baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7062944","version":"1","preferredName":"Ancillary Study ETV Rearrangement Status Finding Outcome","preferredDefinition":"A finding following an examination or observation looking for rearrangements involving ETV family genes.","longName":"7054920v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97C58E4A-B8AC-376E-E053-F662850A01B5","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"1/2/20 jk Released per CPTAC SME (Linda). 11/20/19 jk created for CPTAC PRAD baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7062945","version":"1","preferredName":"Ancillary Study Microsatellite Instability Overall Status","preferredDefinition":"The state or condition of a subject's microsatellite sequences with respect to the inability of their mismatch repair (MMR) proteins to fix a DNA replication error.","longName":"7052740v1.0:7058771v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97C72052-3CCD-668D-E053-F662850A61CE","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"1/9/20 jk added CSI for STAD Path Rev and Local CRFs.  1/2/20 jk Released per CPTAC SME (Linda). 11/20/19 jk created for CPTAC STAD baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7063047","version":"1","preferredName":"Metastatic Diagnosis Family History of Stomach Cancer CPTAC Indicator","preferredDefinition":"A response to indicate if a family history of stomach cancer.","longName":"7063045v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97CAE81E-C163-14FB-E053-F662850AC17E","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"JKNABLE","dateModified":"2022-07-29","changeNote":"1/2/20 jk Released per CPTAC SME (Linda). 11/20/19 jk created for CPTAC STAD baseline CRF.","administrativeNotes":"7/29/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7063048","version":"1","preferredName":"Metastatic Diagnosis Any Metastatic Diagnosis CPTAC Indicator","preferredDefinition":"An indicator response which documents whether a diagnosis of metastatic disease has or has not been made.","longName":"7063036v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97CB1E37-2DE9-14F7-E053-F662850A2CA2","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"1/2/20 jk Released per CPTAC SME (Linda) for PRAD Baseline CRF. 11/20/19 jk created for CPTAC baseline CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7063067","version":"1","preferredName":"Metastatic Diagnosis Residual Tumor Status","preferredDefinition":"The state of the cancer cells that remain after attempts to remove the cancer.","longName":"7063041v1.0:7062948v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97CB9A2D-6E59-0B9C-E053-F662850A1F93","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"CLOHNES","dateModified":"2022-11-09","changeNote":"1/2/20 jk Released per CPTAC SME (Linda) for PRAD Baseline CRF. 11/23/19 jk corrected PQT.  11/20/19 jk created for CPTAC baseline CRFs.4/20/21 ls classified HNSCC BSLN.4/21/21 ls classified CM bsln","administrativeNotes":"11/9/22 added AQT for ticket number CADSR0001669 cjl;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7063075","version":"1","preferredName":"Ancillary Study Additional Testing Performed CPTAC Indicator","preferredDefinition":"A response to indicate whether or not  other testing was provided as part of secondary study data.","longName":"7063071v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97CBDA08-271A-0B98-E053-F662850A8A37","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"KNABLEJ","dateModified":"2021-06-20","changeNote":"5/10/21 jk added Phase 3 BSLN CSI.  5/14/20 jk added CPTAC GBM Baseline CSI. 1/2/20 jk Released per CPTAC SME (Linda).   11/20/19 jk created for CPTAC PRAD and THCA baseline CRFs. 4/21/21 classifed CM bsln","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7063204","version":"1","preferredName":"Tumor Mass Tumor Level Prostate Anatomic Site","preferredDefinition":"Text term to describe the site (apex, middle, base) within the prostate zonal anatomy used to identify the location of the tumor.","longName":"7063197v1.0:7060275v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97CD2CF2-4095-71CD-E053-F662850ABEA5","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"1/2/20 jk Released per CPTAC SME (Linda). 11/20/19 jk created for CPTAC PRAD baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7063226","version":"1","preferredName":"Pathologic Metastatic Diagnosis Sites if pM1 Anatomic Site","preferredDefinition":"The named locations within the body if metastasis is categorized as pM1.","longName":"PMET_DIAG_IF_pM1_ANAT_SITE","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97CF4641-320D-0542-E053-F662850AFA54","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"1/2/20 jk Released per CPTAC SME (Linda) for STAD Baseline CRF. 11/20/19 jk created for CPTAC baseline CESC, CHOL, ESCA, LIHC, STAD, THCA, UVM CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7063230","version":"1","preferredName":"Pathologic Metastatic Diagnosis Sites if pM1b Anatomic Site","preferredDefinition":"The named locations within the body if metastasis is categorized as pM1b.","longName":"PMET_DIAG_IF_pM1b_ANAT_SITE","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97CF7CEF-9A8B-23A3-E053-F662850A3680","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"KNABLEJ","dateModified":"2020-09-30","changeNote":"9/30/20 jk corrected RS. 7/31/20 jk Released per SME (NGM) review and approval email. 11/20/19 jk created for CPTAC BLCA baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7063231","version":"1","preferredName":"Pathologic Metastatic Diagnosis Distant Metastasis Anatomic Site","preferredDefinition":"The named location within the body where the presence of distant metastasis (pM) is documented.","longName":"PMET_DIAG_IF_DIS_MET_ANAT_SITE","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97CF6B18-19F4-2602-E053-F662850AD016","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-20","modifiedBy":"KNABLEJ","dateModified":"2021-07-27","changeNote":"1/2/20 jk Released per CPTAC SME (Linda) for PRAD Baseline CRF.  11/20/19 jk created for CPTAC PRAD baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7063440","version":"1","preferredName":"Tumor Mass PSA Measurement Lab Value","preferredDefinition":"The determination of the PSA (prostate specific antigen) present in a sample.","longName":"7063431v1.0:2019133v2.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97DFA21C-71B8-6A26-E053-F662850AAF40","latestVersionIndicator":"Yes","beginDate":"2019-11-21","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-21","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"1/2/20 jk Released per CPTAC SME (Linda).  11/21/19 jk created for CPTAC PRAD baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7063447","version":"1","preferredName":"Ancillary Study Additional Testing Performed Other Specify","preferredDefinition":"A textual description of additional test(s) that were performed during the study which is different than the ones previously specified or mentioned.","longName":"7063071v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"97E07DF7-61DC-2DEC-E053-F662850ABDD2","latestVersionIndicator":"Yes","beginDate":"2019-11-21","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-21","modifiedBy":"KNABLEJ","dateModified":"2021-05-24","changeNote":"5/10/21 jk added Phase 3 CSI.  5/14/20 jk added CPTAC GBM Baseline CSI.  2/27/20 jk Added PCTAC THCA CSI.  1/2/20 jk Released per CPTAC SME (Linda). 11/23/19 jk added PRAD CSI.  11/20/19 jk created for CPTAC PRAD and THCA baseline CRFs. 4/21/21 ls classified CM bsln","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7065914","version":"1","preferredName":"Ancillary Study ERBB2 Amplification Status Finding Outcome","preferredDefinition":"A finding following an examination or observation used to detect amplifications involving all or part of the ERBB2 gene.","longName":"7065913v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"98095B46-7AA6-2A33-E053-F662850A6B6F","latestVersionIndicator":"Yes","beginDate":"2019-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-11-23","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeNote":"1/2/20 jk Released per CPTAC SME (Linda). 11/23/19 jk created for CPTAC STAD and ESCA baseline CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7074562","version":"1","preferredName":"Performance Status Follow-Up Assessment Eastern Cooperative Oncology Group Score","preferredDefinition":"The score based on the Eastern Cooperative Oncology Group (ECOG) scale representing the functional capabilities of a person on the date of last contact or death.","longName":"6848785v1.0:7062878v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"994645C2-A52A-3995-E053-F662850A75BA","latestVersionIndicator":"Yes","beginDate":"2019-12-09","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-09","modifiedBy":"COLBERTM","dateModified":"2021-12-03","changeNote":"12/3/21 mr Added alt name, AQT, alt def, ref doc, CSI for MCL PCA breast per DCT.   4/21/21 jk added CM, SAR, HNSCC CSIs.  2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified.12/9/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7074570","version":"1","preferredName":"Performance Status Follow-Up Assessment Karnofsky Score","preferredDefinition":"The score based on the Karnofsky Performance status scale representing the functional capabilities of a person on the date of last contact or death.","longName":"6848785v1.0:7062868v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"994634F5-7822-39B5-E053-F662850AA85C","latestVersionIndicator":"Yes","beginDate":"2019-12-09","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-09","modifiedBy":"KNABLEJ","dateModified":"2021-04-24","changeNote":"4/24/21 jk added CM, SAR, HNSCC CSIs.  2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 12/9/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7074719","version":"1","preferredName":"Follow-Up Vital Status","preferredDefinition":"The state or condition of being alive or deceased at the date of last contact; also includes the case where the vital status is unknown.","longName":"6848738v1.0:7072653v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"994C99F2-75F9-3A7F-E053-F662850A3243","latestVersionIndicator":"Yes","beginDate":"2019-12-09","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-09","modifiedBy":"KNABLEJ","dateModified":"2021-04-15","changeNote":"4/15/21 jk Added CM, HNSCC, and SAR FU CSI.  2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified 12/9/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7074721","version":"1","preferredName":"Follow-Up Number of Days from Date of Initial Cancer Diagnosis to Date of Last Contact Count","preferredDefinition":"The number of days from the date of initial cancer diagnosis to the date of last contact.","longName":"6848746v1.0:7069460v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"994C22F7-03F3-3D5E-E053-F662850A153E","latestVersionIndicator":"Yes","beginDate":"2019-12-09","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-09","modifiedBy":"KNABLEJ","dateModified":"2021-04-15","changeNote":"4/15/21 jk Added CM, HNSCC, and SAR FU CSI.  2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified;12/9/19 jk created for CPTAC generic follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7074722","version":"1","preferredName":"Follow-Up Number of Days from Date of Collection to Date of Last Contact Count","preferredDefinition":"The number of days from the date of collection of the specimen to the date of last contact.","longName":"6848751v1.0:7069460v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"994BB7AD-4AED-4B34-E053-F662850A0352","latestVersionIndicator":"Yes","beginDate":"2019-12-09","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-09","modifiedBy":"SOKKERL","dateModified":"2020-02-13","changeNote":"2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 12/9/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7074723","version":"1","preferredName":"Follow-Up Number of Days from Date of Initial Cancer Diagnosis to Date of Death Day Count","preferredDefinition":"The number of days from the date of initial cancer diagnosis to the date of death.","longName":"6848753v1.0:7069460v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"99514ECB-7979-0E59-E053-F662850A4FA4","latestVersionIndicator":"Yes","beginDate":"2019-12-09","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-09","modifiedBy":"KNABLEJ","dateModified":"2021-08-16","changeNote":"8/16/21 jk CM FU CSI.  4/26/21 jk HNSCC CSI, AQT.  2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 12/9/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7074769","version":"1","preferredName":"Post-operative Therapy Treatment Regimen Code","preferredDefinition":"A symbol or combination of symbols which identifies the after surgery treatment intended to achieve the best possible surgical outcome.","longName":"6848759v1.0:7074620v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"995D2C19-1AF3-4A8A-E053-F662850A79CE","latestVersionIndicator":"Yes","beginDate":"2019-12-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-10","modifiedBy":"SOKKERL","dateModified":"2020-02-13","changeNote":"2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 12/9/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7074773","version":"1","preferredName":"Treatment Regimen Modality Type","preferredDefinition":"The type of treatment plan associated with a specific manner, characteristic, pattern of application or the employment of, any therapeutic agent or method of treatment, especially involving the physical treatment of a condition.","longName":"6848763v1.0:7074764v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"995D4077-AA4C-498D-E053-F662850A10D1","latestVersionIndicator":"Yes","beginDate":"2019-12-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-10","modifiedBy":"SOKKERL","dateModified":"2020-02-13","changeNote":"2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 12/18/19 jk revised PQT.  12/10/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7074778","version":"1","preferredName":"Treatment Regimen Therapeutic Agent Name","preferredDefinition":"Text which records the therapeutic agent or agents used in a treatment regimen.","longName":"6848767v1.0:7074768v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"995D8225-E6F5-7DE3-E053-F662850A4B22","latestVersionIndicator":"Yes","beginDate":"2019-12-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-10","modifiedBy":"SOKKERL","dateModified":"2020-02-13","changeNote":"2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 12/10/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7074831","version":"1","preferredName":"Best Overall Lesion Response CPTAC RECIST Type","preferredDefinition":"The CPTAC standard parameter used to document the response having the most positive qualities for a specific treatment regimen.","longName":"3861381v1.0:7074781v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"995DF9C5-3CAC-4C51-E053-F662850A078C","latestVersionIndicator":"Yes","beginDate":"2019-12-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-10","modifiedBy":"KNABLEJ","dateModified":"2020-02-20","changeNote":"2/20/20 jk CPTAC/Linda approved CDE; CDE released, RS kept Application. 12/10/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092630","version":"1","preferredName":"Follow-Up Outcome after Follow-Up Form Completion Status","preferredDefinition":"The state or condition of an individual's outcome at completion of the follow-up period.","longName":"6848779v1.0:7074666v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"99C48A0C-9A72-2FA8-E053-F662850A25A6","latestVersionIndicator":"Yes","beginDate":"2019-12-15","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-15","modifiedBy":"COLBERTM","dateModified":"2022-06-15","changeNote":"4/14/21 jk added to remaining Ph3 FU CSI.  4/12/21 jk added AQT for Phase 3 (old) tumor types.  2/25/21 jk update question text based on revised generic Follow-up CRF.  2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 12/15/19 jk created for CPTAC follow up CRF.","administrativeNotes":"6/15/22 Added period to end of alt def. MR\r\n6/8/22  Added AQT and alt def per CPTAC/Nicollette’s XLS review. MR","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092631","version":"1","preferredName":"Follow-Up Tumor Status at Date of Last Contact Status","preferredDefinition":"The state or condition of the tumor as of the date of last contact or death.","longName":"6848783v1.0:6788102v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"99C48A0C-9AA0-2FA8-E053-F662850A25A6","latestVersionIndicator":"Yes","beginDate":"2019-12-15","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-15","modifiedBy":"KNABLEJ","dateModified":"2021-07-29","changeNote":"7/28/21 jk added Phase 3 CM FU CSI.  4/24/21 jk added HNSCC FU CSI, Alt VM for Unknown.  12/15/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092632","version":"1","preferredName":"Follow-Up Performance Status Assessment Date","preferredDefinition":"The date on which the follow up performance status assessment occurred.","longName":"6848790v1.0:2018550v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"99C75C06-72FA-2FB0-E053-F662850A1925","latestVersionIndicator":"Yes","beginDate":"2019-12-15","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-15","modifiedBy":"SOKKERL","dateModified":"2020-02-14","changeNote":"2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 12/15/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092633","version":"1","preferredName":"New Tumor Event Present After Initial Treatment CPTAC Indicator","preferredDefinition":"A response to indicate if a newly discovered tumor was present after the initial treatment.","longName":"6848796v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"99C76107-D972-2FC0-E053-F662850A41B8","latestVersionIndicator":"Yes","beginDate":"2019-12-15","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-15","modifiedBy":"KNABLEJ","dateModified":"2021-04-26","changeNote":"4/26/21 jk added HNSCC FU CSI.  2/20/20 jk CPTAC/Linda approved CDE; AI released, RS chg to Qualified.  2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified 12/15/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092634","version":"1","preferredName":"New Tumor Event Type","preferredDefinition":"The kind of newly discovered tumor identified in the new tumor event.","longName":"6848800v1.0:7074673v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"99C48A0C-9ACE-2FA8-E053-F662850A25A6","latestVersionIndicator":"Yes","beginDate":"2019-12-15","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-15","modifiedBy":"SOKKERL","dateModified":"2020-02-14","changeNote":"2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified 12/15/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092635","version":"1","preferredName":"New Tumor Event Anatomic Site","preferredDefinition":"The named location of or within the body which identifies a newly discovered tumor.","longName":"6848804v1.0:7074675v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"99C75C06-7328-2FB0-E053-F662850A1925","latestVersionIndicator":"Yes","beginDate":"2019-12-15","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-15","modifiedBy":"KNABLEJ","dateModified":"2021-08-10","changeNote":"8/10/21 jk upd def for wording consistency.  4/23/20 jk added CSI for Consent CRF.  2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 12/15/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092636","version":"1","preferredName":"New Tumor Event Date","preferredDefinition":"The date on which a newly discovered tumor occurred.","longName":"6848812v1.0:2018550v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"99C48A0C-9AFC-2FA8-E053-F662850A25A6","latestVersionIndicator":"Yes","beginDate":"2019-12-15","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-15","modifiedBy":"KNABLEJ","dateModified":"2021-08-02","changeNote":"8/2/21 jk added Phase 3 CM FU CSI.  4/26/21 jk added HNSCC FU CSI. 2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified.12/15/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092637","version":"1","preferredName":"New Tumor Event Additional Surgery Date","preferredDefinition":"The date on which the additional surgery for a newly discovered tumor was performed.","longName":"6848824v1.0:2018550v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"99C7D876-0EEA-2FA0-E053-F662850A902C","latestVersionIndicator":"Yes","beginDate":"2019-12-15","endDate":"2021-03-02","createdBy":"KNABLEJ","dateCreated":"2019-12-15","modifiedBy":"KNABLEJ","dateModified":"2021-08-02","changeNote":"4/25/21 jk For Phase 3 types; use CDE 7588855 for new tumor types.  2/12/270926370 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 12/15/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092638","version":"1","preferredName":"New Tumor Event Number of Days from Date of Initial Cancer Diagnosis to Date of New Tumor Event after Initial Treatment Count","preferredDefinition":"The number of days from the date of the initial cancer diagnosis to the date of a newly discovered tumor after initial treatment.","longName":"6848816v1.0:7069460v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"99C76107-D9A0-2FC0-E053-F662850A41B8","latestVersionIndicator":"Yes","beginDate":"2019-12-15","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-15","modifiedBy":"KNABLEJ","dateModified":"2021-04-26","changeNote":"4/26/21 jk added HNSCC FU CSI, AQT.  2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 12/15/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092639","version":"1","preferredName":"New Tumor Event Number of Days from Date of Initial Pathologic Diagnosis to Date of Additional Surgery for New Tumor Event Count","preferredDefinition":"The number of days from the date of the initial pathologic diagnosis to the date of additional surgery for new tumor event.","longName":"6848828v1.0:7069460v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"99C8461F-EA11-2FBC-E053-F662850AC462","latestVersionIndicator":"Yes","beginDate":"2019-12-15","endDate":"2021-03-02","createdBy":"KNABLEJ","dateCreated":"2019-12-15","modifiedBy":"KNABLEJ","dateModified":"2021-08-02","changeNote":"4/25/21 jk For Phase 3 types; use CDE 7588892 for new tumor types.  2/12/20 jk ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 12/15/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092640","version":"1","preferredName":"New Tumor Event Additional Surgery for New Tumor Event Indicator","preferredDefinition":"A response to indicate if any additional surgery was performed on a newly discovered tumor.","longName":"6848820v1.0:7074638v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"99C48A0C-9B2A-2FA8-E053-F662850A25A6","latestVersionIndicator":"Yes","beginDate":"2019-12-15","endDate":"2021-03-02","createdBy":"KNABLEJ","dateCreated":"2019-12-15","modifiedBy":"KNABLEJ","dateModified":"2021-08-02","changeNote":"4/25/21 jk For Phase 3 types; use CDE 7587377 for new tumor types.  2/25/21 jk update question text based on revised generic Follow-up CRF. 2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 12/15/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092641","version":"1","preferredName":"New Tumor Event Additional Therapeutic Procedure Treatment Regimen Modality Type","preferredDefinition":"The type of treatment plan associated with a specific manner, characteristic, pattern of application or the employment of, any therapeutic agent or method of treatment, involving the physical treatment of a a newly discovered tumor.","longName":"6848831v1.0:7074764v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"99C75C06-7356-2FB0-E053-F662850A1925","latestVersionIndicator":"Yes","beginDate":"2019-12-15","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-15","modifiedBy":"SOKKERL","dateModified":"2020-02-13","changeNote":"2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 12/15/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092642","version":"1","preferredName":"New Tumor Event Therapeutic Agent Text","preferredDefinition":"A textual field which records the therapeutic agent or agents used to treat a newly discovered tumor.","longName":"6848833v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"99C8E495-4C37-2FC4-E053-F662850A9581","latestVersionIndicator":"Yes","beginDate":"2019-12-15","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-15","modifiedBy":"SOKKERL","dateModified":"2020-02-14","changeNote":"2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified. 12/15/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7113204","version":"1","preferredName":"Ancillary Study 1p/19q Codeletion Status Finding Outcome","preferredDefinition":"A secondary study finding following an examination or observation looking for concurrent deletion of chromosome arms 1p and 19q.","longName":"7113113v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9A7A3B49-0F1C-6542-E053-F662850A3050","latestVersionIndicator":"Yes","beginDate":"2019-12-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-24","modifiedBy":"KNABLEJ","dateModified":"2020-07-01","changeNote":"7/1/20 jk added secondary study in def.  5/14/20 jk Released per SME (NGM) review and approval email.  4/30/20 jk added CPTAC LGG Path CSI. 12/24/19 jk created for CPTAC LGG baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7113205","version":"1","preferredName":"Ancillary Study ATRX Mutation Status by Sequencing Finding Outcome","preferredDefinition":"A finding following an examination or observation looking for the presence or absence of ATRX gene mutations as determined using sequencing techniques.","longName":"7113135v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9A7A9ABB-8623-652E-E053-F662850AD2A9","latestVersionIndicator":"Yes","beginDate":"2019-12-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-24","modifiedBy":"KNABLEJ","dateModified":"2020-05-14","changeNote":"5/14/20 jk Released per SME (NGM) review and approval email.  4/30/20 jk added CPTAC LGG Path CSI.  12/24/19 jk created for CPTAC LGG baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7113206","version":"1","preferredName":"Ancillary Study IDH1/IDH2 Mutation Status Finding Outcome","preferredDefinition":"A finding following an examination or observation to detect and identify mutations in the IDH1 and IDH2 genes.","longName":"7118700v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9A7A9ABB-8651-652E-E053-F662850AD2A9","latestVersionIndicator":"Yes","beginDate":"2019-12-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-24","modifiedBy":"KNABLEJ","dateModified":"2020-05-14","changeNote":"5/14/20 jk Released per SME (NGM) review and approval email. 4/30/20 jk added CPTAC LGG Path CSI. 1/8/20 jk per Linda, associate with DEC 7118700 - retire Retired DEC 7113139.  Remove \"by sequencing\" and use \"IDH1 / IDH21\" in question; use for LGG and CHOL.  Retired DEC 7113139 created for LGG.  2/24/19 jk created for CPTAC LGG baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7113207","version":"1","preferredName":"Ancillary Study MGMT Methylation Assay Finding Outcome","preferredDefinition":"A finding based on an assay used to determine the pattern of methylation in the promoter of the MGMT gene. Aberrant methylation of the MGMT promoter is associated with squamous cell carcinoma.","longName":"7113150v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9A7BCEA0-AFC5-1BED-E053-F662850ACC27","latestVersionIndicator":"Yes","beginDate":"2019-12-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-24","modifiedBy":"KNABLEJ","dateModified":"2020-05-14","changeNote":"5/14/20 jk Released per SME (NGM) review and approval email.  4/30/20 jk added CPTAC LGG Path CSI.  12/24/19 jk created for CPTAC LGG baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7113208","version":"1","preferredName":"Ancillary Study TP53 Mutation Status by Sequencing Finding Outcome","preferredDefinition":"A finding following an examination or observation looking for the presence or absence of TP53 gene mutations was determined using sequencing techniques.","longName":"7113154v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9A7AA8A0-7DBD-7875-E053-F662850A448D","latestVersionIndicator":"Yes","beginDate":"2019-12-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-24","modifiedBy":"HARTLEYG","dateModified":"2022-02-07","changeNote":"5/14/20 jk Released per SME (NGM) review and approval email.  4/30/20 jk added CPTAC LGG Path CSI.  12/24/19 jk created for CPTAC LGG baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7114315","version":"1","preferredName":"Tumor Mass Low Grade Glioma Anatomic Site","preferredDefinition":"The named locations of a benign or malignant lower grade glioma pathologic structure in the brain.","longName":"TMR_LGG_ANAT_SITE","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9AB2F3EA-34A4-6D40-E053-F662850A8F58","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-27","modifiedBy":"KNABLEJ","dateModified":"2020-05-14","changeNote":"5/14/20 jk Released per SME (NGM) review and approval email. 4/30/20 jk added CPTAC LGG Path CSI.  12/27/19 jk created for CPTAC LGG baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7114318","version":"1","preferredName":"Tumor Mass Hepatocellular Carcinoma Anatomic Site","preferredDefinition":"The named locations of a benign or malignant pathologic structure in the liver.","longName":"TMR_LIHC_ANAT_SITE","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9AB30D14-8DC1-4C47-E053-F662850A703A","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-27","modifiedBy":"KNABLEJ","dateModified":"2020-02-14","changeNote":"2/14/20 jk Released per CPTAC SME (Linda) review and approval. 1/29/20 jk added CSI for LIHC Path Rev and Local CRFs.  1/27/20 jk upd definition per CPTAC format.  12/27/19 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7114355","version":"1","preferredName":"Low Grade Glioma Supratentorial Localization Anatomic Site","preferredDefinition":"The named locations of a grade I or grade II glioma arising from the  intracranial venous sinus that lies in a superior and midline location above the interhemispheric fissure along the superior border of the falx cerebri of the brain.","longName":"7113174v1.0:7113006v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9AB3DBCA-3F0D-59D2-E053-F662850A12F1","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-27","modifiedBy":"KNABLEJ","dateModified":"2020-05-14","changeNote":"5/14/20 jk Released per SME (NGM) review and approval email.  12/27/19 jk created for CPTAC LGG baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7114357","version":"1","preferredName":"Tumor Mass Low Grade Glioma Histologic Type","preferredDefinition":"The type of tissue in which a carcinoma arising from a Low Grade Glioma originated.","longName":"6796606v1.0:7113061v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9AB4204F-216F-59E4-E053-F662850AAF97","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-27","modifiedBy":"KNABLEJ","dateModified":"2020-05-14","changeNote":"5/14/20 jk Released per SME (NGM) review and approval email.  4/30/20 jk added CPTAC LGG Path CSI.  12/27/19 jk created for CPTAC LGG baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7114364","version":"1","preferredName":"Tumor Mass Liver Histologic Type","preferredDefinition":"The type of tissue in which a carcinoma arising from the liver originated.","longName":"6796606v1.0:7114150v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9AB43851-962E-5BEC-E053-F662850AFA03","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-27","modifiedBy":"KNABLEJ","dateModified":"2020-04-02","changeNote":"2/14/20 jk Released per CPTAC SME (Linda) review and approval.  1/29/20 jk added CSI for LIHC Path Rev and Local CRFs.  12/27/19 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7115526","version":"1","preferredName":"Tumor Mass Histologic Low Grade Glioma WHO Classification of Tumors Grade","preferredDefinition":"The World Health Organization (WHO) classification of grade I or grade II glioma tumors based primarily on histologic findings.","longName":"7113170v1.0:7113078v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9AB2B392-BAAA-7E59-E053-F662850AAFB1","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-27","modifiedBy":"KNABLEJ","dateModified":"2020-05-14","changeNote":"5/14/20 jk Released per SME (NGM) review and approval email.  4/30/20 jk added CPTAC LGG Path CSI.  12/27/19 jk created for CPTAC LGG baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7117957","version":"1","preferredName":"Ancillary Study CTNNB1 Mutation Status Finding Outcome","preferredDefinition":"A secondary study finding following an examination or observation looking for mutations in the CTNNB1 gene.","longName":"7115539v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B043F65-CC16-1B6F-E053-F662850ABD06","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"KNABLEJ","dateModified":"2020-07-01","changeNote":"7/1/20 jk added secondary study to def.  2/14/20 jk Released per CPTAC SME (Linda) review and approval. 12/31/19 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7117958","version":"1","preferredName":"Ancillary Study Hepatitis B Virus Core Antibody Finding Outcome","preferredDefinition":"A finding following an examination or observation looking for the presence of Hepatitis B virus core antibody present in a sample.","longName":"7115542v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B040CD0-AE7F-01C7-E053-F662850A0B1A","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"KNABLEJ","dateModified":"2020-02-14","changeNote":"2/14/20 jk Released per CPTAC SME (Linda) review and approval. 12/31/19 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7117959","version":"1","preferredName":"Ancillary Study Hepatitis B Virus DNA Finding Outcome","preferredDefinition":"A finding following an examination or observation looking for the presence of the hepatitis B virus DNA in a sample.","longName":"7115545v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B046C19-7F3E-1889-E053-F662850A183F","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"KNABLEJ","dateModified":"2020-02-14","changeNote":"2/14/20 jk Released per CPTAC SME (Linda) review and approval. 12/31/19 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7117976","version":"1","preferredName":"Ancillary Study Hepatitis B Surface Antibody Finding Outcome","preferredDefinition":"A finding following an examination or observation looking for surface antibody reaction of a sample to the Hepatitis B virus.","longName":"7117941v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B04A1EC-7BBA-216A-E053-F662850A7F57","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"KNABLEJ","dateModified":"2020-02-14","changeNote":"2/14/20 jk Released per CPTAC SME (Linda) review and approval. 12/31/19 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7118003","version":"1","preferredName":"Ancillary Study Hepatitis B Virus Surface Antigen Finding Outcome","preferredDefinition":"A finding following an examination or observation looking for the presence  of hepatitis B virus surface antigen.","longName":"7117853v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B052DDE-802E-1AA1-E053-F662850AFADF","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"KNABLEJ","dateModified":"2020-02-14","changeNote":"2/14/20 jk Released per CPTAC SME (Linda) review and approval. 12/31/19 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7118026","version":"1","preferredName":"Ancillary Study Hepatitis C Virus Antibody Finding Outcome","preferredDefinition":"A finding following an examination or observation looking for the antibody reaction of a biological specimen to the Hepatitis C virus.","longName":"7117949v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B057235-55DA-3BBF-E053-F662850A4C11","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"KNABLEJ","dateModified":"2020-02-14","changeNote":"2/14/20 jk Released per CPTAC SME (Linda) review and approval. 12/31/19 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7118027","version":"1","preferredName":"Ancillary Study Hepatitis C Virus RNA Finding Outcome","preferredDefinition":"A finding following an examination or observation looking for the presence of hepatitis C virus RNA in a sample.","longName":"7117952v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B04ED16-18E7-1BB0-E053-F662850A86C7","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"KNABLEJ","dateModified":"2020-02-14","changeNote":"2/14/20 jk Released per CPTAC SME (Linda) review and approval. 12/31/19 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7118028","version":"1","preferredName":"Ancillary Study TERT Promoter Mutation Status Finding Outcome","preferredDefinition":"A finding following an examination or observation looking for mutations in the promoter sequences for the TERT gene.","longName":"7117956v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B058F86-4DC5-1FC7-E053-F662850AE8F9","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"KNABLEJ","dateModified":"2020-02-14","changeNote":"2/14/20 jk Released per CPTAC SME (Linda) review and approval. 12/31/19 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7118703","version":"1","preferredName":"Tumor Mass Cholangiocarcinoma Histologic Type","preferredDefinition":"The type of tissue in which an intrahepatic bile duct, the hepatic duct, or the common bile duct distal to the insertion of the cystic duct  tumor originated.","longName":"6796604v1.0:7114173v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B01B763-B10D-1D73-E053-F662850AEBFB","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"COLBERTM","dateModified":"2022-09-19","changeNote":"12/31/19 jk created for CPTAC CHOL baseline CRF.","administrativeNotes":"7/7/22 Added CSI for CPTAC CHOL Local Path. mr; 9/19/22 Released/Qualified per jk for CPTAC. mr;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7118704","version":"1","preferredName":"Ancillary Study HBV Genotype Assay Text","preferredDefinition":"A textual description of an assay used to determine which hepatitis B virus genome(s) is present in an infection. Seven genotypes of HBV (designated A through G) have been identified. Different genotypes are prevalent in different geographical areas and each carries a different risk of development of hepatocellular carcinoma.","longName":"7117850v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B036A78-46C7-7E80-E053-F662850ACB64","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"COLBERTM","dateModified":"2022-07-11","changeNote":"2/14/20 jk Released per CPTAC SME (Linda) review and approval. 12/31/19 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":"7/11/22 Updated def for consistency per spreadsheet from JK.  MR","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7118705","version":"1","preferredName":"Ancillary Study HCV Genotype Finding Text","preferredDefinition":"A textual description of the determination of the genotype of hepatitis c virus in a blood sample.","longName":"7117945v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B01D91D-4C2E-1326-E053-F662850AC624","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"COLBERTM","dateModified":"2022-07-11","changeNote":"2/14/20 jk Released per CPTAC SME (Linda) review and approval. 12/31/19 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":"7/11/22 Updated def per spreadsheet from JK.  MR","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7118706","version":"1","preferredName":"Tumor Mass Extent of Resection Category","preferredDefinition":"The degree to which the lesion has been cut out, or resected.","longName":"7063439v1.0:7113086v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B01F909-8089-7EF6-E053-F662850A2EF8","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"KNABLEJ","dateModified":"2020-05-14","changeNote":"5/14/20 jk Released per SME (NGM) review and approval email.  12/31/19 jk created for CPTAC LGG baseline CRF; no Metastatic Diagnosis section.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7118707","version":"1","preferredName":"Tumor Mass Therapeutic Ionizing Radiation to Head History CPTAC Indicator","preferredDefinition":"An indicator response which documents an individual's history of exposure to ionizing radiation of their head.","longName":"7063435v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B052DDE-80A6-1AA1-E053-F662850AFADF","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"KNABLEJ","dateModified":"2020-05-14","changeNote":"5/14/20 jk Released per SME (NGM) review and approval email.  12/31/19 jk created for CPTAC LGG baseline CRF; no Metastatic Diagnosis section.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7118708","version":"1","preferredName":"Metastatic Diagnosis First Degree Family History of Cancer CPTAC Indicator","preferredDefinition":"A response to indicate whether parents, siblings or children of an individual have a history of cancer.","longName":"7113161v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B04ED16-1936-1BB0-E053-F662850A86C7","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"JKNABLE","dateModified":"2022-07-29","changeNote":"5/14/20 jk Released per SME (NGM) review and approval email.  12/31/19 jk created for CPTAC LGG baseline CRF; no Metastatic Diagnosis section.","administrativeNotes":"7/29/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7118709","version":"1","preferredName":"Metastatic Diagnosis First Degree Family History of Primary Brain Tumor CPTAC Indicator","preferredDefinition":"A response to indicate whether the parents, siblings or children of an individual have a history of a primary brain tumor.","longName":"7113165v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B04C19E-8C4B-1BCE-E053-F662850AE086","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"JKNABLE","dateModified":"2022-07-29","changeNote":"5/14/20 jk Released per SME (NGM) review and approval email.  12/31/19 jk created for CPTAC LGG baseline CRF; no Metastatic Diagnosis section.","administrativeNotes":"7/29/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7118710","version":"1","preferredName":"Metastatic Diagnosis First Presenting Symptom Related to Disease Category","preferredDefinition":"The first symptom that is related to the metastatic disease of interest.","longName":"7113168v1.0:7113098v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B0190CA-F654-059E-E053-F662850A482E","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"KNABLEJ","dateModified":"2020-05-14","changeNote":"5/14/20 jk Released per SME (NGM) review and approval email.  12/31/19 jk created for CPTAC LGG baseline CRF; no Metastatic Diagnosis section.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7118711","version":"1","preferredName":"Metastatic Diagnosis Hepatocellular Carcinoma Non-Neoplastic Finding Outcome","preferredDefinition":"The clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease of a malignant tumor that arises from hepatocytes.","longName":"7115529v1.0:7114205v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B0190CA-F682-059E-E053-F662850A482E","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"KNABLEJ","dateModified":"2020-02-14","changeNote":"2/14/20 jk Released per CPTAC SME (Linda) review and approval.  1/29/20 jk added CSI for LIHC Path Rev and Local CRFs. 12/31/19 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7118712","version":"1","preferredName":"Metastatic Diagnosis Non-Neoplastic Finding Other Specify","preferredDefinition":"A textual description of the clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease which is different than the ones previously specified or mentioned.","longName":"7115529v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B0498C9-5C3B-1C49-E053-F662850AD4B2","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"KNABLEJ","dateModified":"2020-02-14","changeNote":"2/14/20 jk Released per CPTAC SME (Linda) review and approval. 1/29/20 jk added CSI for LIHC Path Rev and Local CRFs.   12/31/19 jk created for CPTAC ESC, LIHC and THCA baseline CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7118713","version":"1","preferredName":"Metastatic Diagnosis Hepatocellular Carcinoma Risk Factor History Category","preferredDefinition":"An individual's attribute, characteristic or exposure that increases the likelihood of developing a disease that arises from hepatocytes resulting in hepatocellular carcinoma, or as diffuse liver involvement.","longName":"7115532v1.0:7114213v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B058F86-4DF9-1FC7-E053-F662850AE8F9","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"KNABLEJ","dateModified":"2020-02-17","changeNote":"2/14/20 jk Released per CPTAC SME (Linda) review and approval. 12/31/19 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7122404","version":"1","preferredName":"Central Pathology Review Same As Prostatectomy Highest Gleason Score CPTAC Indicator","preferredDefinition":"A response to indicate which documents if the Gleason Score of the submitted sample represents the highest Gleason Score for the prostatectomy specimen.","longName":"7119318v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B8E5AC4-3E30-0826-E053-F662850A5769","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"ZHWENDY","dateModified":"2022-07-19","changeNote":"2/13/20 jk RS chg to Qualified.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set.  1/7/20 jk created for CPTAC PRAD Path Review and Local Path CRFs.","administrativeNotes":"7/8/22 Edits made to definition for format consistency per CPTAC SME. jk 7/19/2022: fixed the box symbol in PQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7122410","version":"1","preferredName":"Central Pathology Review Comment Text","preferredDefinition":"A free text field documenting a specimen sent to a central lab for confirmatory analysis using standardized methods and result criteria of pathology data.","longName":"7119320v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B8F3108-0066-0623-E053-F662850A24F7","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"KNABLEJ","dateModified":"2021-08-17","changeNote":"8/17/21 jk added Phase 3 CM Path Review CSI. 7/12/21 jk added HNSCC Path Rpt CSI. 2/10/20 jk removed references to Local Path CRFs; Local Path should use CDE 7165768. 1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/9/20 jk added CSI for STAD Local Path CRF.  1/7/20 jk created for CPTAC Path Review CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7122413","version":"1","preferredName":"Central Pathology Review Confirmed Histologic Type Indicator","preferredDefinition":"A yes/no indicator response which documents whether the pathology review of tumor tissue confirm the histologic type to be eligible for the CPTAC study.","longName":"7119323v1.0:3506068v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B8D4E42-00A4-412B-E053-F662850A910E","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"KNABLEJ","dateModified":"2021-08-17","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI.  4/30/20 jk added LGG CSI; this CDE for CPTAC review; use CDE 7165771 for Local Path CRFs. 1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/7/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7122414","version":"1","preferredName":"QC Slide Review Tumor Segment Identifier Integer","preferredDefinition":"A number used to identify the tumor segment collected as part of the quality control review of the tumor biospecimen for proteomic and genomic analysis.","longName":"7119482v1.0:6847952v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B8F7703-3079-23EE-E053-F662850A45A7","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"KNABLEJ","dateModified":"2021-08-17","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI.  4/30/20 jk added CPTAC LGG Path CSI.  4/17/20 jk def mods per SME review to support Slide Creation CRF.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/7/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7122802","version":"1","preferredName":"QC Slide Review Normal Tissue Segment Identifier Integer","preferredDefinition":"A number used to identify the normal tissue segment collected as part of the quality control review of the tumor biospecimen for proteomic and genomic analysis.","longName":"7119485v1.0:6847952v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B90F217-91B9-1C06-E053-F662850AE5EB","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"KNABLEJ","dateModified":"2021-08-17","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI. 6/14/20 jk added CPTAC ESCA Pathology CSI.  4/30/20 jk added CPTAC LGG Path CSI.  4/17/20 jk def mod per SME review to support Slide Creation CRF; alt quest added for \"Aliquot\". 1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/7/20 jk created for CPTAC Path Review and CRF; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7124243","version":"1","preferredName":"Tumor Segment Biospecimen CPTAC Identifier","preferredDefinition":"The CPTAC specimen identifier of the tumor segment collected for review.  The identifier utilizes the pre-defined CPTAC identifier format.","longName":"7119490v1.0:7121849v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B9294D1-8218-55AA-E053-F662850AFBC0","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"COLBERTM","dateModified":"2022-09-09","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI. 9/23/20 jk LN upd for consistency to match CDEs reusing same VD. 8/27/20 jk added Procurement CSI, AQT.  4/30/20 jk added CPTAC LGG Path CSI.  4/17/20 jk def mod per SME review to support Slide Creation CRF.  1/22/20 jk offset date CDE created for MCL Core data variable.  1/7/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7124246","version":"1","preferredName":"Tumor Segment FFPE Block CPTAC Biospecimen Identifier","preferredDefinition":"The CPTAC specimen identifier of the cassette and Formalin-Fixed Paraffin-Embedded (FFPE) block in which the tumor tissue segment was embedded.  The identifier utilizes the pre-defined CPTAC identifier format.","longName":"7119499v1.0:7121849v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B946ACA-8809-3A30-E053-F662850A33DB","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"COLBERTM","dateModified":"2022-09-09","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI. 8/27/20 jk added Procurement CSI, AQT.  4/30/20 jk added CPTAC LGG Path CSI.  4/20/20 jk Def revised per SME review; added AQT and to Slide CSI. 1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/7/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7124503","version":"1","preferredName":"Tumor Segment Slide ID Examined by Pathologist CPTAC Biospecimen Identifier","preferredDefinition":"The slide identifier of the tumor segment collected for examination by the pathologist.  The identifier utilizes the pre-defined CPTAC identifier format.","longName":"7119502v1.0:7121849v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B946ACA-88DF-3A30-E053-F662850A33DB","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"COLBERTM","dateModified":"2022-09-11","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI. 4/30/20 jk added CPTAC LGG Path CSI.  4/20/20 jk Def revised per SME review; added AQT and to Slide CSI. 1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/7/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7124624","version":"1","preferredName":"Tumor Segment Image ID Examined by Pathologist Aperio Format Identifier","preferredDefinition":"The image identifier in the Aperio format of the tumor segment examined by the pathologist.","longName":"7119508v1.0:7121847v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B94E317-97A7-15F8-E053-F662850AA194","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"KNABLEJ","dateModified":"2021-08-17","changeNote":"8/17/21 jk added CM Path Rpt CSI.  7/12/21 jk added HNSCC Path Rpt CSI. 4/30/20 jk added CPTAC LGG Path CSI.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/7/20 jk created for CPTAC Path Review CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7124629","version":"1","preferredName":"Normal Tissue Segment CPTAC Biospecimen Identifier","preferredDefinition":"The CPTAC specimen identifier of the normal tissue segment collected for review.  The identifier utilizes the pre-defined CPTAC identifier format.","longName":"7120747v1.0:7121849v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B94F0F0-4546-1657-E053-F662850A3273","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"KNABLEJ","dateModified":"2021-08-17","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI. 12/14/20 jk removed Normal tissue procurement CSI; new CDE created per SME review. 10/30/20 jk added Normal Tissue CSI. 9/23/20 jk revised LN te remove redundant biospecimen term.  8/27/20 jk 7/23/20 jk added Procurement CSI, AQT.  4/17/20 jk def mod per SME review to support Slide Creation CRF.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/7/20 jk created for CPTAC Path Review CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7124658","version":"1","preferredName":"Normal Tissue Segment FFPE Block CPTAC Biospecimen Identifier","preferredDefinition":"The CPTAC specimen identifier of the Formalin-Fixed Paraffin-Embedded (FFPE) block in which the normal tissue segment was embedded.  The identifier utilizes the pre-defined CPTAC identifier format.","longName":"7120749v1.0:7121849v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B950CA4-108E-154B-E053-F662850A9C12","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"KNABLEJ","dateModified":"2021-08-17","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI. 12/14/20 jk removed Normal tissue procurement CSI; new CDE created per SME review. 10/30/20 jk added Normal Tissue CSI. 8/27/20 jk added Procurement CSI, AQT.  4/20/20 jk Def revised per SME review; added AQT and to Slide CSI. 4/2/20 jk added CPTAC THCA Path Rev CSI.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/7/20 jk created for CPTAC Path Review CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7124666","version":"1","preferredName":"Normal Tissue Segment Slide ID Examined by Pathologist CPTAC Biospecimen Identifier","preferredDefinition":"The slide identifier of the normal tissue segment collected for examination by the pathologist.  The identifier utilizes the pre-defined CPTAC identifier format.","longName":"7120751v1.0:7121849v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B94F0F0-4604-1657-E053-F662850A3273","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"KNABLEJ","dateModified":"2021-08-17","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI. 4/20/20 jk Def revised per SME review; added AQT and to Slide CSI.  4/2/20 jk added CPTAC THCA Path Rev CSI.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/7/20 jk created for CPTAC Path Review CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7124676","version":"1","preferredName":"Normal Tissue Segment Image ID Examined by Pathologist Aperio Format Identifier","preferredDefinition":"The image identifier in the Aperio format of the normal tissue  segment examined by the pathologist.","longName":"7120769v1.0:7121847v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B952492-FD18-16B3-E053-F662850A9C3E","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"KNABLEJ","dateModified":"2021-07-12","changeNote":"7/12/21 jk added HNSCC Path Rpt CSI.  4/2/20 jk added CPTAC THCA Path Rev CSI.   1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/7/20 jk created for CPTAC Path Review CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7124712","version":"1","preferredName":"Normal Tissue Segment Histologic Type Text","preferredDefinition":"A free text field documenting the type of tissue in the normal tissue sampled.","longName":"7120774v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B955A0B-7461-3DA0-E053-F662850AECD3","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"KNABLEJ","dateModified":"2021-08-17","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI. 4/2/20 jk added CPTAC THCA Path Rev CSI.   1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/7/20 jk created for CPTAC Path Review CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7124737","version":"1","preferredName":"Normal Tissue Segment Finding Tissue Slide Status","preferredDefinition":"The status related to evidence of disease in the tissue section mounted on the normal tissue slide.","longName":"7120778v1.0:7121840v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B946ACA-8967-3A30-E053-F662850A33DB","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"KNABLEJ","dateModified":"2021-08-17","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI. 4/2/20 jk added CPTAC THCA Path Rev CSI.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/7/20 jk created for CPTAC Path Review CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7124742","version":"1","preferredName":"Normal Tissue Segment QC Slide Review Comment Text","preferredDefinition":"A free text field for specifying comments for a particular normal tissue slide as part of the QC review of the tumor biospecimen.","longName":"7120780v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B9442DC-4021-359C-E053-F662850A038C","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"KNABLEJ","dateModified":"2021-08-17","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI.  4/2/20 jk added CPTAC THCA Path Rev CSI.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/7/20 jk created for CPTAC Path Review CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7124752","version":"2","preferredName":"Concordance With Local Pathology Report Indicator","preferredDefinition":"A yes/no response to indicate whether the review of tumor tissue is consistent with the findings of the Local Pathology Report for this case.","longName":"7121826v2.0:3506068v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A476CE70-BF51-251F-E053-F662850AB5F2","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-29","modifiedBy":"COLBERTM","dateModified":"2022-09-09","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI.  5/14/20 jk Released per SME (NGM) review and approval email.  4/29/20 jk versioned to use new DEC version.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/7/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to all tumor types.","administrativeNotes":"8/4/22 Added CSI for CPTAC CHOL Local Path per jk. MR;  8/12/22 Removed incorrect Path Review classifications and replaced with Local Path classifications, per JK.  MR;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7124768","version":"2","preferredName":"Concordance Inconsistent With Local Pathology Report Text","preferredDefinition":"A free text field documenting what findings are not consistent with the Local Pathology Report.","longName":"7121829v2.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A4828ED4-E7DB-4592-E053-F662850AE786","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-30","modifiedBy":"COLBERTM","dateModified":"2022-09-11","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI.  5/14/20 jk Released per SME (NGM) review and approval email.  4/29/20 jk CDE versioned; this CDE is for Path Review CRFs; use CDE 7125117 for Local Path CRFs.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set.  1/7/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to all tumor types.","administrativeNotes":"8/4/22 Added CSI CPTAC CHOL Local Path per jk. MR;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7124778","version":"1","preferredName":"Concordance Reviewing Pathologist Name","preferredDefinition":"The name of the pathologist that inspects and verifies diagnoses and clinical data for consistency with a Pathology Report.","longName":"7121832v1.0:5406151v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B92B334-8197-6E3C-E053-F662850AC720","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"COLBERTM","dateModified":"2022-09-12","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI.  5/14/20 jk per SME review, revised def to remove \"Local\" for consistency with semantics.  4/30/20 jk added CPTAC LGG Path CSI. 1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/7/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7124811","version":"1","preferredName":"Concordance QC Slide Review Date","preferredDefinition":"The date the Tissue Source Sites (TSS) performs a QC review of tumor biospecimen slide.","longName":"7121835v1.0:2018550v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B93AB68-B0B0-25F6-E053-F662850AF326","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"COLBERTM","dateModified":"2022-09-11","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI. 4/30/20 jk added CPTAC LGG Path CSI.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/7/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7124841","version":"1","preferredName":"Tumor Segment Non-Cellular Component Text","preferredDefinition":"A free text field documenting the non-cellular component (includes cytokines, chemokines, complements, and other mediators of inflammation, to the non-cellular component of blood (plasma), or the non-cellular component of body fluids and broncoalveolar lavage fluid) in the tumor segment.","longName":"7119784v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B955A0B-7507-3DA0-E053-F662850AECD3","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-07","modifiedBy":"COLBERTM","dateModified":"2022-09-11","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI. 4/30/20 jk added CPTAC LGG Path CSI. 1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/7/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7124979","version":"1","preferredName":"Tumor Segment Percent Total Cellularity Integer","preferredDefinition":"An integer number between 0 and 100 to capture the percent of total cellularity in the tumor segment.","longName":"7120634v1.0:6847952v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9BA237E7-EEF5-590C-E053-F662850AEBDF","latestVersionIndicator":"Yes","beginDate":"2020-01-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-08","modifiedBy":"COLBERTM","dateModified":"2022-09-11","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI. 4/30/20 jk added CPTAC LGG Path CSI. 1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/8/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7124980","version":"1","preferredName":"Tumor Segment Percent Tumor Cell Nuclei Integer","preferredDefinition":"An integer number between 0 and 100 to capture the percent of tumor cell nuclei in a sample compared to the total number of nuclei in the sample.","longName":"7120640v1.0:6847952v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9BA1D9F6-83AB-5936-E053-F662850A02EC","latestVersionIndicator":"Yes","beginDate":"2020-01-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-08","modifiedBy":"COLBERTM","dateModified":"2022-09-11","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI. 4/30/20 jk added CPTAC LGG Path CSI.   1/29/20 jk added coding instruction from Linda.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/8/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7125037","version":"1","preferredName":"Tumor Segment Percent Immune Cell Nuclei Integer","preferredDefinition":"An integer number between 0 and 100 to capture the percent of immune cell nuclei in a sample compared to the total number of nuclei in the sample.","longName":"7120637v1.0:6847952v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9BA40FA7-FA80-72A6-E053-F662850A59B7","latestVersionIndicator":"Yes","beginDate":"2020-01-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-08","modifiedBy":"ONEDATA","dateModified":"2022-09-08","changeNote":"7/12/21 jk added HNSCC Path Rpt CSI. 5/7/20 jk added LGG CSI. 1/29/20 jk added coding instruction from Linda.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/8/20 jk created for CPTAC Path Review CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7125041","version":"1","preferredName":"Tumor Segment Percent Stromal Cell Nuclei Integer","preferredDefinition":"An integer number between 0 and 100 to capture the percent of stromal cell nuclei in a sample compared to the total number of nuclei in the sample.","longName":"7120643v1.0:6847952v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9BA1A37F-8D65-592E-E053-F662850AE350","latestVersionIndicator":"Yes","beginDate":"2020-01-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-08","modifiedBy":"ONEDATA","dateModified":"2022-09-08","changeNote":"7/12/21 jk added HNSCC Path Rpt CSI. 5/7/20 jk added LGG CSI. 1/29/20 jk added coding instruction from Linda.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/8/20 jk created for CPTAC Path Review CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7125052","version":"1","preferredName":"Tumor Segment Percent Necrotic Surface Area Integer","preferredDefinition":"An integer number between 0 and 100 to capture the percent of the area of tissue surface undergoing necrosis compared to the total tissue area present the sample.","longName":"7120646v1.0:6847952v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9BA3DB66-F99A-7701-E053-F662850A4E71","latestVersionIndicator":"Yes","beginDate":"2020-01-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-08","modifiedBy":"COLBERTM","dateModified":"2022-09-11","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI. 4/30/20 jk added CPTAC LGG Path CSI.  1/29/20 jk added coding instruction from Linda.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/8/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7125098","version":"1","preferredName":"Tissue Slide Greater Than or Equal To Eighty Percent Tumor Cell Nuclei Eligible Histologic Type Indicator","preferredDefinition":"A yes/no response to indicate whether a tumor segment slide meet the acceptance criteria of necrosis ≤20%, total cellularity ≥50%, tumor nuclei ≥80%.","longName":"7120688v1.0:3506068v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9BA49D1D-6A3C-75AA-E053-F662850A0F4A","latestVersionIndicator":"Yes","beginDate":"2020-01-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-08","modifiedBy":"COLBERTM","dateModified":"2022-09-09","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI.  2/12/20 jk CPTAC/Linda approved CDE; AI released, RS chg to Qualified.   1/8/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to BLCA, CESC, LIHC, STAD, UVM tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7125099","version":"1","preferredName":"Tissue Slide Greater Than or Equal To Sixty Percent Tumor Cell Nuclei Eligible Histologic Type Indicator","preferredDefinition":"A yes/no response to indicate whether a tumor segment slide meet the acceptance criteria of necrosis ≤20%, total cellularity ≥50%, tumor nuclei ≥60%.","longName":"7120706v1.0:3506068v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9BA4A7B9-2818-5162-E053-F662850A86F8","latestVersionIndicator":"Yes","beginDate":"2020-01-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-08","modifiedBy":"KNABLEJ","dateModified":"2020-04-09","changeNote":"4/9/20 jk Released per SME review and approval. 1/8/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to CHOL, ESCA, THCA tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7125100","version":"1","preferredName":"Tissue Slide Greater Than or Equal To Twenty Percent Tumor Cell Nuclei Eligible Histologic Type Indicator","preferredDefinition":"A yes/no response to indicate whether a tumor segment slide meet the acceptance criteria of necrosis ≤20%, total cellularity ≥50%, tumor nuclei ≥20%.","longName":"7120717v1.0:3506068v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9BA4B420-A5CC-60B7-E053-F662850AE25F","latestVersionIndicator":"Yes","beginDate":"2020-01-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-08","modifiedBy":"KNABLEJ","dateModified":"2021-07-12","changeNote":"7/12/21 jk added HNSCC Path Rpt CSI in error. 2/13/20 jk RS chg to Qualified.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/8/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to PRAD tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7125101","version":"1","preferredName":"Tissue Slide Zero Percent of Necrosis Greater Than or Equal To Thirty Percent Tumor Cell Nuclei Eligible Histologic Type Indicator","preferredDefinition":"A yes/no response to indicate whether a tumor segment slide meet the acceptance criteria of necrosis 0%, total cellularity ≥50%, tumor nuclei ≥30%.","longName":"7120738v1.0:3506068v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9BA2C4E1-0809-5926-E053-F662850ACE67","latestVersionIndicator":"Yes","beginDate":"2020-01-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-08","modifiedBy":"KNABLEJ","dateModified":"2020-05-14","changeNote":"5/14/20 jk Released per SME (NGM) review and approval email.  4/30/20 jk added CPTAC LGG Path CSI.  1/8/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to LGG tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7125117","version":"1","preferredName":"Tissue Slide Did Not Meet Eligibility Criteria Text","preferredDefinition":"A free text field specifying the findings do not meet the required acceptance criteria for a tumor tissue slide.","longName":"7120741v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9BA4E889-9C22-5CD0-E053-F662850A468F","latestVersionIndicator":"Yes","beginDate":"2020-01-08","endDate":"2020-04-30","createdBy":"KNABLEJ","dateCreated":"2020-01-08","modifiedBy":"COLBERTM","dateModified":"2022-09-11","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI. 7/23/20 jk added BLCA Path Rpt CSI.  7/2/20 jk CESC Path CSIs.  6/14/20 jk added CPTAC ESCA Pathology CSI.  5/13/20 jk added CPTAC UVM CSI.  4/30/20 jk added CPTAC LGG Path CSI. 1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/8/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to BLCA, CESC, LIHC, STAD, UVM tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7125121","version":"1","preferredName":"Tumor Segment QC Slide Review Comment Text","preferredDefinition":"A free text field for specifying comments for a particular tumor slide as part of the QC review of the tumor biospecimen.","longName":"7120744v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9BA52BE7-E163-5975-E053-F662850A8068","latestVersionIndicator":"Yes","beginDate":"2020-01-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-08","modifiedBy":"KNABLEJ","dateModified":"2021-08-17","changeNote":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI. 4/30/20 jk added CPTAC LGG Path CSI.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/8/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7128425","version":"1","preferredName":"Concordance Local Pathology Review Data Entry Performed By Name","preferredDefinition":"The name of the person that inspected and verified the local institution's source data reported in the local pathology review form.","longName":"7128424v1.0:5406151v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9BA62691-ED2B-1438-E053-F662850A9634","latestVersionIndicator":"Yes","beginDate":"2020-01-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-08","modifiedBy":"COLBERTM","dateModified":"2022-09-11","changeNote":"4/30/20 jk added CPTAC LGG Path CSI. 2/13/20 jk RS chg to Qualified 1/23/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/8/20 jk created for CPTAC Local Path CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7135791","version":"1","preferredName":"Central Pathology Review Biospecimen Histologic Grade","preferredDefinition":"The assignment of a position on a scale of quality to describe the microscopic physical features of cells by a central lab using standardized methods and result criteria.","longName":"7135767v1.0:7135768v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9BBC0972-6A8B-49E6-E053-F662850A6936","latestVersionIndicator":"Yes","beginDate":"2020-01-09","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-09","modifiedBy":"KNABLEJ","dateModified":"2020-02-12","changeNote":"2/12/20 jk CPTAC/Linda approved CDE; AI released, RS chg to Qualified.    2/10/20 jk remove Local Path CSI references; Local Path should use CDE 7165774.  1/9/20 jk created for CPTAC Path Rpt CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7153857","version":"1","preferredName":"Metastatic Diagnosis Child-Pugh Classification Category","preferredDefinition":"The rating assigned based on a standardized scale to describe the severity of liver cirrhosis.  It is used to determine the prognosis of metastatic disease and required strength of treatment.","longName":"7115535v1.0:7114290v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9D33F3BD-A7AE-18EA-E053-F662850ACE7C","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-28","modifiedBy":"KNABLEJ","dateModified":"2020-02-14","changeNote":"2/14/20 jk Released per CPTAC SME (Linda) review and approval.  1/28/20 jk created for CPTAC LIHC and CHOL baseline CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7153884","version":"1","preferredName":"Metastatic Diagnosis Risk Factor History Other Specify","preferredDefinition":"A textual description of an individual's attribute, characteristic or exposure that increases the likelihood of developing a disease which is different than the ones previously specified or mentioned.","longName":"7115532v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9D3456DB-EE12-0761-E053-F662850AA2E2","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-28","modifiedBy":"KNABLEJ","dateModified":"2020-02-14","changeNote":"2/14/20 jk Released per CPTAC SME (Linda) review and approval. 1/28/20 jk created for CPTAC CHOL, LIHC and ESCA baseline CRFs..","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7155057","version":"1","preferredName":"Ancillary Study Albumin Level Float","preferredDefinition":"A quantitative measurement of albumin present in a sample determined as part of a secondary study.","longName":"7118696v1.0:6841619v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"9D4913AE-85B6-4A39-E053-F662850A4A70","latestVersionIndicator":"Yes","beginDate":"2020-01-29","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-29","modifiedBy":"KNABLEJ","dateModified":"2020-01-29","changeNote":"1/29/20 jk created for CPTAC CHOL baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7155073","version":"1","preferredName":"Metastatic Diagnosis ISHAK Fibrosis Score Value","preferredDefinition":"A numeric value assigned to indicate the histopathologic degree of liver damage based on a scoring system described by Dr. Ishak.","longName":"7118702v1.0:7114310v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9D4A299E-3C38-4A2B-E053-F662850A1C47","latestVersionIndicator":"Yes","beginDate":"2020-01-29","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-29","modifiedBy":"KNABLEJ","dateModified":"2020-02-14","changeNote":"2/14/20 jk Released per CPTAC SME (Linda) review and approval. 1/29/20 jk created for CPTAC LIHC and CHOL baseline CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7155077","version":"1","preferredName":"Ancillary Study Platelet Count Number","preferredDefinition":"A quantitative measurement of the number of platelets in a sample determined as part of a secondary study.","longName":"7155076v1.0:6631029v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"9D49A2E1-461B-74BA-E053-F662850A5EB6","latestVersionIndicator":"Yes","beginDate":"2020-01-29","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-29","modifiedBy":"KNABLEJ","dateModified":"2020-01-29","changeNote":"1/29/20 jk created for CPTAC CHOL baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7155078","version":"1","preferredName":"Ancillary Study Ki-67 Labeling Index Integer","preferredDefinition":"An integer number between 0 and 100 to capture the percentage of cells in a sample that are dividing as determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody.","longName":"7113142v1.0:6847952v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9D4837C8-C5C7-3CA2-E053-F662850A33D6","latestVersionIndicator":"Yes","beginDate":"2020-01-29","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-29","modifiedBy":"KUMMEROA","dateModified":"2021-07-14","changeNote":"20217-6 ak Added context alt short name. 5/14/20 jk Released per SME (NGM) review and approval email.  4/30/20 jk added CPTAC LGG Path CSI. 1/29/20 jk created for CPTAC LGG baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7165768","version":"1","preferredName":"Local Pathology Review Comment Text","preferredDefinition":"A free text field documenting a specimen based on the local pathology review.","longName":"7165767v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9E2799C5-99F7-5B57-E053-F662850AD18E","latestVersionIndicator":"Yes","beginDate":"2020-02-09","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-09","modifiedBy":"COLBERTM","dateModified":"2022-09-09","changeNote":"4/30/20 jk added CPTAC LGG Path CSI.   2/12/20 jk CPTAC/Linda approved CDE; AI released, RS chg to Qualified.  2/10/19 jk  added CSIs for Local Path CRFs from CDE 7122410.  2/9/20 jk created for CPTAC Local Path Review CRFs; applicable to all tumor types.","administrativeNotes":"9/8/22 Added HNSCC Local Path CS/CSI. mr;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7165771","version":"1","preferredName":"Local Pathology Review Confirmed Histologic Type Indicator","preferredDefinition":"A yes/no indicator response which documents whether the local pathology review of tumor tissue confirm the histologic type to be eligible for the CPTAC study.","longName":"7165770v1.0:3506068v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9E28AD6B-2DA7-5B5F-E053-F662850A36BF","latestVersionIndicator":"Yes","beginDate":"2020-02-09","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-09","modifiedBy":"KNABLEJ","dateModified":"2020-04-30","changeNote":"2/12/20 jk CPTAC/Linda approved CDE; AI released, RS chg to Qualified.  2/9/20 jk created for CPTAC Local Path CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7165774","version":"1","preferredName":"Local Pathology Review Biospecimen Histologic Grade","preferredDefinition":"The assignment of a position on a scale of quality to describe the microscopic physical features of cells by a local lab using standardized methods and result criteria.","longName":"7165773v1.0:7135768v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9E28A05A-E8D6-5B47-E053-F662850AA8F3","latestVersionIndicator":"Yes","beginDate":"2020-02-09","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-09","modifiedBy":"KNABLEJ","dateModified":"2020-07-03","changeNote":"7/2/20 jk added CESC CSI.  6/14/20 jk added CPTAC ESCA Pathology CSI. 2/12/20 jk CPTAC/Linda approved CDE; AI released, RS chg to Qualified.   2/9/20 jk created for CPTAC Local Path ReviewCRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7171860","version":"1","preferredName":"Metastatic Diagnosis Cholangiocarcinoma Risk Factor History Category","preferredDefinition":"An individual's attribute, characteristic or exposure that increases the likelihood of developing metastatic disease that arises from the intrahepatic bile ducts, the hepatic ducts, or the common bile duct distal to the insertion of the cystic duct.","longName":"7115532v1.0:7114227v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9EC9B64F-2815-6756-E053-F662850A8F46","latestVersionIndicator":"Yes","beginDate":"2020-02-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-17","modifiedBy":"COLBERTM","dateModified":"2022-09-19","changeNote":"2/17/20 jk created for CPTAC CHOL baseline CRF.","administrativeNotes":"7/7/22 Added CSI CHOL Local Path. mr; 8/3/22 Added AQT per CRF/spreadsheet. mr; 9/19/22 Released/Qualified per jk; mr;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7171872","version":"1","preferredName":"Metastatic Diagnosis Esophageal Neoplasm Risk Factor History Category","preferredDefinition":"An individual's attribute, characteristic or exposure that increases the likelihood of developing metastatic disease involving the esophagus.","longName":"7115532v1.0:7171862v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9ECC3C32-2629-04D9-E053-F662850A5516","latestVersionIndicator":"Yes","beginDate":"2020-02-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-17","modifiedBy":"KNABLEJ","dateModified":"2020-06-22","changeNote":"6/22/20 jk Released per SME (NGM) review and approval email.  2/14/20 jk created for CPTAC ESCA baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7185575","version":"1","preferredName":"Ancillary Study BRAF Mutation Status Finding Outcome","preferredDefinition":"A secondary study finding based on an examination used to detect and identify mutations in the BRAF gene.","longName":"7185539v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9F81173C-E4F8-62B7-E053-F662850A606A","latestVersionIndicator":"Yes","beginDate":"2020-02-26","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-26","modifiedBy":"KNABLEJ","dateModified":"2020-04-28","changeNote":"4/28/20 jk Released per SME review and approval.  2/27/20 jk created for CPTAC THCA baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7185576","version":"1","preferredName":"Ancillary Study BRAF Rearrangement Status Finding Outcome","preferredDefinition":"A secondary study finding based on an examination used to detect and identify rearrangements involving the BRAF gene.","longName":"7185543v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9F828D54-8B1F-0EDF-E053-F662850A8703","latestVersionIndicator":"Yes","beginDate":"2020-02-26","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-26","modifiedBy":"KNABLEJ","dateModified":"2020-04-28","changeNote":"4/28/20 jk Released per SME review and approval. 2/27/20 jk created for CPTAC THCA baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7185577","version":"1","preferredName":"Ancillary Study HRAS Mutation Status Finding Outcome","preferredDefinition":"A secondary study finding based on an examination used to detect and identify mutations in the HRAS gene.","longName":"7185547v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9F81A9D5-42A1-70BC-E053-F662850A4200","latestVersionIndicator":"Yes","beginDate":"2020-02-26","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-26","modifiedBy":"KNABLEJ","dateModified":"2020-04-28","changeNote":"4/28/20 jk Released per SME review and approval. 2/26/20 jk created for CPTAC THCA baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7185578","version":"1","preferredName":"Ancillary Study KRAS Mutation Status Finding Outcome","preferredDefinition":"A secondary study finding based on an examination used to detect the presence of mutations in the KRAS gene.","longName":"7185550v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9F817C91-E2B0-0E17-E053-F662850A24F9","latestVersionIndicator":"Yes","beginDate":"2020-02-26","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-26","modifiedBy":"KNABLEJ","dateModified":"2020-04-28","changeNote":"4/28/20 jk Released per SME review and approval. 2/26/20 jk created for CPTAC THCA baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7185579","version":"1","preferredName":"Ancillary Study NRAS Mutation Status Finding Outcome","preferredDefinition":"A secondary study finding based on an examination used to detect and identify mutations in the NRAS gene.","longName":"7185554v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9F81A9D5-42CF-70BC-E053-F662850A4200","latestVersionIndicator":"Yes","beginDate":"2020-02-26","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-26","modifiedBy":"KNABLEJ","dateModified":"2020-04-28","changeNote":"4/28/20 jk Released per SME review and approval. 2/26/20 jk created for CPTAC THCA baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7185580","version":"1","preferredName":"Ancillary Study PAX8 Rearrangement Status Finding Outcome","preferredDefinition":"A secondary study finding based on an examination used to detect and identify rearrangements involving the PAX8 gene.","longName":"7185558v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9F80BABC-58D2-1F16-E053-F662850A27A0","latestVersionIndicator":"Yes","beginDate":"2020-02-26","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-26","modifiedBy":"KNABLEJ","dateModified":"2020-04-28","changeNote":"4/28/20 jk Released per SME review and approval.  2/27/20 jk created for CPTAC THCA baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7185600","version":"1","preferredName":"Ancillary Study RET Rearrangement Status Finding Outcome","preferredDefinition":"A secondary study finding based on an examination used to detect and identify rearrangements involving the RET gene.","longName":"7185562v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9F80BABC-5900-1F16-E053-F662850A27A0","latestVersionIndicator":"Yes","beginDate":"2020-02-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-27","modifiedBy":"KNABLEJ","dateModified":"2020-04-28","changeNote":"4/28/20 jk Released per SME review and approval.  2/27/20 jk created for CPTAC THCA baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7185601","version":"1","preferredName":"Ancillary Study BAP1 Mutation Status Finding Outcome","preferredDefinition":"A secondary study finding based on an examination used to detect and identify mutations in the BAP1 gene.","longName":"7185566v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9F81173C-E53A-62B7-E053-F662850A606A","latestVersionIndicator":"Yes","beginDate":"2020-02-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-27","modifiedBy":"KNABLEJ","dateModified":"2020-05-28","changeNote":"5/28/20 jk Re-release post db reload; released 5/20/20 per SME (LH) review and approval email. 2/27/20 jk created for CPTAC UVM baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7185603","version":"1","preferredName":"Ancillary Study GNA11 Mutation Status Finding Outcome","preferredDefinition":"A secondary study finding based on an examination used to detect and identify mutations in the GNA11 gene.","longName":"7185570v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9F83F9EF-252E-27D8-E053-F662850A2F90","latestVersionIndicator":"Yes","beginDate":"2020-02-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-27","modifiedBy":"KNABLEJ","dateModified":"2020-05-28","changeNote":"5/28/20 jk Re-release post db reload; released 5/20/20 per SME (LH) review and approval email.   2/27/20 jk created for CPTAC UVM baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7185604","version":"1","preferredName":"Ancillary Study GNAQ Mutation Status Finding Outcome","preferredDefinition":"A secondary study finding based on a procedure used to detect and identify mutations in the GNAQ gene.","longName":"7185574v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9F81A848-66EC-59C8-E053-F662850A0A12","latestVersionIndicator":"Yes","beginDate":"2020-02-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-27","modifiedBy":"KNABLEJ","dateModified":"2020-07-14","changeNote":"5/28/20 jk Re-release post db reload; released 5/20/20 per SME (LH) review and approval email. 2/27/20 jk created for CPTAC UVM baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7185609","version":"1","preferredName":"Metastatic Diagnosis Adjuvant I-131 Therapy Administered CPTAC Indicator","preferredDefinition":"A response to indicate whether radioiodine therapy was administered with the intent of suppressing secondary tumor formation in the presence of metastatic disease.","longName":"7185608v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9F912683-28B6-187B-E053-F662850AF973","latestVersionIndicator":"Yes","beginDate":"2020-02-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-27","modifiedBy":"JKNABLE","dateModified":"2022-07-29","changeNote":"4/28/20 jk Released per SME review and approval.  2/27/20 jk created for CPTAC THCA baseline CRF.","administrativeNotes":"7/29/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7185686","version":"1","preferredName":"Metastatic Diagnosis First Degree Family History of Thyroid Cancer CPTAC Indicator","preferredDefinition":"An indicator response which documents a family history of thyroid cancer in first degree relatives.","longName":"7185681v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9F93647C-1AFE-124E-E053-F662850ADE93","latestVersionIndicator":"Yes","beginDate":"2020-02-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-27","modifiedBy":"KNABLEJ","dateModified":"2020-04-28","changeNote":"4/28/20 jk Released per SME review and approval.  2/27/20 jk created for CPTAC THCA baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7185687","version":"1","preferredName":"Metastatic Diagnosis History of Radiation Exposure CPTAC  Indicator","preferredDefinition":"An indicator response which documents if a history of radiation exposure.","longName":"7185685v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9F8169B5-710E-0EE3-E053-F662850A9E0B","latestVersionIndicator":"Yes","beginDate":"2020-02-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-27","modifiedBy":"KNABLEJ","dateModified":"2020-04-28","changeNote":"4/28/20 jk Released per SME review and approval.  2/27/20 jk created for CPTAC THCA baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7185804","version":"1","preferredName":"Metastatic Diagnosis Eye Color Type","preferredDefinition":"The color of the iris of the eyes of a  subject with metastatic disease.","longName":"7185803v1.0:7185798v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9FA38A18-8AAF-04BD-E053-F662850A70DD","latestVersionIndicator":"Yes","beginDate":"2020-02-28","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-28","modifiedBy":"KNABLEJ","dateModified":"2020-05-28","changeNote":"5/28/20 jk Re-release post db reload; released 5/20/20 per SME (LH) review and approval email. 5/12/20 jk corrected PQT. 2/28/20 jk created for CPTAC UVM baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7185805","version":"1","preferredName":"Metastatic Diagnosis Eye Color Other Specify","preferredDefinition":"A textual description of the color of the iris of the eye which is different than the ones previously specified or mentioned.","longName":"7185803v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9FA39773-A164-02F4-E053-F662850A1BDA","latestVersionIndicator":"Yes","beginDate":"2020-02-28","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-28","modifiedBy":"KNABLEJ","dateModified":"2020-05-28","changeNote":"5/28/20 jk Re-release post db reload; released 5/20/20 per SME (LH) review and approval email. 2/28/20 jk created for CPTAC UVM baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7185820","version":"1","preferredName":"Tumor Mass Mitotic Count Number","preferredDefinition":"The number of mitoses identified under the microscope in the tumor which was determined based on the number of mitoses per high power field (40X).","longName":"7185807v1.0:6631029v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9FA41312-19A8-28CD-E053-F662850A3A7F","latestVersionIndicator":"Yes","beginDate":"2020-02-28","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-28","modifiedBy":"KNABLEJ","dateModified":"2020-05-28","changeNote":"5/28/20 jk Re-release post db reload; released 5/20/20 per SME (LH) review and approval email. 2/28/20 jk created for CPTAC UVM baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7185821","version":"1","preferredName":"Tumor Mass Infiltrating Lymphocytes Present Category","preferredDefinition":"A term used to describe the level of tumor infiltrating lymphocytes that are present in a tumor.","longName":"7185811v1.0:7185813v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9FA4377B-267A-7F90-E053-F662850A5D28","latestVersionIndicator":"Yes","beginDate":"2020-02-28","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-02-28","modifiedBy":"KNABLEJ","dateModified":"2020-05-28","changeNote":"5/28/20 jk Re-release post db reload; released 5/20/20 per SME (LH) review and approval email. 2/28/20 jk created for CPTAC UVM baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7217378","version":"1","preferredName":"Disability Hearing Difficulty Indicator","preferredDefinition":"A response to indicate whether or not a physical impairment exists that interferes with an individual's auditory faculty, the perception of sound by the ear.","longName":"7217301v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A18D39C9-E402-393B-E053-F662850AEBBB","latestVersionIndicator":"Yes","beginDate":"2020-03-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-23","modifiedBy":"KNABLEJ","dateModified":"2020-06-19","changeNote":"6/19/20 jk Released per SME (NGM) review and approval email.  2/27/20 jk created for CPTAC Consent CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7217422","version":"1","preferredName":"Disability Impaired Vision Or Unable to See Well Enough Even With Correction Indicator","preferredDefinition":"A response to indicate whether or not a physical impairment exists that results in an individual's vision loss not correctable by glasses.","longName":"7217295v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A18E21D7-2AEC-7CD8-E053-F662850AC1FD","latestVersionIndicator":"Yes","beginDate":"2020-03-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-23","modifiedBy":"KNABLEJ","dateModified":"2020-06-19","changeNote":"6/19/20 jk Released per SME (NGM) review and approval email.  2/27/20 jk created for CPTAC Consent CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7217430","version":"1","preferredName":"Disability Have Difficulty Concentrating Or Memory Impairment Indicator","preferredDefinition":"A response to indicate whether or not an impairment exists that results in an individual's memory deficiency or impairment.","longName":"7217298v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A18D6C2D-8E0B-7D19-E053-F662850AAF0E","latestVersionIndicator":"Yes","beginDate":"2020-03-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-23","modifiedBy":"KNABLEJ","dateModified":"2020-06-19","changeNote":"6/19/20 jk Released per SME (NGM) review and approval email.  2/27/20 jk created for CPTAC Consent CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7217431","version":"1","preferredName":"Disability Ability to Walk Up Stairs Difficulty CPTAC Indicator","preferredDefinition":"A response to indicate whether or not an impairment exists that interferes with an individual's ability to perform physical activities such as walking or climbing stairs.","longName":"7217273v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A18E4537-6BB9-09F7-E053-F662850A32ED","latestVersionIndicator":"Yes","beginDate":"2020-03-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-23","modifiedBy":"COLBERTM","dateModified":"2022-06-06","changeNote":"4/13/20 jk remove preceding space in PQT.  2/27/20 jk created for CPTAC Consent CRF.","administrativeNotes":"6/6/22 mr  Released and RS updated to Qualified per CPTAC/Nicollette’s XLS review as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7217432","version":"1","preferredName":"Disability Ability to Run Errands and Shop Difficulty Indicator","preferredDefinition":"A response to indicate whether or not an impairment exists that interferes with an individual's ability to perform errands such as visiting a doctor's office or shopping.","longName":"7217354v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A18D94C7-82DB-67D9-E053-F662850A2E85","latestVersionIndicator":"Yes","beginDate":"2020-03-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-23","modifiedBy":"KNABLEJ","dateModified":"2020-06-19","changeNote":"6/19/20 jk Released per SME (NGM) review and approval email.  2/27/20 jk created for CPTAC Consent CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7217437","version":"1","preferredName":"Disability Personal Care Difficulty Indicator","preferredDefinition":"A response to indicate whether or not an impairment exists that interferes with an individual's ability to perform self-care, such as dressing or bathing.","longName":"7217436v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A18E8B0A-217B-70FB-E053-F662850AB873","latestVersionIndicator":"Yes","beginDate":"2020-03-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-23","modifiedBy":"KNABLEJ","dateModified":"2020-06-19","changeNote":"6/19/20 jk Released per SME (NGM) review and approval email.  2/27/20 jk created for CPTAC Consent CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218812","version":"1","preferredName":"Consent Not Obtained Other Specify","preferredDefinition":"A reason different than the one(s) previously specified describing why consent was not obtained.","longName":"5215899v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A19ABF32-22B4-2D9A-E053-F662850A65DB","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-24","modifiedBy":"KNABLEJ","dateModified":"2020-06-11","changeNote":"6/11/20 jk def upd; released per SME approval.  3/24/20 jk created for CPTAC Consent CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218817","version":"1","preferredName":"Assent CPTAC Participation Obtained Indicator","preferredDefinition":"A response to indicate whether or not consent was obtained to participate in CPTAC.","longName":"7218816v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A1A032C1-00FF-34FE-E053-F662850A1179","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-24","modifiedBy":"KNABLEJ","dateModified":"2020-06-02","changeNote":"6/3/20 jk upd RS. 4/25/20 jk Released per Mathangi 4/31/email. 4/6/20 jk updated to reflect SME review comment.  3/24/20 jk created for CPTAC Consent CRF; incomplete for what is being consented to.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218827","version":"1","preferredName":"Data Collection United States Location Indicator","preferredDefinition":"A response to indicate whether or not the collection is being performed in the United States.","longName":"7218825v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A19BB84B-E92F-36DA-E053-F662850ABA4C","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-24","modifiedBy":"KNABLEJ","dateModified":"2020-06-22","changeNote":"6/22/20 jk Released per SME (NGM) review and approval email.  3/24/20 jk created for CPTAC Consent CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218831","version":"1","preferredName":"Person Geographic Birth Place Country Origin Name","preferredDefinition":"The country in which a person was born.","longName":"7339959v1.0:7217050v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A19BA71C-5E04-2D8E-E053-F662850AAEA4","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-24","modifiedBy":"KNABLEJ","dateModified":"2020-06-19","changeNote":"6/19/20 jk Revised CDE for new DEC per SME review comment for consistency with maternal/paternal questions on CRF; released.  3/24/30 jk created for CPTAC Consent CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218836","version":"1","preferredName":"Person Geographic Birth Place Other Specify","preferredDefinition":"The country different than the one(s) previously specified in which a person was born.","longName":"7339959v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A19ABF32-22E2-2D9A-E053-F662850A65DB","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-24","modifiedBy":"KNABLEJ","dateModified":"2020-06-19","changeNote":"6/19/20 DEC replaced with revised DEC 7339959; CDE released. 3/24/30 jk created for CPTAC Consent CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218838","version":"1","preferredName":"Maternal Grandmother Geographic Birth Place Country Origin Name","preferredDefinition":"The country in which the maternal grandmother was born.","longName":"2789895v1.0:7217050v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A1A0E696-8AA9-34DA-E053-F662850A8763","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-24","modifiedBy":"KNABLEJ","dateModified":"2020-07-26","changeNote":"6/19/20 jk Released per SME (NGM) review and approval email.   3/24/20 jk created for CPTAC Consent CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218842","version":"1","preferredName":"Maternal Grandfather Geographic Birth Place Country Origin Name","preferredDefinition":"The country in which the maternal grandfather was born.","longName":"2789898v1.0:7217050v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A1A123BB-ADB7-2BF8-E053-F662850ADC8E","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-24","modifiedBy":"KNABLEJ","dateModified":"2020-06-19","changeNote":"6/19/20 jk Released per SME (NGM) review and approval email.  3/24/20 jk created for CPTAC Consent CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218843","version":"1","preferredName":"Paternal Grandmother Geographic Birth Place Country Origin Name","preferredDefinition":"The country in which the paternal grandmother was born.","longName":"2789904v1.0:7217050v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A1A135A0-1103-2B86-E053-F662850A56F2","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-24","modifiedBy":"KNABLEJ","dateModified":"2020-06-19","changeNote":"6/19/20 jk Released per SME (NGM) review and approval email.  3/24/30 jk created for CPTAC Consent CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218844","version":"1","preferredName":"Paternal Grandfather Geographic Birth Place Country Origin Name","preferredDefinition":"The country in which the paternal grandfather was born.","longName":"2789901v1.0:7217050v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A1A12F8A-F866-34F6-E053-F662850A1AE9","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-24","modifiedBy":"KNABLEJ","dateModified":"2020-06-19","changeNote":"6/19/20 jk Released per SME (NGM) review and approval email.  3/24/20 jk created for CPTAC Consent CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218849","version":"1","preferredName":"Participant Self-Report Epidemiology Origin Text","preferredDefinition":"Text which describes an individual's perspective or subjective interpretation of their race and/or ethnic origin.","longName":"7218847v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A1A157F2-C3F7-564B-E053-F662850A0E2D","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-24","modifiedBy":"KNABLEJ","dateModified":"2020-06-23","changeNote":"6/22/20 jk Released per SME (NGM) review and approval email.   3/24/20 jk created for CPTAC Consent CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218851","version":"1","preferredName":"Person Gender Sex Type","preferredDefinition":"A person's gender which is based on the assemblage of properties that distinguish people on the basis of their societal roles.","longName":"2200600v3.0:7218850v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A1A12E00-4AC5-32D9-E053-F662850ACF3B","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-24","modifiedBy":"TAYLORT","dateModified":"2021-09-16","changeNote":"2021-3-15 ak Corrected spelling \"with\" to \"which\" in def. 6/22/20 jk Released per SME (NGM) review and approval email. 6/3/20 jk upd PQT to match CRF. 3/24/20 jk created for CPTAC Consent CRF; incomplete for what is being consented to.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218853","version":"1","preferredName":"Person Gender Other Specify","preferredDefinition":"A person's gender different than the one(s) previously specified based on the assemblage of properties that distinguish people on the basis of their societal roles.","longName":"2200600v3.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A1A3DCE5-02B8-5A7C-E053-F662850A20C5","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-24","modifiedBy":"MMADDINENI","dateModified":"2023-07-26","changeNote":"6/22/20 jk Released per SME (NGM) review and approval email.  3/24/20 jk created for CPTAC Consent CRF; incomplete for what is being consented to.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218858","version":"1","preferredName":"Candidate Pediatric Clinical Study CPTAC Indicator","preferredDefinition":"A response to indicate whether or not the candidate participating in the pediatric study.","longName":"7218857v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A1A4119F-ABB9-770D-E053-F662850A293E","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-24","modifiedBy":"KNABLEJ","dateModified":"2020-06-12","changeNote":"6/11/20 jk Released per SME (NGM) review and approval email.   3/24/20 jk created for CPTAC Consent CRF; incomplete for what is being consented to.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218861","version":"1","preferredName":"Consent Form Comment Text","preferredDefinition":"Text which provides a written explanation, observation or additional information explaining relevant information about the individual and their expectations and risks in making a decision about a procedure. This document is presented to and signed by the individual or guardian.","longName":"7218860v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A1A123DE-0414-2BF2-E053-F662850A47B8","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-24","modifiedBy":"KNABLEJ","dateModified":"2020-07-08","changeNote":"7/8/20 jk Released per SME (NGM) review and approval 7/6 email.  6/27/20 jk upd DEC semantics per SME; revised definition. 6/25/20 jk per SME chg to 4000 Char VD.  6/24/20 jk Per SME, revised semantics to broaden comment to include any additional info related to consent process.  3/24/20 jk created for CPTAC Consent CRF","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7222663","version":"1","preferredName":"Disability Reporting Status","preferredDefinition":"A status to indicate whether a candidate's physical, mental, or emotional impairment was captured.","longName":"7221515v1.0:7221511v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A1C711E2-FF54-489A-E053-F662850A2B99","latestVersionIndicator":"Yes","beginDate":"2020-03-26","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-26","modifiedBy":"KNABLEJ","dateModified":"2020-06-19","changeNote":"6/19/20 jk Def upd, CDE released per SME (NGM) review and approval email. 6/3/20 jk upd PQT to match CRF. 3/26/20 jk created for CPTAC Consent CRF; incomplete for what is being consented to.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7231908","version":"1","preferredName":"Metastatic Diagnosis Thyroid Carcinoma Non-Neoplastic Finding Outcome","preferredDefinition":"The clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease of a malignant tumor that arises from the thyroid gland.","longName":"7115529v1.0:7231899v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A2183DBB-9547-0C29-E053-F662850A456E","latestVersionIndicator":"Yes","beginDate":"2020-03-30","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-30","modifiedBy":"KNABLEJ","dateModified":"2020-04-08","changeNote":"4/8/20 jk Rleased per SME review and approval.  4/1/20 jk per CPTAC use same \"None\" PV and CUI from Hepatocellular CRF.  Chg RS to \"Application\".  3/30/20 jk created for CPTAC THCA baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7238944","version":"1","preferredName":"Tumor Mass Thyroid Carcinoma Histologic Type","preferredDefinition":"The type of tissue in which a carcinoma arising from the thyroid gland originated.","longName":"6796606v1.0:7238880v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A253ECD1-1BD3-70F3-E053-F662850AD9DB","latestVersionIndicator":"Yes","beginDate":"2020-04-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-02","modifiedBy":"KNABLEJ","dateModified":"2020-04-27","changeNote":"4/27/20 jk Released per SME 4/8/20 review and approval.  4/2/20 jk  created for CPTAC THCA baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7244879","version":"2","preferredName":"Tissue Source Site Biospecimen Donor Identifier","preferredDefinition":"A non-PHI ID assigned by the Tissue Source Site (TSS), the site of origination, which is used to identify the person who donated blood or tissue samples.","longName":"7318763v1.0:7344497v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A75DB255-3F85-3E04-E053-4EBD850AE9D7","latestVersionIndicator":"Yes","beginDate":"2020-04-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-05","modifiedBy":"KNABLEJ","dateModified":"2021-05-10","changeNote":"4/15/21 jk Added CM, HNSCC, and SAR FU, BSLN CSI. 10/30/20 jk added Normal Tissue CSI.  2020-9-8 ak Added CS/CSI. 8/27/20 jk added Procurement CSI.   7/9/20 jk Released per SME (NGM) review and approval 7/6 email.  6/29/20 jk revised for updated DEC, property semantics changed to reflect the donor of a biospecimen, not transplant donor. Superceded CDE 6770753. Add all new tumor baseline CSIs.  6/5/20 jk clarified DEC and Def to reflect ID associated with donor, not biospecimen.   4/25/20 jk Released per Mathangi. 4/10/20 jk Created for CPTAC Consent CRF. AQT added. AK 2020-5-26","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7245275","version":"1","preferredName":"Tissue Source Site Contract Responsibility Entity Name","preferredDefinition":"The entity responsible for the contract of the reporting Tissue Source Site (TSS).","longName":"7245274v1.0:7245265v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2ED48E3-8F77-37C3-E053-F662850A1BD0","latestVersionIndicator":"Yes","beginDate":"2020-04-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-10","modifiedBy":"KNABLEJ","dateModified":"2020-04-25","changeNote":"4/25/20 jk Released per Mathangi. 4/10/20 jk Created for CPTAC Consent CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7245843","version":"1","preferredName":"Differentiated Thyroid Gland Carcinoma Stage Grouping CPTAC Stage","preferredDefinition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for differentiated thyroid carcinoma.","longName":"7245705v1.0:7245661v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3433F9F-7E83-7C32-E053-F662850AAE6B","latestVersionIndicator":"Yes","beginDate":"2020-04-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-14","modifiedBy":"KNABLEJ","dateModified":"2020-05-12","changeNote":"5/12/20 jk Released per Linda 4/30 email 4/14/20 jk Created for CPTAC THCA Baseline CRF.  CPTAC question combines all possible ages, AJCC ed  8 THCA concepts used for response values.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7245944","version":"1","preferredName":"Initial Pathologic Diagnosis Biopsy Confirmed Prior To Tumor Excision CPTAC Indicator","preferredDefinition":"An indicator response to document whether a biopsy confirmed the initial pathologic diagnosis prior to the surgical removal all or part of a benign or malignant tissue growth.","longName":"7245943v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A3479517-B5E3-1920-E053-F662850A9249","latestVersionIndicator":"Yes","beginDate":"2020-04-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-14","modifiedBy":"KNABLEJ","dateModified":"2021-07-29","changeNote":"6/24/30 upd RS. 5/14/20 jk added CPTAC GBM Baseline CSI.  4/28/20 jk Released per SME review and approval. 4/28/20 jk confirmed CDE applicable to all new tumor type baseline CRFs; added CSIs.  4/14/20 jk created for CPTAC THCA baseline CRF. 4/20/21 classified CM BSLN","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7254061","version":"1","preferredName":"Tissue Slide Preparation Procedure Comment Text","preferredDefinition":"A free text field for specifying comments related to the slide creation process of the tissue segment collected for review.","longName":"7252911v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3CF0104-2824-2278-E053-F662850A2EE8","latestVersionIndicator":"Yes","beginDate":"2020-04-21","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-21","modifiedBy":"KNABLEJ","dateModified":"2020-05-29","changeNote":"5/29/20 jk CDE mods redone due to db rollback. 5/15/20 jk per SME, CDE generalized to support tumor and normal tissue, def mod.  4/21/20 jk created for CPTAC Slide Creation Process CRF; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7263153","version":"1","preferredName":"Metastatic Diagnosis cM Finding Incomplete Checkbox Indicator","preferredDefinition":"A checkbox indicator to designate that staging for the clinical Metastasis (cM) category was incomplete, lacking some necessary part or detail.","longName":"7263148v1.0:2185839v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A436E469-46A3-365F-E053-F662850AA1A4","latestVersionIndicator":"Yes","beginDate":"2020-04-26","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-26","modifiedBy":"KNABLEJ","dateModified":"2021-07-26","changeNote":"7/26/21 jk added Phase 3 CM Baseline CSI.  7/29/20 jk added CESC CSI.  7/22/20 jk added BLCA CSI.  6/24/20 jk added LIHC and CHOL CSIs.  6/14/20 jk added CPTAC ESCA Baseline CSI. 4/28/20 jk DEC generalized to support multiple tumor types; CDE released per SME review and approval.  4/26/20 jk created for CPTAC THCA Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7263158","version":"1","preferredName":"Metastatic Diagnosis pM Finding Incomplete Checkbox Indicator","preferredDefinition":"A checkbox indicator to designate that staging for the pathologic Metastasis (pM) category was incomplete, lacking some necessary part or detail.","longName":"7263152v1.0:2185839v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A436E84A-C965-365B-E053-F662850AD1DC","latestVersionIndicator":"Yes","beginDate":"2020-04-26","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-26","modifiedBy":"KNABLEJ","dateModified":"2021-07-26","changeNote":"7/26/21 jk added Phase 3 CM Baseline CSI.  7/29/20 jk added CESC CSI.   7/22/20 jk added BLCA CSI.  6/24/20 jk Added LIHC ad CHOL CSIs.  6/14/20 jk added CPTAC ESCA Baseline CSI.  4/28/20 jk DEC generalized to support multiple tumor types; CDE released per SME review and approval.   4/26/20 jk created for CPTAC THCA Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7263433","version":"1","preferredName":"Tumor Mass H&E Staining Not Done Checkbox Indicator","preferredDefinition":"A checkbox indicator to designate that Hematoxylin and Eosin (H&E) staining was not performed.","longName":"7263296v1.0:2185839v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A44AE26E-A5A2-4EB2-E053-F662850ACCF1","latestVersionIndicator":"Yes","beginDate":"2020-04-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-27","modifiedBy":"COLBERTM","dateModified":"2022-08-18","changeNote":"7/27/21 jk added Phase 3 CM Baseline CSI.  7/22/20 jk added BLCA CSI.  7/1/20 jk added CESC CSI. 6/23/20 jk added LIHC and CHOL CSIs. 6/14/20 jk added CPTAC ESCA Baseline CSI.   5/13/20 jk added for UVM pending SME approval. 4/28/20 jk Released per SME review and approval.  4/27/20 jk created for CPTAC THCA Baseline CRF.","administrativeNotes":"8/18/22 Added HSNCC Baseline CSI per jk. and spreadsheet. MR;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7267481","version":"1","preferredName":"Concordance With Diagnostic Pathology Report Indicator","preferredDefinition":"A yes/no response to indicate whether the review of tumor tissue is consistent with the findings of the Diagnostic Pathology Report for this case.","longName":"7264867v1.0:3506068v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A4770443-4D23-7618-E053-F662850AC6ED","latestVersionIndicator":"Yes","beginDate":"2020-04-29","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-29","modifiedBy":"COLBERTM","dateModified":"2022-08-12","changeNote":"5/14/20 jk Released per SME (NGM) review and approval email.  4/29/20 jk created for concordance with Diagnostic Path Rpt (rather than Local); used on Local Path CRFs.","administrativeNotes":"8/11/22 Removed CSI for CHOL Local Path per CRF and spreadsheet. MR; 8/12/22 Removed incorrect Local Path classifications and replaced with Path Review per JK. MR;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7267518","version":"1","preferredName":"Concordance Inconsistent With Diagnostic Pathology Report Text","preferredDefinition":"A free text field documenting what findings are not consistent with the Diagnostic Pathology Report.","longName":"7267517v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A476EED6-48EC-25F3-E053-F662850AB455","latestVersionIndicator":"Yes","beginDate":"2020-04-30","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-30","modifiedBy":"COLBERTM","dateModified":"2022-09-12","changeNote":"5/14/20 jk Released per SME (NGM) review and approval email.  4/30/20 jk Created for CPTAC new tumor Local Path CRFs.","administrativeNotes":"8/11/22 Removed CSI CHOL Local Path per CRF and spreadsheet. MR;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7291030","version":"1","preferredName":"Tumor Mass Uveal Melanoma Histologic Type","preferredDefinition":"The type of tissue in which a neoplasm that affects the uvea originated. Uveal melanoma is a representative example.","longName":"6796606v1.0:7185691v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A574030D-1A1B-130E-E053-F662850A0146","latestVersionIndicator":"Yes","beginDate":"2020-05-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-05-12","modifiedBy":"KNABLEJ","dateModified":"2020-05-28","changeNote":"5/28/20 jk Re-release post db reload; released 5/20/20 per SME (LH) review and approval email. 5/13/20 jk added CPTAC UVM CSI. 5/12/20 jk created for CPTAC UVM baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7292253","version":"1","preferredName":"Cell Morphology Percent Uveal Epithelioid Cell Melanoma Integer","preferredDefinition":"The percent of uveal melanoma characterized by the presence of malignant large epithelioid melanocytes.","longName":"7292248v1.0:6847952v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A58D755C-4861-0F9F-E053-F662850A54C3","latestVersionIndicator":"Yes","beginDate":"2020-05-13","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-05-13","modifiedBy":"KNABLEJ","dateModified":"2020-05-28","changeNote":"5/28/20 jk Re-release post db reload; released 5/20/20 per SME (LH) review and approval email. 5/13/20 jk created for CPTAC UVM Pathology CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7292254","version":"1","preferredName":"Cell Morphology Percent Uveal Spindle Cell Melanoma Integer","preferredDefinition":"The percent of uveal melanoma arising from the choroid, ciliary body, or the iris and characterized by the presence of of spindle-shaped melanocytes.","longName":"7292252v1.0:6847952v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A58DF19E-0353-6F71-E053-F662850A756D","latestVersionIndicator":"Yes","beginDate":"2020-05-13","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-05-13","modifiedBy":"KNABLEJ","dateModified":"2020-05-28","changeNote":"5/28/20 jk Re-release post db reload; released 5/20/20 per SME (LH) review and approval email. 5/13/20 jk created for CPTAC UVM Pathology CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7295351","version":"1","preferredName":"Tumor Mass Site Glioblastoma Glioblastoma Anatomic Site","preferredDefinition":"The named locations of a malignant astrocytic tumor (WHO grade IV) which is preferentially located in the cerebral hemispheres of the brain.","longName":"6796604v1.0:7295350v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"A5A37A39-9406-245E-E053-F662850A29FC","latestVersionIndicator":"Yes","beginDate":"2020-05-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-05-14","modifiedBy":"KNABLEJ","dateModified":"2020-05-14","changeNote":"5/14/20 jk created for CPTAC GBM baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7297233","version":"1","preferredName":"Eligibility Criteria Untreated Primary Malignant Neoplasm Study Protocol CPTAC Indicator","preferredDefinition":"A response to indicate whether the candidate meets all eligibility criteria defined in the study protocol for a primary, untreated malignant neoplasm.","longName":"7297232v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A6910D8C-8DB0-373A-E053-4EBD850A2AB2","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"JKNABLE","dateModified":"2022-07-08","changeNote":"6/8/20 jk Released per SME (NGM) review and approval email.","administrativeNotes":"7/8/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7297242","version":"1","preferredName":"Minimum Requirement Peripheral Whole Blood Biospecimen Collection CPTAC Indicator","preferredDefinition":"A response to indicate whether it is likely that the minimum required peripheral whole blood can be collected.","longName":"7297237v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A6917299-1407-6754-E053-4EBD850A3D10","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"JKNABLE","dateModified":"2022-07-29","changeNote":"6/11/20 jk Released per SME (NGM) review and approval email.","administrativeNotes":"7/29/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7297247","version":"1","preferredName":"Adjacent Normal Tissue Biospecimen Collection Indicator","preferredDefinition":"The indicator response as to whether normal adjacent tissue can be collected.","longName":"7297246v1.0:3506036v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A6911761-E89E-3A86-E053-4EBD850A8564","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"KNABLEJ","dateModified":"2020-06-12","changeNote":"6/11/20 jk Released per SME (NGM) review and approval email.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7297254","version":"1","preferredName":"Eligibility Criteria Protocol Approval Malignant Neoplasm CPTAC Indicator","preferredDefinition":"A response to indicate whether the candidate has been or likely to be diagnosed with a protocol approved malignancy.","longName":"7297250v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A691AEED-94E4-659E-E053-4EBD850A9ECD","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"JKNABLE","dateModified":"2022-07-08","changeNote":"6/11/20 jk Released per SME (NGM) review and approval email.","administrativeNotes":"7/8/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7297537","version":"1","preferredName":"Eligibility Criteria Protocol Approval Malignant Neoplasm Pathologic Criterion Verification CPTAC Indicator","preferredDefinition":"A response to indicate whether the protocol approved malignancy will undergo verification to meet the pathologic quality criteria.","longName":"7297257v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A6910D8C-8DE0-373A-E053-4EBD850A2AB2","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"JKNABLE","dateModified":"2022-07-08","changeNote":"6/11/20 jk Released per SME (NGM) review and approval email.","administrativeNotes":"7/8/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7297559","version":"1","preferredName":"No Medical History Exception Skin Basal Cell Carcinoma Malignant Neoplasm CPTAC Indicator","preferredDefinition":"A response to indicate whether the candidate does not have a prior history of malignancies with the exception of basal cell skin cancer.","longName":"7297556v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6910D8C-8E67-373A-E053-4EBD850A2AB2","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"JKNABLE","dateModified":"2022-08-03","changeNote":"6/11/20 jk Released per SME (NGM) review and approval email.","administrativeNotes":"8/3/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7297579","version":"1","preferredName":"No Prior Systemic Therapy For Malignant Neoplasm Administered CPTAC Indicator","preferredDefinition":"A response to indicate whether no prior systemic (chemotherapy or biological) treatment for any malignancy was administered.","longName":"7297573v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A691D865-C1E2-6181-E053-4EBD850AEABD","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"JKNABLE","dateModified":"2022-08-03","changeNote":"6/11/20 jk Released per SME (NGM) review and approval email.","administrativeNotes":"8/3/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7297599","version":"1","preferredName":"No Prior Hormone Therapy For Malignant Neoplasm Administered CPTAC Indicator","preferredDefinition":"A response to indicate whether no prior hormone therapy for any malignancy was administered within the stated timeframe.","longName":"7297593v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A69147CA-C59B-62CE-E053-4EBD850AA7DC","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"JKNABLE","dateModified":"2022-08-03","changeNote":null,"administrativeNotes":"8/3/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7297603","version":"1","preferredName":"No Prior Radiation Therapy For Malignant Neoplasm Administered CPTAC Indicator","preferredDefinition":"A response to indicate whether no prior radiation therapy for any malignancy was administered.","longName":"7297602v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A690F74F-0CAF-33A8-E053-4EBD850A2A4B","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"JKNABLE","dateModified":"2022-08-03","changeNote":"6/11/20 jk Released per SME (NGM) review and approval email.","administrativeNotes":"8/3/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7297608","version":"1","preferredName":"Diagnostic Pathology Report Repository Upload CPTAC Indicator","preferredDefinition":"A response to indicate whether the diagnostic pathology report will be uploaded to a repository.","longName":"7297607v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A69160EE-96DF-3EBE-E053-4EBD850A42B7","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"JKNABLE","dateModified":"2022-07-08","changeNote":"6/11/20 Released per SME approval.","administrativeNotes":"7/8/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7297612","version":"1","preferredName":"Candidate Prior CPTAC Participant Indicator","preferredDefinition":"A response to indicate whether the candidate was a prior CPTAC participant.","longName":"7297611v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A69152CD-18D1-36FD-E053-4EBD850A7CDB","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"JKNABLE","dateModified":"2022-07-08","changeNote":"6/11/20 jk Released per SME (NGM) review and approval email.","administrativeNotes":"7/8/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7297633","version":"1","preferredName":"Biospecimen Pathologic Quality Criteria Verification CPTAC Indicator","preferredDefinition":"A response to indicate whether the biospecimen will undergo verification to meet the pathologic quality criteria.","longName":"7297627v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A69389FD-B148-34F1-E053-4EBD850A52E8","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"JKNABLE","dateModified":"2022-07-08","changeNote":"6/11/20 Released per SME approval.","administrativeNotes":"7/8/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7312568","version":"1","preferredName":"Choroid And Ciliary Body Uveal Melanoma Pathologic CPTAC N Category","preferredDefinition":"Extent of the regional lymph node involvement for choroidal and ciliary body melanoma based on clinical stage information combined with operative findings, and evidence obtained from pathology review when surgery is the first definitive therapy.","longName":"6586423v1.0:7312564v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6BD3F30-A0D9-43E3-E053-4EBD850A341C","latestVersionIndicator":"Yes","beginDate":"2020-05-28","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-05-28","modifiedBy":"KNABLEJ","dateModified":"2020-05-28","changeNote":"5/28/20 jk Re-created post db reload; CPTAC requires N0, and NX in addition to AJCC ed 8 PVs.  Replaced CDE 7284009.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7312569","version":"1","preferredName":"Choroid And Ciliary Body Uveal Melanoma Pathologic CPTAC T Category","preferredDefinition":"Extent of the primary choroidal and ciliary body melanoma based on clinical stage information combined with operative findings, and evidence obtained from pathology review when surgery is the first definitive therapy.","longName":"6586421v1.0:7312562v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6BD4CE5-D817-43C3-E053-4EBD850A997A","latestVersionIndicator":"Yes","beginDate":"2020-05-28","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-05-28","modifiedBy":"KNABLEJ","dateModified":"2020-05-28","changeNote":"5/28/20 jk Re-created post db reload; CPTAC requires N0, and NX in addition to AJCC ed 8 PVs.  Replaced CDE 7284010.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318708","version":"1","preferredName":"CPTAC Case Original Occurrence Identifier","preferredDefinition":"A character identifier within the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC), associating a new tumor event with the case from the same CPTAC donor from which it originated.","longName":"7318707v1.0:6770748v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A758BE0B-FF8A-167C-E053-4EBD850ACB50","latestVersionIndicator":"Yes","beginDate":"2020-06-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-05","modifiedBy":"KNABLEJ","dateModified":"2020-10-14","changeNote":"9/14/2020 jk added CSI, AQT.  2020-9-8 ak Added CS/CSI. 6/11/20 jk added Alt Question text.  6/10/20 jk SME reviewed and approved ; CDE released.  6/10/2020 jk revised def per SME input. 6/5/2020 jk Created per discussion with SME for Consent CRF; this is the original CPTAC Case ID used to link a new tumor case with original/initial case.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318861","version":"1","preferredName":"Metastatic Diagnosis Esophageal Neoplasm Non-Neoplastic Finding Outcome","preferredDefinition":"The clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease of a malignant neoplasm involving the esophagus","longName":"7115529v1.0:7318859v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A783C927-B652-372F-E053-4EBD850A5BC8","latestVersionIndicator":"Yes","beginDate":"2020-06-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-07","modifiedBy":"KNABLEJ","dateModified":"2020-06-22","changeNote":"6/22/20 jk Released per SME (NGM) review and approval email.  6/7/20 jk created for CPTAC ESCA baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318864","version":"1","preferredName":"Tumor Mass Esophageal Histologic Type","preferredDefinition":"The type of tissue in which a malignant neoplasm involving the esophagus originated.","longName":"6796606v1.0:7318857v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A784176C-1466-3713-E053-4EBD850A85B2","latestVersionIndicator":"Yes","beginDate":"2020-06-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-07","modifiedBy":"KNABLEJ","dateModified":"2020-06-22","changeNote":"6/22/20 jk Released per SME (NGM) review and approval email.  6/14/20 jk added CPTAC ESCA Pathology CSI.  6/7/20 jk created for CPTAC ESCA baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318869","version":"1","preferredName":"Ancillary Study If Yes Specify Level Float","preferredDefinition":"A measurement from secondary study data captured as a number that can have its decimal point in any position.","longName":"7318868v1.0:6848361v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A792185E-CE7B-2E3F-E053-4EBD850A6E23","latestVersionIndicator":"Yes","beginDate":"2020-06-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-08","modifiedBy":"KNABLEJ","dateModified":"2020-06-27","changeNote":"6/27/20 jk Released per SME (NGM) review and approval.   6/24/20 jk Updated for CPTAC LIHC baseline v1.03 CRF revision.  6/8/2020 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7330130","version":"1","preferredName":"Esophageal Neoplasm Pathologic AJCC Edition 8 T Category","preferredDefinition":"Extent of the malignant neoplasm involving the esophagus based on clinical stage information combined with operative findings, and evidence obtained from pathology review when surgery is the first definitive therapy, using AJCC Ed. 8 criteria.","longName":"7320538v1.0:6437843v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A7C3A73B-3BCC-6F81-E053-4EBD850AB432","latestVersionIndicator":"Yes","beginDate":"2020-06-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-11","modifiedBy":"KNABLEJ","dateModified":"2020-06-22","changeNote":"6/22/20 jk Released per SME (NGM) review and approval email.  6/10/20 jk created for CPTAC ESCA Baseline CRF - generalized AJCC 3 subtype levels.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7331582","version":"1","preferredName":"Esophageal Neoplasm Pathologic AJCC Edition 8 N Category","preferredDefinition":"Extent of the regional lymph node involvement of the malignant neoplasm involving the esophagus based on clinical stage information combined with operative findings, and evidence obtained from pathology review when surgery is the first definitive therapy, using AJCC Ed. 8 criteria.","longName":"7329956v1.0:6437882v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A7E59FD9-17EE-4319-E053-4EBD850A29CE","latestVersionIndicator":"Yes","beginDate":"2020-06-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-12","modifiedBy":"KNABLEJ","dateModified":"2020-06-22","changeNote":"6/22/20 jk Released per SME (NGM) review and approval email.  6/11/20 jk created for CPTAC ESCA Baseline CRF - generalized AJCC 3 subtype levels.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7331626","version":"1","preferredName":"Esophageal Neoplasm Pathologic AJCC Edition 8 M Category","preferredDefinition":"Extent of the distant metastasis of the malignant neoplasm involving the esophagus based on  clinical stage information combined with operative findings, and evidence obtained from pathology review when surgery is the first definitive therapy, using AJCC Ed. 8 criteria.","longName":"7329958v1.0:6437951v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A7E790C7-8DD0-09DC-E053-4EBD850A796B","latestVersionIndicator":"Yes","beginDate":"2020-06-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-12","modifiedBy":"KNABLEJ","dateModified":"2020-06-22","changeNote":"6/22/20 jk Released per SME (NGM) review and approval email.  6/11/20 jk created for CPTAC ESCA Baseline CRF - generalized AJCC 3 subtype levels.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7331628","version":"1","preferredName":"Esophageal Neoplasm Clinical AJCC Edition 8 M Category","preferredDefinition":"Extent of the distant metastasis of the malignant neoplasm involving the esophagus based on  information obtained from the date of cancer diagnosis until the start of definitive treatment, or within four months (whichever is shorter), using AJCC Ed. 8 criteria.","longName":"7329961v1.0:6437951v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A7E59FD9-1885-4319-E053-4EBD850A29CE","latestVersionIndicator":"Yes","beginDate":"2020-06-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-12","modifiedBy":"KNABLEJ","dateModified":"2020-06-22","changeNote":"6/22/20 jk Released per SME (NGM) review and approval email.   6/11/20 jk created for CPTAC ESCA Baseline CRF - generalized AJCC 3 subtype levels.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7331629","version":"1","preferredName":"Esophageal Neoplasm Pathologic Stage Grouping CPTAC Stage","preferredDefinition":"Stage group based on the combination of T, N, and M categories and relevant prognostic factors for the malignant neoplasm involving the esophagus.","longName":"7329968v1.0:7331798v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A7E59FD9-18B3-4319-E053-4EBD850A29CE","latestVersionIndicator":"Yes","beginDate":"2020-06-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-12","modifiedBy":"KNABLEJ","dateModified":"2020-06-22","changeNote":"6/22/20 jk Released per SME (NGM) review and approval email.  6/14/20 jk upd VD adding histologic type to PV.  6/12/20 jk created for CPTAC ESCA Baseline CRF - generalized AJCC 3 subtype levels.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7332103","version":"1","preferredName":"Tumor Mass Cervical Neoplasm Histologic Type","preferredDefinition":"The type of tissue in which a malignant neoplasm involving the cervix originated.","longName":"6796606v1.0:7332089v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A825C1DC-B348-4DE2-E053-4EBD850AC776","latestVersionIndicator":"Yes","beginDate":"2020-06-15","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-15","modifiedBy":"KNABLEJ","dateModified":"2020-07-29","changeNote":"7/29/20 jk Released per SME (NGM) review and approval email. 6/15/20 jk created for CPTAC CESC baseline, path review and local path CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7332404","version":"1","preferredName":"Metastatic Diagnosis Menopause Status Indicator","preferredDefinition":"An indicator of the current status of menopause for a female subject with metastatic disease.","longName":"7332254v1.0:7332114v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A8345E20-E18E-4DEE-E053-4EBD850AA90B","latestVersionIndicator":"Yes","beginDate":"2020-06-16","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-16","modifiedBy":"KNABLEJ","dateModified":"2020-07-29","changeNote":"7/29/20 jk Released per SME (NGM) review and approval email.  6/16/20 jk created for CPTAC CESC Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7342481","version":"1","preferredName":"Ancillary Study Prothrombin Time CPTAC Indicator","preferredDefinition":"A response to indicate whether or not the prothrombin time for the sample was provided as part of a secondary study data.","longName":"7118661v1.0:7339794v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A8D880BB-84B8-16F3-E053-4EBD850AB22B","latestVersionIndicator":"Yes","beginDate":"2020-06-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-24","modifiedBy":"KNABLEJ","dateModified":"2020-07-09","changeNote":"7/9/20 jk Released per SME (NGM) review and approval 7/6 email. 6/24/20 jk Created for updated CPTAC LIHC baseline v1.03 CRF; replaced CDE 7155070.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7342557","version":"1","preferredName":"Ancillary Study AFP Level CPTAC Indicator","preferredDefinition":"A response to indicate whether or not the the alpha-fetoprotein level for the sample was provided as part of a secondary study data.","longName":"7118694v1.0:7339794v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A8DA3B67-20AB-0667-E053-4EBD850A7B8D","latestVersionIndicator":"Yes","beginDate":"2020-06-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-24","modifiedBy":"KNABLEJ","dateModified":"2020-07-09","changeNote":"7/9/20 jk Released per SME (NGM) review and approval 7/6 email. 6/24/20 jk created for updated CPTAC LIHC baseline v1.03 CRF; replaced CDE 7155054.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7342561","version":"1","preferredName":"Ancillary Study Total Bilirubin Level CPTAC Indicator","preferredDefinition":"A response to indicate whether or not the total amount of bilirubin present in a sample was provided as part of a secondary study data.","longName":"7118657v1.0:7339794v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A8DA67DE-8D4F-67C3-E053-4EBD850AF2FD","latestVersionIndicator":"Yes","beginDate":"2020-06-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-24","modifiedBy":"KNABLEJ","dateModified":"2020-07-09","changeNote":"7/9/20 jk Released per SME (NGM) review and approval 7/6 email.   6/24/20 jk created for updated CPTAC LIHC baseline v1.03 CRF; replaced CDE 7155072.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7342562","version":"1","preferredName":"Ancillary Study Creatinine Level CPTAC Indicator","preferredDefinition":"A response to indicate whether or not the quantitative measurement of creatinine in a sample was provided as part of a secondary study data.","longName":"7118664v1.0:7339794v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A8DA8F61-6A4C-6930-E053-4EBD850AA352","latestVersionIndicator":"Yes","beginDate":"2020-06-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-24","modifiedBy":"KNABLEJ","dateModified":"2020-07-09","changeNote":"7/9/20 jk Released per SME (NGM) review and approval 7/6 email.  6/24/20 jk created for updated CPTAC LIHC baseline v1.03 CRF; replaced CDE 7155069.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7342599","version":"1","preferredName":"Ancillary Study If Yes Specify Unit of Measure Text","preferredDefinition":"A textual description of the unit of measure for a measurement from secondary study data.","longName":"7339858v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A8DA8F61-6AA1-6930-E053-4EBD850AA352","latestVersionIndicator":"Yes","beginDate":"2020-06-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-24","modifiedBy":"COLBERTM","dateModified":"2022-07-11","changeNote":"7/9/20 jk Released per SME (NGM) review and approval 7/6 email.   6/24/20 jk Updated for CPTAC LIHC baseline v1.03 CRF revision.","administrativeNotes":"7/11/22 Updated definition per spreadsheet from JK. MR","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7342870","version":"1","preferredName":"Ancillary Study If Yes Specify Prothrombin Time Float","preferredDefinition":"A measurement from secondary study data capturing the clotting time of plasma recalcified in the presence of excess tissue thromboplastin in seconds.","longName":"7342494v1.0:6848361v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A8DB700A-7E13-6B8F-E053-4EBD850AF7B7","latestVersionIndicator":"Yes","beginDate":"2020-06-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-24","modifiedBy":"KNABLEJ","dateModified":"2020-07-09","changeNote":"7/9/20 jk Released per SME (NGM) review and approval 7/6 email.  6/24/20 jk Created for CPTAC LIHC baseline v1.03 CRF revision.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7344503","version":"1","preferredName":"Tissue Source Site Organizational Unit Name","preferredDefinition":"The name of the clinical site that collects and provides patient samples and clinical metadata for research use.","longName":"7344502v1.0:6770741v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A93B3652-BE05-12ED-E053-4EBD850ACB72","latestVersionIndicator":"Yes","beginDate":"2020-06-29","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-29","modifiedBy":"KNABLEJ","dateModified":"2021-05-10","changeNote":"4/15/21 jk Added CM, HNSCC, and SAR FU, BSLN CSI.   2020-9-8 ak Added AQT/CS/CSI.  8/27/20 jk added Procurement CSI.  7/9/20 jk Released per SME (NGM) review and approval 7/6 email.   6/29/20 jk  New CDE, replaced/superceded CDE 6770752 to reflect TSS organization name ID, not biospecimen ID. 4/14/20 jk Released per Mathangi. 4/6/20 jk CDE versioned for new DEC using CPTAC term for TSS. 2/12/20 jk \"TSS\" AQT for LIHC Baseline added.  11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  6/11/19 jk added CSIs for 11 CPTAC Baseline CRFs. 5/28/19 jk created for CPTAC Medical History CRF","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7346787","version":"1","preferredName":"Metastatic Diagnosis Use of Hormonal Contraceptives Indicator","preferredDefinition":"The current status of an individual with metastatic disease with regards to contraceptive use.","longName":"7332265v1.0:7332121v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A9609F3B-3B6A-551A-E053-4EBD850A9745","latestVersionIndicator":"Yes","beginDate":"2020-07-01","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-01","modifiedBy":"KNABLEJ","dateModified":"2020-07-29","changeNote":"7/29/20 jk Released per SME (NGM) review and approval email.   7/1/20 jk created for CPTAC CESC Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7346788","version":"1","preferredName":"Metastatic Diagnosis Number of Pregnancies Count","preferredDefinition":"A measurement of the total number of pregnancy events experienced by the female subject with metastatic disease.","longName":"7332275v1.0:7001795v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A9609F3B-3B98-551A-E053-4EBD850A9745","latestVersionIndicator":"Yes","beginDate":"2020-07-01","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-01","modifiedBy":"KNABLEJ","dateModified":"2020-07-28","changeNote":"7/28/20 jk Released per SME (NGM) review and approval email. 7/1/20 jk created for CPTAC CESC Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7346803","version":"1","preferredName":"Metastatic Diagnosis HIV Status Finding Outcome","preferredDefinition":"A finding following an examination or observation looking for the presence of the human immunodeficiency virus (HIV) in an individual with metastatic disease.","longName":"7332278v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A9625D01-34BB-0AED-E053-4EBD850AD23C","latestVersionIndicator":"Yes","beginDate":"2020-07-01","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-01","modifiedBy":"KNABLEJ","dateModified":"2020-07-28","changeNote":"7/28/20 jk Released per SME (NGM) review and approval email. 7/1/20 jk created for CPTAC CESC Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7346809","version":"1","preferredName":"Ancillary Study HPV Risk DNA Test Category","preferredDefinition":"The risk sub-type assigned based on a secondary study laboratory test in which cells scraped from the cervix are looked at for DNA of human papillomaviruses (HPV).","longName":"7332286v1.0:7332202v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A962AF68-1C76-5510-E053-4EBD850A8B14","latestVersionIndicator":"Yes","beginDate":"2020-07-01","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-01","modifiedBy":"KNABLEJ","dateModified":"2020-07-28","changeNote":"7/28/20 jk Released per SME (NGM) review and approval email. 7/2/20 jk created for CPTAC CESC Baseline and Path CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7346810","version":"1","preferredName":"Ancillary Study HPV Risk Other Specify","preferredDefinition":"The risk sub-type different than the ones previously specified based on a secondary study laboratory test in which cells scraped from the cervix are looked at for DNA of human papillomaviruses (HPV).","longName":"7332286v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A960E0B2-BDBD-551C-E053-4EBD850AC175","latestVersionIndicator":"Yes","beginDate":"2020-07-01","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-01","modifiedBy":"KNABLEJ","dateModified":"2020-07-28","changeNote":"7/28/20 jk Released per SME (NGM) review and approval email. 7/2/20 jk created for CPTAC CESC Baseline and Path CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7346811","version":"1","preferredName":"Ancillary Study HPV Typing Method Other Specify","preferredDefinition":"The method different than the ones previously specified used in a secondary study to perform human papillomavirus (HPV) genotyping.","longName":"7332294v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A9603C5A-8E14-5514-E053-4EBD850A6E97","latestVersionIndicator":"Yes","beginDate":"2020-07-01","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-01","modifiedBy":"KNABLEJ","dateModified":"2020-07-28","changeNote":"7/28/20 jk Released per SME (NGM) review and approval email. 7/1/20 jk created for CPTAC CESC Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7346812","version":"1","preferredName":"Ancillary Study HPV Typing Method Type","preferredDefinition":"The method used in a secondary study to perform human papillomavirus (HPV) genotyping.","longName":"7332294v1.0:7332237v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A962FCD0-3253-0B8F-E053-4EBD850A0BD5","latestVersionIndicator":"Yes","beginDate":"2020-07-01","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-01","modifiedBy":"KNABLEJ","dateModified":"2020-07-28","changeNote":"7/28/20 jk Released per SME (NGM) review and approval email. 7/1/20 jk created for CPTAC CESC Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7346813","version":"1","preferredName":"Ancillary Study HPV Genotype Text","preferredDefinition":"A secondary study result specifying the genotype determined by  human papillomaviruses (HPV) DNA testing.","longName":"7332400v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A962AF68-1CA7-5510-E053-4EBD850A8B14","latestVersionIndicator":"Yes","beginDate":"2020-07-01","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-01","modifiedBy":"KNABLEJ","dateModified":"2020-07-28","changeNote":"7/28/20 jk Released per SME (NGM) review and approval email. 7/2/20 jk created for CPTAC CESC Baseline and Path CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7351747","version":"1","preferredName":"Ancillary Study ESR1 Status by Immunohistochemistry Finding Outcome","preferredDefinition":"A secondary study result providing an indication that expression or absence of ESR1 in a sample was determined using immunohistochemical staining techniques.","longName":"7351237v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AA67A02F-4811-310E-E053-4EBD850A02B6","latestVersionIndicator":"Yes","beginDate":"2020-07-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-14","modifiedBy":"KNABLEJ","dateModified":"2020-07-31","changeNote":"7/31/20 jk Released per SME (NGM) review and approval email.  7/14/20 jk created for CPTAC BLCA baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7351781","version":"1","preferredName":"Ancillary Study ESR2 Status by Immunohistochemistry Finding Outcome","preferredDefinition":"A secondary study result providing an indication that expression or absence of ESR2 in a sample was determined using immunohistochemical staining techniques.","longName":"7351275v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AA67C27E-2037-33F4-E053-4EBD850A0B88","latestVersionIndicator":"Yes","beginDate":"2020-07-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-14","modifiedBy":"KNABLEJ","dateModified":"2020-07-31","changeNote":"7/31/20 jk Released per SME (NGM) review and approval email.  7/14/20 jk created for CPTAC BLCA baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7351809","version":"1","preferredName":"Ancillary Study AR Status by Immunochemistry Finding Outcome","preferredDefinition":"A secondary study result providing an indication that expression or absence of AR in a sample was determined using immunohistochemical staining techniques.","longName":"7351285v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AA67A02F-483F-310E-E053-4EBD850A02B6","latestVersionIndicator":"Yes","beginDate":"2020-07-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-14","modifiedBy":"KNABLEJ","dateModified":"2020-07-31","changeNote":"7/31/20 jk Released per SME (NGM) review and approval email. 7/14/20 jk created for CPTAC BLCA baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7351838","version":"1","preferredName":"Ancillary Study ERBB2 HER2 Mutation Status Finding Outcome","preferredDefinition":"A secondary study result based on a procedure used to detect and identify mutations in the ERBB2/HER2 gene.","longName":"7351297v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AA697D15-2145-241D-E053-4EBD850A227F","latestVersionIndicator":"Yes","beginDate":"2020-07-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-14","modifiedBy":"KNABLEJ","dateModified":"2020-07-31","changeNote":"7/31/20 jk Released per SME (NGM) review and approval email.  7/14/20 jk created for CPTAC BLCA baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7351842","version":"1","preferredName":"Ancillary Study FGFR1 Mutation Status Finding Outcome","preferredDefinition":"A secondary study result based on a procedure used to detect and identify mutations in the FGFR1 gene.","longName":"7351304v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AA67AF56-BB83-37FD-E053-4EBD850ADCED","latestVersionIndicator":"Yes","beginDate":"2020-07-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-14","modifiedBy":"KNABLEJ","dateModified":"2020-08-01","changeNote":"7/31/20 jk Released per SME (NGM) review and approval email.  7/14/20 jk created for CPTAC BLCA baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7351845","version":"1","preferredName":"Ancillary Study FGFR2 Mutation Status Finding Outcome","preferredDefinition":"A secondary study result based on a procedure used to detect and identify mutations in the FGFR2 gene.","longName":"7351308v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AA69AA1B-D611-225A-E053-4EBD850AD080","latestVersionIndicator":"Yes","beginDate":"2020-07-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-14","modifiedBy":"KNABLEJ","dateModified":"2020-08-01","changeNote":"7/31/20 jk Released per SME (NGM) review and approval email.  7/14/20 jk created for CPTAC BLCA baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7351846","version":"1","preferredName":"Ancillary Study FGFR3 Mutation Status Finding Outcome","preferredDefinition":"A secondary study result based on a procedure used to detect and identify mutations in the FGFR3 gene.","longName":"7351312v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AA67DD8A-F8C4-380E-E053-4EBD850A6F30","latestVersionIndicator":"Yes","beginDate":"2020-07-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-14","modifiedBy":"KNABLEJ","dateModified":"2020-08-01","changeNote":"7/31/20 jk Released per SME (NGM) review and approval email.  7/14/20 jk created for CPTAC BLCA baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7351847","version":"1","preferredName":"Ancillary Study FGFR1 Rearrangement Status Finding Outcome","preferredDefinition":"A secondary study result based on a procedure used to detect and identify rearrangements involving the FGFR1 gene.","longName":"7351324v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AA67A02F-48A2-310E-E053-4EBD850A02B6","latestVersionIndicator":"Yes","beginDate":"2020-07-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-14","modifiedBy":"KNABLEJ","dateModified":"2020-08-01","changeNote":"7/31/20 jk Released per SME (NGM) review and approval email.  7/14/20 jk created for CPTAC BLCA baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7351848","version":"1","preferredName":"Ancillary Study FGFR2 Rearrangement Status Finding Outcome","preferredDefinition":"A secondary study result based on a procedure used to detect and identify rearrangements involving the FGFR2 gene.","longName":"7351328v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AA69EBFD-99AD-21AE-E053-4EBD850A5FB3","latestVersionIndicator":"Yes","beginDate":"2020-07-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-14","modifiedBy":"KNABLEJ","dateModified":"2020-08-01","changeNote":"7/31/20 jk Released per SME (NGM) review and approval email.   7/14/20 jk created for CPTAC BLCA baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7351869","version":"1","preferredName":"Ancillary Study FGFR3 Rearrangement Status Finding Outcome","preferredDefinition":"A secondary study result based on a procedure used to detect and identify rearrangements involving the FGFR3 gene.","longName":"7351332v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AA67DD8A-F8F2-380E-E053-4EBD850A6F30","latestVersionIndicator":"Yes","beginDate":"2020-07-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-14","modifiedBy":"KNABLEJ","dateModified":"2020-08-01","changeNote":"7/31/20 jk Released per SME (NGM) review and approval email.  7/14/20 jk created for CPTAC BLCA baseline CRF; use term syn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7352216","version":"1","preferredName":"Tumor Mass Bladder Neoplasm Histologic Type","preferredDefinition":"The type of tissue in which a malignant neoplasm involving the bladder originated.","longName":"6796606v1.0:7351874v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AA6C2FC3-03AE-5B75-E053-4EBD850A5A87","latestVersionIndicator":"Yes","beginDate":"2020-07-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-14","modifiedBy":"KNABLEJ","dateModified":"2020-07-31","changeNote":"7/31/20 jk Released per SME (NGM) review and approval email.  7/22/20 jk added BLCA Path CSIs.  7/14/20 jk created for CPTAC BLCA baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7359925","version":"1","preferredName":"Tumor Mass Muscle Invasion CPTAC Indicator","preferredDefinition":"An indicator response documenting whether a morphologic finding indicating the presence of a malignant cellular infiltrate invading muscle in a tissue sample.","longName":"7359899v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAE2CCBD-FF50-6EFD-E053-4EBD850A1E6C","latestVersionIndicator":"Yes","beginDate":"2020-07-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-07-20","modifiedBy":"KNABLEJ","dateModified":"2020-07-31","changeNote":"7/31/20 jk Released per SME (NGM) review and approval email.  7/23/20 jk added BLCA Path CSIs.  7/20/20 jk created for CPTAC BLCA baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7409391","version":"1","preferredName":"Blood Product Collection Minimum Required Peripheral Blood Indicator","preferredDefinition":"A response to indicate whether or not the minimum amount of blood drawn from a limb was collected.","longName":"7409390v1.0:3506068v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"ADDEB0A1-15B0-2C08-E053-4EBD850A3F83","latestVersionIndicator":"Yes","beginDate":"2020-08-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-27","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval.  8/27/20 jk created for solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7409539","version":"1","preferredName":"Surgical Tumor Tissue Anticipated CPTAC Neoplasm Type","preferredDefinition":"The anticipated CPTAC tissue type assigned to a malignant neoplasm sample that was surgically removed from an organ.","longName":"7409538v1.0:7385481v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"ADE3D055-FD28-5509-E053-4EBD850AF2F8","latestVersionIndicator":"Yes","beginDate":"2020-08-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-27","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 10/8/20 jk replaced system generated definition.  8/27/20 jk created for solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7409540","version":"1","preferredName":"Surgical Tumor Tissue Anticipated CPTAC Neoplasm Other Specify","preferredDefinition":"An explanation different than the one(s) previously specified of the anticipated CPTAC tissue type assigned to a malignant neoplasm sample that was surgically removed from an organ.","longName":"7409538v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"ADE3DB76-419D-5505-E053-4EBD850AD0D3","latestVersionIndicator":"Yes","beginDate":"2020-08-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-27","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 10/8/20 jk replaced system generated definition.  8/27/20 jk created for solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7410645","version":"1","preferredName":"New Donor Primary Tumor CPTAC Indicator","preferredDefinition":"A response to indicate whether or not a new CPTAC donor is contributing a tumor from the original site of disease origin.","longName":"7409272v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE2CCADD-B7D2-2128-E053-4EBD850AB04E","latestVersionIndicator":"Yes","beginDate":"2020-08-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-31","modifiedBy":"KUMMEROA","dateModified":"2020-11-12","changeNote":"11/12/20 AK Updated def per SME (NGM) comment; released per SME approval email.  2020-9-8 ak Added CS/CSI.  8/31/20 jk created for solid tumor and AML procurement CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412282","version":"1","preferredName":"Bone Marrow Aspirate Collection Performed Indicator","preferredDefinition":"A response to indicate whether or not a bone marrow aspirate collection was performed.","longName":"7412281v1.0:3506068v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE61512B-80AD-0C4B-E053-4EBD850AF823","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-03","modifiedBy":"KUMMEROA","dateModified":"2020-11-12","changeNote":"11/12/20 AK Released per SME approval email.  Created for CPTAC AML Specimen Procurement Form.  2020-9-3 AK","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412286","version":"1","preferredName":"Peripheral Blood Collection Performed Indicator","preferredDefinition":"A response to indicate whether or not a peripheral blood collection was performed.","longName":"7412285v1.0:3506068v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE61512B-80DB-0C4B-E053-4EBD850AF823","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-03","modifiedBy":"KUMMEROA","dateModified":"2020-11-12","changeNote":"2020-11-12 ak Released per SME approval email.  Created for CPTAC AML Specimen Procurement Form. AK 2020-9-3","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412327","version":"1","preferredName":"Bone Marrow Or Peripheral Blood Specimen Not Collected Reason","preferredDefinition":"An indication of why the bone marrow or peripheral blood was not collected.","longName":"7412289v1.0:7412324v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE695BEB-B73E-5BDA-E053-4EBD850A8668","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-03","modifiedBy":"KUMMEROA","dateModified":"2020-11-13","changeNote":"11/13/20 AK Updated def per SME (NGM) comment; released per SME approval email.  Created for CPTAC AML Specimen Procurement Form. 2020-9-3 AK","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412330","version":"1","preferredName":"Bone Marrow Or Peripheral Blood Specimen Not Collected Other Specify","preferredDefinition":"A textual description of the reason bone marrow or peripheral blood was not collected which is different than the ones previously specified.","longName":"7412289v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE6989A8-BD71-0646-E053-4EBD850A4EB4","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-03","modifiedBy":"KNABLEJ","dateModified":"2021-01-11","changeNote":"1/11/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 11/12/20 AK Updated def per SME (NGM) comment.  Created for CPTAC AML Specimen Procurement Form. 2020-9-3 AK","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412336","version":"1","preferredName":"Bone Marrow Aspirate Tube Collected Number","preferredDefinition":"The number of bone marrow aspirate tubes collected.","longName":"7412333v1.0:7412335v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE54A958-A772-7403-E053-4EBD850ACF24","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-03","modifiedBy":"KUMMEROA","dateModified":"2020-11-13","changeNote":"2020-11-12 ak Released per SME approval email. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-3","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412412","version":"1","preferredName":"Bone Marrow Aspirate Specimen CPTAC Identifier","preferredDefinition":"The CPTAC specimen identifier of the bone marrow aspirate.","longName":"7412411v1.0:7121849v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE6AF5B4-4BDF-3D49-E053-4EBD850AA183","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-03","modifiedBy":"KUMMEROA","dateModified":"2020-11-12","changeNote":"2020-11-12 ak Released per SME approval email. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-3","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412420","version":"1","preferredName":"Bone Marrow Aspirate Slide CPTAC Biospecimen Identifier","preferredDefinition":"The CPTAC specimen identifier of the bone marrow aspirate slide.","longName":"7412416v1.0:7121849v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE6B1D6E-FDC1-46E0-E053-4EBD850AF14F","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-03","modifiedBy":"KUMMEROA","dateModified":"2020-11-16","changeNote":"2020-11-12 ak Released per SME approval email. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-3","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412450","version":"1","preferredName":"Bone Marrow Aspirate Volume Measurement  Milliliter Value","preferredDefinition":"The numeric milliliter volume of the bone marrow aspirate.","longName":"7412449v1.0:2823505v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE695BEB-B866-5BDA-E053-4EBD850A8668","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-03","modifiedBy":"KUMMEROA","dateModified":"2020-11-12","changeNote":"2020-11-12 ak Released per SME approval email. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-3","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412470","version":"1","preferredName":"Bone Marrow Aspirate Cell Count Instrument Text","preferredDefinition":"A free text field describing the type of instrument used for counting cells in the bone marrow aspirate.","longName":"7412468v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE6CB793-7D53-2669-E053-4EBD850A77E5","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-03","modifiedBy":"KUMMEROA","dateModified":"2020-11-12","changeNote":"2020-11-12 ak Released per SME approval email. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-3","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412494","version":"1","preferredName":"Bone Marrow Aspirate Comment Text","preferredDefinition":"A free text field to provide additional information regarding the specified tube of the bone marrow collection.","longName":"7412488v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE6CED1C-D045-43C0-E053-4EBD850A219B","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-03","modifiedBy":"KNABLEJ","dateModified":"2021-01-11","changeNote":"1/11/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 11/12/20 AK Updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-3","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412504","version":"1","preferredName":"Blood Specimen Tube Collected Number","preferredDefinition":"The number of blood specimen tubes collected.","longName":"7502582v1.0:7412335v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE6CBDDA-BEAA-27C9-E053-4EBD850A692A","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-03","modifiedBy":"KNABLEJ","dateModified":"2021-01-11","changeNote":"1/11/21 jk  Released, upd Reg Status per SME (NGM) review and approval.  9-3-20 jk added Solid Tumor Procurement CSI.   2020-9-3 AK Created for CPTAC AML Specimen Procurement Form.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412514","version":"1","preferredName":"Blood Specimen Tube Collected CPTAC Biospecimen Identifier","preferredDefinition":"The CPTAC specimen identifier of the blood specimen collection tube.","longName":"7502582v1.0:7121849v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE6D85C8-AA4A-1DE0-E053-4EBD850A4837","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-03","modifiedBy":"KUMMEROA","dateModified":"2020-11-16","changeNote":"2020-11-16 Ak Released per SME approval email. 9/29/20 jk added CPTAC Solid tumor procurement CSI. --- Created for CPTAC AML Specimen Procurement Form. AK 2020-9-3","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412521","version":"1","preferredName":"Blood Specimen Slide CPTAC Biospecimen Identifier","preferredDefinition":"The CPTAC specimen identifier of the blood specimen collection tube slide.","longName":"7505059v1.0:7121849v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE6DB8C6-ABB8-3C38-E053-4EBD850AF000","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-03","modifiedBy":"KNABLEJ","dateModified":"2021-01-11","changeNote":"1/11/21 jk  Released, upd def and Reg Status per SME (NGM) review and approval. 11/16/20 AK Updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-3","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412527","version":"1","preferredName":"Whole Blood Volume Measurement Milliliter Value","preferredDefinition":"The numeric milliliter volume of the whole blood collected.","longName":"7412523v1.0:2823505v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE6DEAAF-94B3-330B-E053-4EBD850A2559","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-03","modifiedBy":"KUMMEROA","dateModified":"2020-11-12","changeNote":"2020-11-12 ak Released per SME approval email. 9/3/20 jk added Solid Tumor Procurement CSI.  --- Created for CPTAC AML Specimen Procurement Form. AK 2020-9-3","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412762","version":"1","preferredName":"Buccal Swab Required Number Collected Indicator","preferredDefinition":"A response to indicate whether or not the required number of buccal swabs were collected.","longName":"7412761v1.0:3506068v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE7CA4CF-C947-79E4-E053-4EBD850A3E22","latestVersionIndicator":"Yes","beginDate":"2020-09-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-04","modifiedBy":"KUMMEROA","dateModified":"2020-11-13","changeNote":"11/13/20 AK  Released per SME approval email. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-4","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412766","version":"1","preferredName":"Buccal Swab Required Number Not Collected Reason Specify","preferredDefinition":"A free text field to provide the reason why the required number of buccal swabs were not collected.","longName":"7412765v1.0:6609353v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE7CCEEF-D7A4-79EE-E053-4EBD850AD2ED","latestVersionIndicator":"Yes","beginDate":"2020-09-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-04","modifiedBy":"KNABLEJ","dateModified":"2021-01-12","changeNote":"1/12/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 11/13/20 AK Updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-4","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412770","version":"1","preferredName":"Buccal Swab Cryovial CPTAC Biospecimen Identifier","preferredDefinition":"The CPTAC specimen identifier of the buccal swab cryovial.","longName":"7412769v1.0:7121849v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE7C9530-5895-79E8-E053-4EBD850A9DDE","latestVersionIndicator":"Yes","beginDate":"2020-09-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-04","modifiedBy":"KUMMEROA","dateModified":"2020-11-13","changeNote":"11/13/20 AK Released per SME approval email. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-4","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412773","version":"1","preferredName":"Blood Specimen Comment Text","preferredDefinition":"A free text field to provide additional information regarding the specified storage vessel of the blood specimen.","longName":"7412772v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AE7CA4CF-C9A6-79E4-E053-4EBD850A3E22","latestVersionIndicator":"Yes","beginDate":"2020-09-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-04","modifiedBy":"KNABLEJ","dateModified":"2021-01-12","changeNote":"1/12/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 11/16/20 AK Updated def per SME (NGM) comment. 9/28/20 jk added CPTAC Solid tumor procurement CSI. -- Created for CPTAC AML Specimen Procurement Form. AK 2020-9-4","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7412962","version":"1","preferredName":"Bone Marrow Aspirate CPTAC Tumor Type","preferredDefinition":"The CPTAC classification of the bone marrow aspirate tumor.","longName":"7412961v1.0:7385481v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AECE2D15-CD54-0E12-E053-4EBD850A9613","latestVersionIndicator":"Yes","beginDate":"2020-09-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-08","modifiedBy":"KNABLEJ","dateModified":"2021-01-12","changeNote":"1/12/21 jk upd RS. 11/20/20 jk released per SME review. 11/12/20 AK Updated def per SME (NGM) comment. 9/8/2020 AK Created for CPTAC AML Specimen Procurement Form.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7413163","version":"1","preferredName":"Bone Marrow Aspirate Anatomic Site","preferredDefinition":"A description of the anatomic site of the bone marrow aspirate.","longName":"7413158v1.0:7413161v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AECFDB95-0ED9-5D09-E053-4EBD850AEF92","latestVersionIndicator":"Yes","beginDate":"2020-09-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-08","modifiedBy":"KUMMEROA","dateModified":"2020-11-12","changeNote":"11/12/20 AK Updated def per SME (NGM) comment; released per SME approval email. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-8","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7413166","version":"1","preferredName":"Bone Marrow Aspirate Anatomic Site Other Specify","preferredDefinition":"A textual description of the anatomic site which is different than the ones previously specified of the bone marrow aspirate.","longName":"7413158v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AECE2D15-CDA9-0E12-E053-4EBD850A9613","latestVersionIndicator":"Yes","beginDate":"2020-09-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-08","modifiedBy":"KNABLEJ","dateModified":"2021-01-11","changeNote":"1/11/21 jk  Released CDE, upd Reg Status per SME (NGM) review and approval.  11/12/20 AK Updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-8","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7413185","version":"1","preferredName":"Time Interval From Bone Marrow Aspirate Collection To Cell Freezing Time","preferredDefinition":"The period of time from bone marrow aspirate collection to freezing, measured in hours and minutes.","longName":"7413184v1.0:7332471v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AED0E828-11A2-6508-E053-4EBD850AF440","latestVersionIndicator":"Yes","beginDate":"2020-09-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-08","modifiedBy":"KUMMEROA","dateModified":"2020-11-16","changeNote":"2020-11-12 ak Def updated and released per ngm. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-8","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7413190","version":"1","preferredName":"Bone Marrow Aspirate Cell Isolation Aliquot Prepared Number","preferredDefinition":"Number of aliquots prepared from cells separated from the bone marrow aspirate.","longName":"7413189v1.0:2016202v3.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AED12733-2794-55E5-E053-4EBD850A7361","latestVersionIndicator":"Yes","beginDate":"2020-09-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-08","modifiedBy":"KNABLEJ","dateModified":"2021-01-11","changeNote":"1/11/21 jk  Released CDE, upd Reg Status per SME (NGM) review and approval. 11/12/20 AK Updated def per SME (NGM) comment.  Created for CPTAC AML Specimen Procurement Form. AK 2020-9-8","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7413338","version":"1","preferredName":"Buccal Swab Comment Text","preferredDefinition":"A free text field to provide additional information regarding the buccal swab collection.","longName":"7413337v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AED2A949-F3A1-1AF2-E053-4EBD850A17C2","latestVersionIndicator":"Yes","beginDate":"2020-09-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-08","modifiedBy":"KNABLEJ","dateModified":"2021-01-12","changeNote":"1/12/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 11/13/20 AK Updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-8","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7413360","version":"1","preferredName":"Time Interval From Buccal Swab Collection To Freezing Time","preferredDefinition":"The period of time from buccal swab collection to freezing measured in hours and minutes.","longName":"7413335v1.0:7332471v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AED3FBCE-8ADD-378B-E053-4EBD850A0016","latestVersionIndicator":"Yes","beginDate":"2020-09-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-08","modifiedBy":"KUMMEROA","dateModified":"2020-11-16","changeNote":"11/13/20 AK Released per SME approval email. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-8","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7414483","version":"1","preferredName":"Blood Specimen Collection Other Specify","preferredDefinition":"A free-text field to describe a method of blood collection different from the one listed.","longName":"5608418v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AEEBE400-B36B-44F5-E053-4EBD850A50A0","latestVersionIndicator":"Yes","beginDate":"2020-09-09","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-09","modifiedBy":"KNABLEJ","dateModified":"2021-01-12","changeNote":"1/12/21 jk upd RS. 11/23/20 AK Updated def per SME (NGM) comment; released. 10/12/20 jk revise LN to match complementary CDE 5227836.   2020-10-5 ak Added CS/CSI. 9/9/2020 jk created for Solid Tumor Procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7414503","version":"1","preferredName":"Blood Collection Tube Preservation Method Type","preferredDefinition":"The method by which the blood was preserved.","longName":"7414497v1.0:7414499v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AEEC35A5-5D04-724B-E053-4EBD850A8F0B","latestVersionIndicator":"Yes","beginDate":"2020-09-09","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-09","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 10/12/20 jk upd RS per upd VD RS.  9/9/2020 jk created for Solid Tumor Procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7414593","version":"1","preferredName":"Tumor Tissue Biospecimen Collection Method Surgical Procedure Type","preferredDefinition":"The type of surgical procedure performed to obtain a tumor sample from a subject for testing, diagnostic, treatment, or research purposes.","longName":"7385468v1.0:7062957v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AEF9B582-8401-6EAD-E053-4EBD850A4DEB","latestVersionIndicator":"Yes","beginDate":"2020-09-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-10","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 9/9/20 New CDE to incorporate TURBT PV and move from Baseline to Procurement CRFs; replaces CDE 7063063.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7425498","version":"1","preferredName":"Bone Marrow Aspirate Aliquot Cryovial CPTAC Biospecimen Identifier","preferredDefinition":"The CPTAC specimen identifier of the bone marrow aspirate aliquot cryovial.","longName":"7425497v1.0:7121849v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AF81CDAF-DCFA-6092-E053-4EBD850AE040","latestVersionIndicator":"Yes","beginDate":"2020-09-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-17","modifiedBy":"KUMMEROA","dateModified":"2020-11-12","changeNote":"2020-11-12 ak Released per SME approval email. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7426110","version":"1","preferredName":"Bone Marrow Aspirate Aliquot Number","preferredDefinition":"Numeric identifier of aliquot of separated cells.","longName":"7426109v1.0:7425863v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AF9A166D-9EAA-79A8-E053-4EBD850AA77A","latestVersionIndicator":"Yes","beginDate":"2020-09-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-18","modifiedBy":"KNABLEJ","dateModified":"2021-01-11","changeNote":"1/11/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 11/12/20 AK Updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7426127","version":"1","preferredName":"Blood Specimen Cell Isolation Aliquot Prepared Number","preferredDefinition":"Number of blood specimen aliquots prepared of the isolated cells.","longName":"7426125v1.0:2016202v3.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AF9AED2D-5EA4-46A4-E053-4EBD850A3F26","latestVersionIndicator":"Yes","beginDate":"2020-09-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-18","modifiedBy":"KNABLEJ","dateModified":"2021-01-12","changeNote":"1/12/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 11/16/20 AK Updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7426130","version":"1","preferredName":"Blood Specimen Aliquot Number","preferredDefinition":"Numeric identifier of aliquots of blood specimen.","longName":"7426129v1.0:7425863v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AF9B666A-4F26-41D6-E053-4EBD850AB786","latestVersionIndicator":"Yes","beginDate":"2020-09-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-18","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk added alt def for Solid Tumor Procurement. 1/12/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 11/16/20 AK Updated def per SME (NGM) comment. 9/28/20 jk added CPTAC Solid tumor procurement CSI. -- Created for CPTAC AML Specimen Procurement Form. AK 2020-9-18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7426133","version":"1","preferredName":"Blood Specimen Aliquot Cryovial CPTAC Biospecimen Identifier","preferredDefinition":"The CPTAC specimen identifier of the blood specimen aliquot cryovial.","longName":"7426132v1.0:7121849v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AF9B061D-01B8-4AA3-E053-4EBD850A541D","latestVersionIndicator":"Yes","beginDate":"2020-09-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-18","modifiedBy":"KNABLEJ","dateModified":"2021-01-12","changeNote":"1/12/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 11/16/20 AK Updated def per SME (NGM) comment. 9/28/20 jk added CPTAC Solid tumor procurement CSI. --- Created for CPTAC AML Specimen Procurement Form.  AK 2020-9-18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7445932","version":"1","preferredName":"Blood Collection Tube Collected Date and Time","preferredDefinition":"The date or date and time the blood specimen was collected.","longName":"7434423v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0612076-89BC-1151-E053-4EBD850A0B97","latestVersionIndicator":"Yes","beginDate":"2020-09-28","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-28","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 9/28/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7446006","version":"1","preferredName":"Time Interval From Blood Specimen Collection To Freezing Time","preferredDefinition":"The period of time from blood specimen collection to freezing, measured in hours and minutes.","longName":"7437704v1.0:7332471v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B062A8D8-5505-50A9-E053-4EBD850A4C90","latestVersionIndicator":"Yes","beginDate":"2020-09-28","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-28","modifiedBy":"KNABLEJ","dateModified":"2021-01-12","changeNote":"1/12/21 jk  Released for AML, upd Reg Status per SME (NGM) review and approval. 11/16/20 AK Updated def per SME (NGM) comment. 2020-10-5 ak Added CS/CSI. 2020-9-28 Added AQT AML for procurement CRF. 9/28/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7446007","version":"1","preferredName":"Blood Specimen Cell Count Instrumentation Text","preferredDefinition":"A free text field describing the type of instrument used for counting cells in the blood specimen.","longName":"7446005v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B062C69D-3906-5C90-E053-4EBD850AC706","latestVersionIndicator":"Yes","beginDate":"2020-09-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-28","modifiedBy":"KNABLEJ","dateModified":"2021-01-12","changeNote":"1/12/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 11/16/20 AK Updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-28","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7446037","version":"1","preferredName":"Time Interval From Freezing To Blood Product Storage Occurrence Time","preferredDefinition":"The period of time from freezing to blood product storage measured in hours and minutes.","longName":"7437707v1.0:7332471v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B062C8C4-89C6-5F4A-E053-4EBD850ACC8C","latestVersionIndicator":"Yes","beginDate":"2020-09-28","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-28","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 9/28/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7448583","version":"1","preferredName":"Blood Collection Tube Whole Blood Frozen Date and Time","preferredDefinition":"The date or date and time the whole blood cryovial was immobilized by severe cold.","longName":"7437688v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0679E56-2E14-5CCF-E053-4EBD850AE28C","latestVersionIndicator":"Yes","beginDate":"2020-09-28","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-28","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd def and Reg Status per SME (NGM) review and approval. 9/28/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7448585","version":"1","preferredName":"Blood Collection Tube Transferred To Blood Product Storage Date and Time","preferredDefinition":"The date or date and time that blood which has not been separated into its various components was transferred to specimen  storage at -80°C.","longName":"7437697v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B065B6BE-FA4C-5CD1-E053-4EBD850A9AA1","latestVersionIndicator":"Yes","beginDate":"2020-09-28","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-28","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd def/Reg Status per SME (NGM) review and approval. 9/28/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7448901","version":"1","preferredName":"Blood Collection Tube Buffy Coat Frozen Date and Time","preferredDefinition":"The date or date and time the middle layer of an anticoagulated blood specimen was immobilized by severe cold.","longName":"7437691v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B075FCAE-A11F-4CE2-E053-4EBD850A1327","latestVersionIndicator":"Yes","beginDate":"2020-09-29","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-29","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd def and Reg Status per SME (NGM) review and approval. 9/29/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7448903","version":"1","preferredName":"Normal Tissue Segment Excision Collection Date and Time","preferredDefinition":"The date or date and time the normal adjacent tissue was surgically removed from an organ.","longName":"7433756v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0764986-22E7-5353-E053-4EBD850AFBEC","latestVersionIndicator":"Yes","beginDate":"2020-09-29","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-29","modifiedBy":"KNABLEJ","dateModified":"2021-01-27","changeNote":"1/27/21 jk Released, upd Reg Status per SME (NGM) review and approval. 12/14/20 jk removed Normal tissue procurement CSI; new CDE created per SME review.  10/30/20 jk added Normal Tissue CSI. 9/29/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449271","version":"1","preferredName":"Tumor Segment Excision Collection Date and Time","preferredDefinition":"The date or date and time malignant neoplasm tissue was surgically removed from an organ.","longName":"7433860v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B076C1AC-D732-3C3E-E053-4EBD850A9903","latestVersionIndicator":"Yes","beginDate":"2020-09-29","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-29","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 9/29/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449283","version":"1","preferredName":"Tumor Segment Liquid Nitrogen Vapor Date and Time","preferredDefinition":"The date or date and time the malignant neoplasm tissue was frozen with Liquid Nitrogen Vapor (LN2 Vapor).","longName":"7433864v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B079162E-A425-7633-E053-4EBD850ADBED","latestVersionIndicator":"Yes","beginDate":"2020-09-29","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-29","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 9/29/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449381","version":"1","preferredName":"Normal Tissue Segment Liquid Nitrogen Vapor Date and Time","preferredDefinition":"The date or date and time the normal adjacent tissue was immobilized with Liquid Nitrogen Vapor (LN2 Vapor).","longName":"7433807v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B07C188F-20CF-3827-E053-4EBD850AF590","latestVersionIndicator":"Yes","beginDate":"2020-09-29","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-29","modifiedBy":"KNABLEJ","dateModified":"2021-02-15","changeNote":"2/15/21 jk Released, upd Reg Status per SME (NGM) review and approval. 12/14/20 jk removed Normal tissue procurement CSI; new CDE created per SME review. 10/30/20 jk added Normal Tissue CSI. 9/29/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449382","version":"1","preferredName":"Surgical Procedure Tumor Tissue First Surgical Clamp Date and Time","preferredDefinition":"The date or date and time when the first surgical device such as a clamp is applied to a tumor sample to reduce or stop blood flow.","longName":"7449297v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B07C9858-3D87-3355-E053-4EBD850A7701","latestVersionIndicator":"Yes","beginDate":"2020-09-29","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-29","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 9/29/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449383","version":"1","preferredName":"Surgical Procedure Tumor Tissue Last Surgical Clamp Date and Time","preferredDefinition":"The date or date and time when the last surgical device such as a clamp is applied to a tumor sample to reduce or stop blood flown.","longName":"7449300v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B07CA84A-773E-3FAF-E053-4EBD850A5F12","latestVersionIndicator":"Yes","beginDate":"2020-09-29","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-29","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 9/29/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449393","version":"1","preferredName":"Bone Marrow Aspirate Collection Date and Time","preferredDefinition":"The date or date and time the bone marrow aspirate was collected.","longName":"7426060v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0894E10-6768-27DB-E053-4EBD850AB108","latestVersionIndicator":"Yes","beginDate":"2020-09-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-30","modifiedBy":"KUMMEROA","dateModified":"2020-11-12","changeNote":"2020-11-12 ak Released per SME approval email. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-30","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449394","version":"1","preferredName":"Bone Marrow Aspirate Begin Cell Isolation Date and Time","preferredDefinition":"The date or date and time the process to separate cells from the bone marrow aspirate began.","longName":"7413174v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B08AA04B-5ACE-56B4-E053-4EBD850A46E9","latestVersionIndicator":"Yes","beginDate":"2020-09-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-30","modifiedBy":"KUMMEROA","dateModified":"2020-11-13","changeNote":"11/12/20 AK Updated def per SME (NGM) comment; released per SME approval email.  Created for CPTAC AML Specimen Procurement Form. AK 2020-9-30","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449395","version":"1","preferredName":"Frozen Specimen From Bone Marrow Aspirate Post Cell Isolation Date and Time","preferredDefinition":"The date or date and time the spearated cells from the bone marrow aspirate were immobilized by severe cold.","longName":"7413181v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B08AE70E-9189-0360-E053-4EBD850AD723","latestVersionIndicator":"Yes","beginDate":"2020-09-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-30","modifiedBy":"KNABLEJ","dateModified":"2021-01-11","changeNote":"1/11/21 jk  Released CDE, upd Reg Status per SME (NGM) review and approval.  2020-11-12 ak Modified OC and updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-30","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449406","version":"1","preferredName":"Blood Specimen Collection Date and Time","preferredDefinition":"The date or date and time the blood specimen was collected.","longName":"5608418v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B08AFBF8-6F90-0363-E053-4EBD850A042D","latestVersionIndicator":"Yes","beginDate":"2020-09-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-30","modifiedBy":"KUMMEROA","dateModified":"2020-11-23","changeNote":"2020-11-23 AK Released per SME approval email. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-30","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449407","version":"1","preferredName":"Blood Specimen Begin Cell Isolation Date and Time","preferredDefinition":"The date or date and time the process to separate cells from the blood specimen began.","longName":"7413325v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B08B1144-4C7D-059A-E053-4EBD850A5BD0","latestVersionIndicator":"Yes","beginDate":"2020-09-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-30","modifiedBy":"KNABLEJ","dateModified":"2021-01-12","changeNote":"1/12/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 11/16/20 AK Updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-30","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449408","version":"1","preferredName":"Frozen Specimen From Blood Specimen Post Cell Isolation Date and Time","preferredDefinition":"The date or date and time the separated cells from the blood specimen were immobilized by severe cold.","longName":"7426122v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B08B2789-F43E-0594-E053-4EBD850AB548","latestVersionIndicator":"Yes","beginDate":"2020-09-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-30","modifiedBy":"KNABLEJ","dateModified":"2021-01-12","changeNote":"1/12/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 11/16/20 AK Updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-30","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449409","version":"1","preferredName":"Buccal Swab First Collection Date and Time","preferredDefinition":"The date or date and time the first buccal swab was collected.","longName":"7413328v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B08B6827-A3F8-56B0-E053-4EBD850ACAF7","latestVersionIndicator":"Yes","beginDate":"2020-09-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-30","modifiedBy":"KUMMEROA","dateModified":"2020-11-13","changeNote":"11/13/20 AK Released per SME approval email. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-30","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449410","version":"1","preferredName":"Buccal Swab Frozen Specimen Date and Time","preferredDefinition":"The date or date and time the buccal swab specimen was immobilized by severe cold.","longName":"7413331v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B08B6827-A426-56B0-E053-4EBD850ACAF7","latestVersionIndicator":"Yes","beginDate":"2020-09-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-30","modifiedBy":"KNABLEJ","dateModified":"2021-01-12","changeNote":"1/12/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 11/13/20 AK Updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-9-30","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449411","version":"1","preferredName":"Normal Tissue Segment Quantity Collected Number","preferredDefinition":"The number of non-neoplastic (\"normal\") adjacent tissue segments collected for proteomic and genomic analysis.","longName":"7433789v1.0:7425863v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B08C3C4A-0D68-0596-E053-4EBD850A496D","latestVersionIndicator":"Yes","beginDate":"2020-09-30","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-30","modifiedBy":"KNABLEJ","dateModified":"2021-01-27","changeNote":"1/27/21 jk Released, upd Reg Status per SME (NGM) review and approval. 12/9/20 jk Normal Tissue CSI removed; new CDE 7527834.  10/30/20 jk added Normal Tissue CSI.  9/30/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449417","version":"1","preferredName":"Surgical Procedure Tumor Tissue Segment Quantity Number","preferredDefinition":"The number of malignant neoplasm tissue segments collected by surgical incision for proteomic and genomic analysis.","longName":"7433871v1.0:7425863v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B08B6827-A454-56B0-E053-4EBD850ACAF7","latestVersionIndicator":"Yes","beginDate":"2020-09-30","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-30","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 9/30/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449429","version":"1","preferredName":"Time Interval From Blood Product Collection To Storage Occurrence Time","preferredDefinition":"The period of time from blood product collection to blood product storage measured in hours and minutes.","longName":"7437711v1.0:7332471v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B08D6A0C-60FA-5EE7-E053-4EBD850A3343","latestVersionIndicator":"Yes","beginDate":"2020-09-30","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-30","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 9/30/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449432","version":"1","preferredName":"Tumor Segment Ischemia Time","preferredDefinition":"The period of time from blood supply separation or reduction to further processing, preservation, or blood supply reconnection of a malignant neoplasm tissue segment.","longName":"7433926v1.0:7332471v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B08B2789-F492-0594-E053-4EBD850AB548","latestVersionIndicator":"Yes","beginDate":"2020-09-30","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-30","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 9/30/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449433","version":"1","preferredName":"Normal Tissue Segment Ischemia Time","preferredDefinition":"The period of time from blood supply separation or reduction to further processing, preservation, or blood supply reconnection of non-neoplastic (\"normal\") adjacent tissue segment.","longName":"7433928v1.0:7332471v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B08DCF1D-1B75-69B6-E053-4EBD850A277E","latestVersionIndicator":"Yes","beginDate":"2020-09-30","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-09-30","modifiedBy":"KNABLEJ","dateModified":"2021-02-15","changeNote":"2/15/21 jk Released, upd Reg Status per SME (NGM) review and approval. 12/14/20 jk removed Normal tissue procurement CSI; new CDE created per SME review.  10/30/20 jk added AQT, Normal Tissue CSI.  9/30/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449894","version":"1","preferredName":"Total Normal Tissue Segment Comment Text","preferredDefinition":"A free text field to provide additional information regarding the entire non-neoplastic (\"normal\") adjacent tissue specimen that was divided into segments for proteomic and genomic analysis.","longName":"7449878v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0A16C8E-EFB3-30BC-E053-4EBD850A595B","latestVersionIndicator":"Yes","beginDate":"2020-10-01","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-01","modifiedBy":"KNABLEJ","dateModified":"2021-02-12","changeNote":"2/12/21 jk  upd def per SME comment; upd Reg Status and released.  12/15/20 jk Removed Normal Tissue CSI; new CDE per SME for CRF.10/30/20 jk added Normal Tissue CSI. 10/1/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449895","version":"1","preferredName":"Total Tumor Tissue Segment Comment Text","preferredDefinition":"A free text field to provide additional information regarding the entire malignant neoplasm tissue specimen collection process.","longName":"7449876v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0A05086-0C45-3690-E053-4EBD850AD245","latestVersionIndicator":"Yes","beginDate":"2020-10-01","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-01","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 10/1/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7449902","version":"1","preferredName":"Tumor Segment Comment Text","preferredDefinition":"A free text field to provide additional information regarding the specified malignant neoplasm tissue segment which is suitable for proteomic and genomic analysis.","longName":"7433858v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0A2BF12-ADF7-41E3-E053-4EBD850A1CB1","latestVersionIndicator":"Yes","beginDate":"2020-10-01","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-01","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd def and Reg Status per SME (NGM) review and approval. 10/1/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7452429","version":"1","preferredName":"Tumor Tissue Segment Not Collected Reason","preferredDefinition":"An explanation as to why sufficient malignant neoplasm tissue was not collected.","longName":"7449871v1.0:7452286v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0B36FBF-4EB8-121F-E053-4EBD850A5BB2","latestVersionIndicator":"Yes","beginDate":"2020-10-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-02","modifiedBy":"KNABLEJ","dateModified":"2021-02-24","changeNote":"2/24/21 jk upd def per SME (NGM) comment; upd Reg Status and released. 10/2/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7452430","version":"1","preferredName":"Normal Tissue Segment Not Collected Reason","preferredDefinition":"An explanation of why sufficient normal adjacent tissue was not collected.","longName":"7449868v1.0:7452286v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"B0B38429-9B8B-0E6E-E053-4EBD850A9E4C","latestVersionIndicator":"Yes","beginDate":"2020-10-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-02","modifiedBy":"KNABLEJ","dateModified":"2021-04-06","changeNote":"12/14/20 jk removed Normal tissue procurement CSI; new CDE created per SME review.  10/30/20 jk added Normal Tissue CSI. 10/2/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7452431","version":"1","preferredName":"Blood Product Not Collected Reason","preferredDefinition":"An explanation of why sufficient blood or blood products were not collected.","longName":"7445876v1.0:7452286v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0B36094-5922-103D-E053-4EBD850A4AD5","latestVersionIndicator":"Yes","beginDate":"2020-10-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-02","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 10/2/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7452432","version":"1","preferredName":"Blood Product Not Collected Other Specify","preferredDefinition":"An explanation different than the one(s) previously specified of why sufficient blood or blood products were not collected.","longName":"7445876v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0B344FE-6BB6-6A88-E053-4EBD850AC319","latestVersionIndicator":"Yes","beginDate":"2020-10-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-02","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 10/2/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7452433","version":"1","preferredName":"Tumor Tissue Segment Not Collected Other Specify","preferredDefinition":"An explanation different than the one(s) previously specified as to why sufficient malignant neoplasm tissue was not collected.","longName":"7449871v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0B4CC3E-BBA3-6A8C-E053-4EBD850A82DA","latestVersionIndicator":"Yes","beginDate":"2020-10-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-02","modifiedBy":"KNABLEJ","dateModified":"2021-02-24","changeNote":"2/24/21 jk upd def per SME (NGM) comment; upd Reg Status and released. 10/2/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7452434","version":"1","preferredName":"Normal Tissue Segment Not Collected Other Specify","preferredDefinition":"An explanation different than the one(s) previously specified as to why sufficient normal adjacent tissue was not collected.","longName":"7449868v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Qualified","id":"B0B5446B-E222-5042-E053-4EBD850AFCEB","latestVersionIndicator":"Yes","beginDate":"2020-10-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-02","modifiedBy":"KNABLEJ","dateModified":"2021-04-06","changeNote":"12/14/20 jk removed Normal tissue procurement CSI; new CDE created per SME review.  10/30/20 jk added Normal Tissue CSI. 10/2/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7452586","version":"1","preferredName":"Total Blood Product Collection Volume Milliliter Value","preferredDefinition":"A numerical quantity documenting the total volume of all blood or blood products collected which are suitable for proteomic and genomic analysis.","longName":"7445871v1.0:2823505v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0ED1BEF-39C7-6E29-E053-4EBD850AC0C5","latestVersionIndicator":"Yes","beginDate":"2020-10-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-05","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 10/5/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7456186","version":"1","preferredName":"Total Tumor Tissue Segment Weight Milligram Value","preferredDefinition":"A numerical quantity documenting the weight of all the malignant neoplasm tissue segments collected which are suitable for proteomic and genomic analysis.","longName":"7449861v1.0:7456175v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0F4306E-2CD7-794B-E053-4EBD850AE5FD","latestVersionIndicator":"Yes","beginDate":"2020-10-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-05","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 10/5/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7457432","version":"1","preferredName":"Total Normal Tissue Segment Weight Milligram Value","preferredDefinition":"A numerical quantity documenting the weight of all non-neoplastic (\"normal\") adjacent tissue segments collected which are suitable for proteomic and genomic analysis.","longName":"7449864v1.0:7456175v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0F7A155-72D4-3F84-E053-4EBD850A5386","latestVersionIndicator":"Yes","beginDate":"2020-10-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-05","modifiedBy":"KNABLEJ","dateModified":"2021-02-15","changeNote":"2/15/21 jk Released, upd Reg Status per SME (NGM) review and approval. 12/14/20 jk removed Normal tissue procurement CSI; new CDE created per SME review..  10/30/20 jk added Normal Tissue CSI. 10/5/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7457433","version":"1","preferredName":"Tumor Segment Weight Milligram Value","preferredDefinition":"A numerical quantity documenting the weight of a malignant neoplasm tissue segment which is suitable for proteomic and genomic analysis.","longName":"7433862v1.0:7456175v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0F7AE4D-0901-3F80-E053-4EBD850A3FE2","latestVersionIndicator":"Yes","beginDate":"2020-10-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-05","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 10/5/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7457434","version":"1","preferredName":"Normal Tissue Segment Weight Milligram Value","preferredDefinition":"A numerical quantity documenting the weight of a non-neoplastic (\"normal\") adjacent tissue segment suitable for proteomic and genomic analysis.","longName":"7433804v1.0:7456175v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"B0F816B2-8AE9-3F82-E053-4EBD850AB930","latestVersionIndicator":"Yes","beginDate":"2020-10-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-05","modifiedBy":"KNABLEJ","dateModified":"2020-12-14","changeNote":"12/14/20 jk removed Normal tissue procurement CSI; new CDE created per SME review. 10/30/20 jk added Normal Tissue CSI. 10/5/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7457435","version":"1","preferredName":"Normal Tissue Segment Distance From Tumor Surgical Margin Measurement","preferredDefinition":"The distance in centimeters of non-neoplastic (\"normal\") tissue from malignant neoplasm tissue after surgical resection of the tumor.","longName":"7433884v1.0:2770316v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0F816B2-8B17-3F82-E053-4EBD850AB930","latestVersionIndicator":"Yes","beginDate":"2020-10-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-05","modifiedBy":"KNABLEJ","dateModified":"2021-02-15","changeNote":"2/15/21 jk Released, upd Reg Status per SME (NGM) review and approval. 10/5/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7457436","version":"1","preferredName":"Normal Tissue Segment Comment Text","preferredDefinition":"A free text field to provide additional information regarding the entire non-neoplastic (\"normal\") adjacent tissue specimen that was divided into aliquots for proteomic and genomic analysis.","longName":"7433839v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0F7AE4D-092F-3F80-E053-4EBD850A3FE2","latestVersionIndicator":"Yes","beginDate":"2020-10-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-05","modifiedBy":"KNABLEJ","dateModified":"2021-02-12","changeNote":"2/12/21 jk upd def per SME (NGM) comment; upd Reg Status and released.  12/14/20 jk removed Normal tissue procurement CSI; new CDE created per SME review.  10/30/20 jk added Normal Tissue CSI. 10/5/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7457437","version":"1","preferredName":"Total Blood Product Collection Comment Text","preferredDefinition":"A free text field to provide additional information regarding the entire blood or blood product collection process.","longName":"7445873v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B0F270C2-DFD0-1DA8-E053-4EBD850AF288","latestVersionIndicator":"Yes","beginDate":"2020-10-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-05","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 10/5/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7461701","version":"1","preferredName":"Surgical Procedure Tumor Tissue Surgical Clamp Indicator","preferredDefinition":"A yes/no response to indicate whether or not surgical clamps (clips, ties, or other method of cessation of blood flow) were used during the collection of surgical tumor tissue.","longName":"7449294v1.0:3506068v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B12E0297-8E1A-2C88-E053-4EBD850A6BF2","latestVersionIndicator":"Yes","beginDate":"2020-10-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-08","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 10/8/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7461706","version":"1","preferredName":"All Tissue Segment Freezing With Optimal Cutting Temperature Compound Indicator","preferredDefinition":"A yes/no response to indicate whether all the surgical tissue segments were frozen with Optimal Cutting Temperature (OCT) embedding media.","longName":"7449323v1.0:3506068v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B12E1F6F-1F2C-2F39-E053-4EBD850A3CEC","latestVersionIndicator":"Yes","beginDate":"2020-10-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-10-08","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeNote":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 10/14/20 jk CDE upd for revised DEC. 10/8/20 jk created CPTAC Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7479321","version":"1","preferredName":"Bone Marrow Aspirate Aliquot Cryovial Cell Count Float","preferredDefinition":"The numeric cell count of the bone marrow aspirate aliquot cryovial.","longName":"7425497v1.0:7479219v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B293C988-307A-73CF-E053-4EBD850A62DD","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-10-26","modifiedBy":"KUMMEROA","dateModified":"2020-11-12","changeNote":"2020-11-12 ak Released per SME approval email. Created for CPTAC AML Specimen Procurement Form. AK 2020-10-26","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7479325","version":"1","preferredName":"Bone Marrow Aspirate Aliquot Cryovial Cell Count Exponential Value","preferredDefinition":"The numeric cell count exponent value of the bone marrow aspirate aliquot cryovial.","longName":"7425497v1.0:7479221v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B293D5D4-FB3C-7964-E053-4EBD850AA665","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-10-26","modifiedBy":"KUMMEROA","dateModified":"2020-11-12","changeNote":"2020-11-12 ak Released per SME approval email.   Created for CPTAC AML Specimen Procurement Form. AK 2020-10-26","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7479329","version":"1","preferredName":"Bone Marrow Aspirate Tube Collection Cell Count Float","preferredDefinition":"The numeric cell count of the specified storage vessel of the bone marrow aspirate collection.","longName":"7412333v1.0:7479219v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B2941CC7-8E9F-4F65-E053-4EBD850A2B03","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-10-26","modifiedBy":"KNABLEJ","dateModified":"2021-01-11","changeNote":"1/11/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 11/12/20 AK Updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-10-26","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7479330","version":"1","preferredName":"Bone Marrow Aspirate Tube Collection Cell Count Exponential Value","preferredDefinition":"The numeric cell count exponent value of the specified storage vessel of the bone marrow aspirate collection.","longName":"7412333v1.0:7479221v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B2942BE9-0F49-785F-E053-4EBD850AD94E","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-10-26","modifiedBy":"KNABLEJ","dateModified":"2021-01-11","changeNote":"1/11/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 11/12/20 AK Updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-10-26","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7479336","version":"1","preferredName":"Blood Specimen Aliquot Cryovial Cell Count Float","preferredDefinition":"The numeric cell count of the blood specimen aliquot cryovial.","longName":"7426132v1.0:7479219v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B2942BE9-0F83-785F-E053-4EBD850AD94E","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-10-26","modifiedBy":"KNABLEJ","dateModified":"2021-01-12","changeNote":"1/12/21 jk  Released, upd Reg Status per SME (NGM) review and approval.  11/16/20 AK Updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-10-26","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7479343","version":"1","preferredName":"Blood Specimen Aliquot Cryovial Cell Count Exponential Value","preferredDefinition":"The numeric cell count exponent value of the blood specimen aliquot cryovial.","longName":"7426132v1.0:7479221v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B2941F94-FB53-720B-E053-4EBD850A55A2","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-10-26","modifiedBy":"KNABLEJ","dateModified":"2021-01-12","changeNote":"1/12/21 jk  Released, upd Reg Status per SME (NGM) review and approval.  Created for CPTAC AML Specimen Procurement Form. AK 2020-10-26","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7479344","version":"1","preferredName":"Blood Specimen Tube Collected Cell Count Float","preferredDefinition":"The numeric cell count of the specified storage vessel of the blood specimen collection.","longName":"7502582v1.0:7479219v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B294E90E-B8C7-5EA7-E053-4EBD850A7E79","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-10-26","modifiedBy":"KNABLEJ","dateModified":"2021-01-12","changeNote":"1/12/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 11/16/20 AK Updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-10-26","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7479348","version":"1","preferredName":"Blood Specimen Tube Collected Cell Count Exponential Value","preferredDefinition":"The numeric cell count exponent value of the specified storage vessel of the blood specimen collection.","longName":"7502582v1.0:7479221v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B2941F94-FB81-720B-E053-4EBD850A55A2","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-10-26","modifiedBy":"KNABLEJ","dateModified":"2021-01-12","changeNote":"1/12/21 - Released CDE, upd def and  RS.11/16/20 AK Updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-10-26","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7479350","version":"1","preferredName":"Bone Marrow Aspirate And Blood Specimen Collection Total Cell Count Float","preferredDefinition":"The numeric total cell count of all bone marrow aspirates and blood specimens collected.","longName":"7414519v1.0:7479219v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B2951CE7-2F6A-5DEA-E053-4EBD850A911D","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-10-26","modifiedBy":"KNABLEJ","dateModified":"2021-01-12","changeNote":"1/12/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 11/13/20 AK Updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-10-26","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7479351","version":"1","preferredName":"Bone Marrow Aspirate And Blood Specimen Collection Total Cell Count Exponential Value","preferredDefinition":"The numeric total cell count exponent value of all bone marrow aspirates and blood specimens collected.","longName":"7414519v1.0:7479221v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B2941CC7-8F63-4F65-E053-4EBD850A2B03","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-10-26","modifiedBy":"KNABLEJ","dateModified":"2021-01-12","changeNote":"1/12/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 11/13/20 AK Updated def per SME (NGM) comment. Created for CPTAC AML Specimen Procurement Form. AK 2020-10-26","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7515635","version":"1","preferredName":"Blood Specimen Collection Method Type","preferredDefinition":"The method by which the blood specimen was collected.","longName":"5608418v1.0:5222615v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B4C9D90B-3CA9-1D9B-E053-4EBD850A01E4","latestVersionIndicator":"Yes","beginDate":"2020-11-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-11-23","modifiedBy":"KUMMEROA","dateModified":"2020-11-23","changeNote":"2020-11-23 AK Released per SME approval email. 9/23/2020 AK created for AML Procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7527834","version":"1","preferredName":"Normal Tissue Collected Segment Quantity Number","preferredDefinition":"A value capturing the amount or number of normal tissue segments collected from non-diseased patients.","longName":"7525563v1.0:7425863v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B6130CCD-A47D-0CD7-E053-4EBD850A9AF1","latestVersionIndicator":"Yes","beginDate":"2020-12-09","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-12-09","modifiedBy":"KNABLEJ","dateModified":"2021-01-21","changeNote":"1/21/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 12/9/20 jk created CPTAC Normal Tissue procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7529226","version":"1","preferredName":"Normal Tissue Devascularization Collection Date and Time","preferredDefinition":"The date or date and time a procedure interrupts blood supply to an organ or normal tissue from a non-diseased patient.","longName":"7529225v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B632AB3E-B7B5-0B8C-E053-4EBD850A6E95","latestVersionIndicator":"Yes","beginDate":"2020-12-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-12-11","modifiedBy":"KNABLEJ","dateModified":"2021-01-21","changeNote":"1/21/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 12/11/20 jk created CPTAC Normal Tissue procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7532186","version":"1","preferredName":"Normal Tissue Excision Collection Date and Time","preferredDefinition":"The date or date and time normal tissue from a non-diseased patient was surgically removed from an organ.","longName":"7527815v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B66FC03B-017E-7AE3-E053-4EBD850AA450","latestVersionIndicator":"Yes","beginDate":"2020-12-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-12-14","modifiedBy":"KNABLEJ","dateModified":"2021-02-02","changeNote":"2/21 jk Released, upd Reg Status per SME (NGM) review and approval. 12/14/20 jk created CPTAC Normal tissue procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7532187","version":"1","preferredName":"Normal Tissue Biospecimen CPTAC Identifier","preferredDefinition":"The CPTAC specimen identifier of normal tissue from a non-diseased patient collected for review.  The identifier utilizes the pre-defined CPTAC identifier format.","longName":"7527817v1.0:7121849v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B66FC03B-01AD-7AE3-E053-4EBD850AA450","latestVersionIndicator":"Yes","beginDate":"2020-12-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-12-14","modifiedBy":"KNABLEJ","dateModified":"2021-01-21","changeNote":"1/21/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 12/14/20 jk created CPTAC Normal tissue procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7532188","version":"1","preferredName":"Normal Tissue Formalin-Fixed Paraffin-Embedded Block CPTAC Biospecimen Identifier","preferredDefinition":"The CPTAC specimen identifier of the Formalin-Fixed Paraffin-Embedded (FFPE) block in which normal tissue from a non-diseased patient was embedded.  The identifier utilizes the pre-defined CPTAC identifier format.","longName":"7527819v1.0:7121849v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B6746D69-AF96-6D9E-E053-4EBD850A99A1","latestVersionIndicator":"Yes","beginDate":"2020-12-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-12-14","modifiedBy":"KNABLEJ","dateModified":"2021-01-21","changeNote":"1/21/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 12/14/20 jk created CPTAC Normal tissue procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7532221","version":"1","preferredName":"Normal Tissue Weight Float","preferredDefinition":"A numerical quantity documenting the weight of normal tissue collected from a non-diseased patient.","longName":"7527821v1.0:6848361v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B6746002-03F3-7716-E053-4EBD850A09D8","latestVersionIndicator":"Yes","beginDate":"2020-12-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-12-14","modifiedBy":"KNABLEJ","dateModified":"2021-02-02","changeNote":"2/2/21 jk Released, upd Reg Status per SME (NGM) review and approval. 12/14/20 jk created CPTAC Normal tissue procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7532225","version":"1","preferredName":"Normal Tissue Liquid Nitrogen Vapor Date and Time","preferredDefinition":"The date or date and time the normal tissue from a non-diseased patient was frozen with Liquid Nitrogen Vapor (LN2 Vapor.","longName":"7527823v1.0:7414605v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B675B952-756C-7AA9-E053-4EBD850A281B","latestVersionIndicator":"Yes","beginDate":"2020-12-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-12-14","modifiedBy":"KNABLEJ","dateModified":"2021-02-02","changeNote":"2/2/21 jk Released, upd Reg Status per SME (NGM) review and approval. 12/14/20 jk created CPTAC Normal tissue procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7532236","version":"1","preferredName":"Normal Tissue Ischemia Time","preferredDefinition":"The period of time from blood supply separation or reduction to further processing, preservation, or blood supply reconnection of normal tissue from a non-diseased patient.","longName":"7527825v1.0:7332471v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B6746D69-AFE3-6D9E-E053-4EBD850A99A1","latestVersionIndicator":"Yes","beginDate":"2020-12-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-12-14","modifiedBy":"KNABLEJ","dateModified":"2021-01-21","changeNote":"1/21/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 12/14/20 jk created CPTAC Normal tissue procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7532237","version":"1","preferredName":"Tissue Collection Comment Text","preferredDefinition":"Free text describing the tissue specimen, cells or cell lines, used for experimental purpose.","longName":"7527827v1.0:6847557v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"B6761CF4-0E0E-7557-E053-4EBD850A4978","latestVersionIndicator":"Yes","beginDate":"2020-12-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-12-14","modifiedBy":"KNABLEJ","dateModified":"2020-12-15","changeNote":"12/14/20 jk created CPTAC Normal tissue procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7532238","version":"1","preferredName":"Total Normal Tissue Weight Milligram Value","preferredDefinition":"A numerical quantity documenting the total weight of all normal tissue collected from a non-diseased patient.","longName":"7527830v1.0:7456175v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B67476D0-281B-0B95-E053-4EBD850A7FE3","latestVersionIndicator":"Yes","beginDate":"2020-12-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-12-14","modifiedBy":"KNABLEJ","dateModified":"2021-01-21","changeNote":"1/21/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 12/14/20 jk created CPTAC Normal tissue procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7532239","version":"1","preferredName":"Normal Tissue Not Collected Reason","preferredDefinition":"An explanation of why sufficient normal tissue from a non-diseased patient was not collected.","longName":"7527832v1.0:7452286v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B67476D0-2851-0B95-E053-4EBD850A7FE3","latestVersionIndicator":"Yes","beginDate":"2020-12-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-12-14","modifiedBy":"KNABLEJ","dateModified":"2021-01-21","changeNote":"1/21/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 12/14/20 jk created CPTAC Normal tissue procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7532240","version":"1","preferredName":"Normal Tissue Not Collected Other Specify","preferredDefinition":"An explanation different than the one(s) previously specified as to why sufficient normal tissue from a non-diseased patient was not collected.","longName":"7527832v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B6745B8C-3723-77DA-E053-4EBD850AF499","latestVersionIndicator":"Yes","beginDate":"2020-12-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-12-14","modifiedBy":"KNABLEJ","dateModified":"2021-01-21","changeNote":"1/21/21 jk  Released, upd Reg Status per SME (NGM) review and approval. 12/14/20 jk created CPTAC Normal tissue procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7587034","version":"1","preferredName":"Treatment Regimen End Date Checkbox Indicator","preferredDefinition":"A checkbox indicator to designate that the treatment plan has not ended.","longName":"TRT_REG_END_DATE","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"BC3046B7-2000-1AB9-E053-4EBD850A5874","latestVersionIndicator":"Yes","beginDate":"2021-02-25","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-02-25","modifiedBy":"RAGUNATU","dateModified":"2022-04-22","changeNote":"4/3/21 jk Released, upd Reg Status per SME (NGM) review and approval.  2/25/21 jk created for new question on updated generic Follow-up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7587377","version":"1","preferredName":"New Tumor Event  Additional Surgery for New Loco-Regional Tumor Performed Indicator","preferredDefinition":"A response to indicate if any additional surgery was performed on a newly discovered loco-regional tumor.","longName":"7587049v1.0:7074638v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"BC42D80F-F339-2698-E053-4EBD850A06A2","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-02-26","modifiedBy":"KNABLEJ","dateModified":"2021-04-04","changeNote":"4/4/21 jk Released, upd Reg Status per SME (NGM) review and approval.  2/26/21 jk created for revised specificity in question on updated generic Follow-up CRF.  Replaced CDE 7092640.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7588855","version":"1","preferredName":"New Tumor Event Additional Surgery for New Loco-Regional Tumor Performed Date","preferredDefinition":"The date on which additional surgery for a newly discovered loco-regional tumor event was performed.","longName":"7587049v1.0:2018550v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"BC7FE33A-8F52-0F8A-E053-4EBD850AF936","latestVersionIndicator":"Yes","beginDate":"2021-03-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-03-02","modifiedBy":"KNABLEJ","dateModified":"2021-10-20","changeNote":"10/20/21 jk def upd per SME to add \"was performed\".  4/4/21 jk Released, upd Reg Status per SME (NGM) review and approval. 3/2/21 jk created for revised specificity in question on updated generic Follow-up CRF.  Replaced CDE 7092637.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7588892","version":"1","preferredName":"New Tumor Event Number of Days from Date of Initial Cancer Diagnosis to Date of Additional Surgery for Loco-Regional Tumor Day Count","preferredDefinition":"The number of days from the date of the initial cancer diagnosis to the date of additional surgery for a newly discovered loco-regional tumor event.","longName":"7587307v1.0:7069460v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"BC93BBFC-48C4-4E2A-E053-4EBD850A10D9","latestVersionIndicator":"Yes","beginDate":"2021-03-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-03-02","modifiedBy":"KNABLEJ","dateModified":"2021-04-06","changeNote":"4/6/21 Chg \"Pathologic\" to \"Cancer\" in LN, def and PQT per SME review; EVS syn.  4/4/21 jk Released, upd Reg Status per SME (NGM) review and approval. 3/2/21 jk created for revised specificity in question on updated generic Follow-up CRF.  Replaced CDE 7092639.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7588893","version":"1","preferredName":"New Tumor Event Number of Days from Date of Initial Cancer Diagnosis to Date of Additional Surgery for  Metastatic Tumor Day Count","preferredDefinition":"The number of days from the date of the initial cancer diagnosis to the date of additional surgery for a newly discovered metastatic tumor event.","longName":"7587341v1.0:7069460v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"BC9414BB-F313-6F48-E053-4EBD850AE102","latestVersionIndicator":"Yes","beginDate":"2021-03-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-03-02","modifiedBy":"KNABLEJ","dateModified":"2021-04-06","changeNote":"4/6/21 Upd \"Pathologic\" to \"Cancer\" in LN, def and PQT per SME review; EVS syn. 4/4/21 Released CDE; added \":\" to CDE question text, upd RS.  3/2/21 jk created for new question on updated generic Follow-up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7588908","version":"1","preferredName":"New Tumor Event Residual Tumor After Surgery for New Loco-regional Tumor Status","preferredDefinition":"The residual tumor status of a reemergent malignant neoplasm after a period of remission at the site of the original tumor or adjacent to it.","longName":"7587312v1.0:7062948v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"BC94EB2A-D917-116B-E053-4EBD850A9B50","latestVersionIndicator":"Yes","beginDate":"2021-03-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-03-02","modifiedBy":"KNABLEJ","dateModified":"2021-04-06","changeNote":"4/6/21 jk corrected PQT for \"Loco-regional\".  4/4/21 jk Released, upd Reg Status per SME (NGM) review and approval. 3/2/21 jk created for new question on updated generic Follow-up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7589997","version":"1","preferredName":"New Tumor Event Residual Tumor After Surgery for New Metastatic Tumor Status","preferredDefinition":"The residual tumor status of a newly discovered malignant neoplasm that has spread or migrated from the original tumor site to another part of the body which contains cells that are like those in the original (primary) tumor.","longName":"7587317v1.0:7062948v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"BCB684AF-71AB-7042-E053-4EBD850A7A60","latestVersionIndicator":"Yes","beginDate":"2021-03-04","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-03-04","modifiedBy":"KNABLEJ","dateModified":"2021-04-04","changeNote":"4/4/21 jk Released, upd Reg Status per SME (NGM) review and approval.   3/4/21 jk created for new question on updated generic Follow-up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7590060","version":"1","preferredName":"New Tumor Event Additional Surgery for New Metastatic Tumor Performed Date","preferredDefinition":"The date on which additional surgery for a newly discovered metastatic tumor event was performed.","longName":"7587053v1.0:2018550v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"BCBB9E31-8272-70D7-E053-4EBD850ABAFC","latestVersionIndicator":"Yes","beginDate":"2021-03-04","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-03-04","modifiedBy":"KNABLEJ","dateModified":"2021-10-20","changeNote":"10/20/21 jk def upd per SME to add \"was performed\".  4/4/21 Released CDE; added \":\" to CDE question, upd RS.  3/4/21 jk created for new question on updated generic Follow-up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7590114","version":"1","preferredName":"New Tumor Event Additional Surgery for New Metastatic Tumor Performed Indicator","preferredDefinition":"A response to indicate if any additional surgery was performed on a newly discovered metastatic tumor event.","longName":"7587053v1.0:7074638v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"BCBBBC8B-817F-09C3-E053-4EBD850A1F9A","latestVersionIndicator":"Yes","beginDate":"2021-03-04","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-03-04","modifiedBy":"KNABLEJ","dateModified":"2021-04-04","changeNote":"4/4/21 Released CDE; added \":\" to CDE question, upd RS.  3/4/21 jk created for new question on updated generic Follow-up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7631794","version":"1","preferredName":"Follow-Up First Course Treatment Completion Measure of Success of Outcome Status","preferredDefinition":"The state or condition of an individual's success outcome when initial first course treatment concluded.","longName":"7631793v1.0:7074666v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"BFCA96E4-7B55-6767-E053-4EBD850A69E4","latestVersionIndicator":"Yes","beginDate":"2021-04-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-04-12","modifiedBy":"COLBERTM","dateModified":"2022-06-14","changeNote":"4/14/21 jk added to remaining Ph3 FU CSI.  4/12/21 jk created for Phase 3 (old tumor types); companion to CDE 7092630.","administrativeNotes":"6/14/22 Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.  MR","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7640439","version":"1","preferredName":"Tumor Mass Melanoma Anatomic Site","preferredDefinition":"The named locations of a benign or malignant pathologic structure in a soft tissue melanoma.","longName":"6796604v1.0:7640307v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0A89404-10A5-7CBA-E053-4EBD850AC353","latestVersionIndicator":"Yes","beginDate":"2021-04-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-23","modifiedBy":"SOKKERL","dateModified":"2023-09-08","changeNote":"8/17/21 jk added Phase 3 CM Path Review CSI.  4/23/21 ls","administrativeNotes":"9/8/23: Released melanoma AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7640475","version":"1","preferredName":"Breslow Depth Measurement","preferredDefinition":"The thickness of the melanoma, also known as Breslow Thickness.","longName":"2008829v3.0:7640468v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0A8CE83-7EDA-7621-E053-4EBD850ABCFC","latestVersionIndicator":"Yes","beginDate":"2021-04-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-23","modifiedBy":"SOKKERL","dateModified":"2023-09-08","changeNote":null,"administrativeNotes":"9/8/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7642143","version":"1","preferredName":"Tumor Mass Melanoma Histologic Type","preferredDefinition":"The type of tissue in which a carcinoma originated in any of the following anatomic sites: the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma.","longName":"6796606v1.0:7640272v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C0DFD5FF-2154-0F5E-E053-4EBD850A89C5","latestVersionIndicator":"Yes","beginDate":"2021-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-26","modifiedBy":"SOKKERL","dateModified":"2023-09-08","changeNote":"8/17/21 jk added \"Subtype\" as PV and CSI for CM Path Review CRF.  6/30/21 jk updated def to match other tumor types.  4/26/21 ls created for Melanoma Baseline CRF.","administrativeNotes":"9/8/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7642152","version":"1","preferredName":"Paraneoplastic Syndrome Present CPTAC Indicator","preferredDefinition":"A response to indicate whether or not a group of symptoms develop when substances released by some cancer cells disrupt the normal function of surrounding cells and tissue are present.","longName":"7640060v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C0E00147-A4E1-67A9-E053-4EBD850A4B44","latestVersionIndicator":"Yes","beginDate":"2021-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-26","modifiedBy":"COLBERTM","dateModified":"2022-06-06","changeNote":null,"administrativeNotes":"6/6/22 mr  Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7642153","version":"1","preferredName":"Paraneoplastic Syndrome Present Text","preferredDefinition":"A textual description of the symptoms that may develop when substances released by some cancer cells disrupt the normal function of surrounding cells and tissue.","longName":"7640060v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0E00147-A50E-67A9-E053-4EBD850A4B44","latestVersionIndicator":"Yes","beginDate":"2021-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-26","modifiedBy":"SOKKERL","dateModified":"2023-09-08","changeNote":"7/28/21 jk created for Phase 3 CM Baseline CRF.","administrativeNotes":"9/8/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7642165","version":"1","preferredName":"Surgical Margins Assessment Melanoma Status","preferredDefinition":"A status to indicate whether the presence of actual or potential neoplastic tissue has been left outside the boundary of a resected specimen of the skin (cutaneous melanomas), other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system, or in metastasized lymph nodes, liver, lungs, and brain sites.","longName":"7642156v1.0:7642159v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C0E2309A-1F38-4C01-E053-4EBD850A1F1D","latestVersionIndicator":"Yes","beginDate":"2021-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-26","modifiedBy":"SOKKERL","dateModified":"2023-09-08","changeNote":"6/22/21 jk upd sys gen def. 4/26/21 ls created for CM CRF.","administrativeNotes":"9/8/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7642194","version":"1","preferredName":"Melanoma Mitotic Activity Rate Category","preferredDefinition":"A category which describes the dividing (proliferating) activity of atypical, neoplastic melanocytes tissue cells.","longName":"7642298v1.0:7642190v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0E3161A-DF59-2D6E-E053-4EBD850AEA5A","latestVersionIndicator":"Yes","beginDate":"2021-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-26","modifiedBy":"SOKKERL","dateModified":"2023-09-08","changeNote":"7/28/21 jk upd sys gen def.  7/28/21 jk upd DEC to match CM DEC format.  4/26/21 ls created for Phase 3 CM Baseline CRF.","administrativeNotes":"9/8/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7642199","version":"1","preferredName":"Melanoma Mitotic Activity Text","preferredDefinition":"A textual description of the dividing (proliferating) activity of atypical, neoplastic melanocytes tissue cells.","longName":"7642298v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C0E32567-2B50-4B8C-E053-4EBD850A5A8D","latestVersionIndicator":"Yes","beginDate":"2021-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-26","modifiedBy":"COLBERTM","dateModified":"2022-07-11","changeNote":"7/28/21 jk upd sys gen def.  7/27/21 jk upd DEC to match CM DEC format.  4/26/21 ls created for Phase 3 CM Baseline CRF.","administrativeNotes":"7/11/22 Updated definition for consistency per spreadsheet from JK. MR","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7642693","version":"1","preferredName":"Ancillary Study Mutational Analysis Performed CPTAC Indicator","preferredDefinition":"A response to indicate whether or not mutational analysis was performed as part of a secondary study data.","longName":"7642652v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C0E36D3F-DCFC-5D11-E053-4EBD850A288F","latestVersionIndicator":"Yes","beginDate":"2021-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-26","modifiedBy":"COLBERTM","dateModified":"2022-06-06","changeNote":"7/25/21 jk generalized for use on 3 CM questions (AQT).  4/26/21 jk created for Phase 3 CM Baseline CRF.","administrativeNotes":"6/6/22 mr  Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7642881","version":"1","preferredName":"Ancillary Study BRAF Gene Mutation Type","preferredDefinition":"A response to capture the change in the nucleotide sequence of the BRAF gene as part of secondary study data.","longName":"7642869v1.0:7642871v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0E66B10-875F-3CDD-E053-4EBD850A7EF7","latestVersionIndicator":"Yes","beginDate":"2021-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-26","modifiedBy":"SOKKERL","dateModified":"2023-09-08","changeNote":"7/28/21 jk upd sys gen def.","administrativeNotes":"9/8/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7642922","version":"1","preferredName":"Ancillary Study BRAF Gene Mutation Other Specify","preferredDefinition":"Text different from the ones previously specified to capture the change in the nucleotide sequence of the BRAF gene.","longName":"7642869v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0F4F00D-1BB6-7F5A-E053-4EBD850AEB6E","latestVersionIndicator":"Yes","beginDate":"2021-04-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-27","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":"7/28/21 jk upd sys gen def.","administrativeNotes":"9/8/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7642969","version":"1","preferredName":"Ancillary Study NRAS Mutation Status Analysis Type","preferredDefinition":"A response to indicate the type of procedure used to detect and identify mutations in the NRAS gene as part of secondary study data.","longName":"7185554v1.0:7642946v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0F56069-4106-7721-E053-4EBD850A4BA6","latestVersionIndicator":"Yes","beginDate":"2021-04-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-27","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":"7/28/21 jk upd sys gen def.","administrativeNotes":"Admin: 9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7642970","version":"1","preferredName":"Ancillary Study NRAS Mutation Status Other Specify","preferredDefinition":"Text different from the ones previously specified to indicate the type of procedure used to detect and identify mutations in the NRAS gene.","longName":"7185554v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0F56069-4133-7721-E053-4EBD850A4BA6","latestVersionIndicator":"Yes","beginDate":"2021-04-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-27","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":null,"administrativeNotes":"Admin: 9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7643131","version":"1","preferredName":"Ancillary Study KIT Gene Mutation Type","preferredDefinition":"A response to indicate the type of molecular genetic abnormality associated with the mutation of the c-kit (CD117) proto-oncogene in the development of gastrointestinal stromal tumor as part of secondary study data.","longName":"7643096v1.0:7643117v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0F6CC03-3925-2708-E053-4EBD850A491B","latestVersionIndicator":"Yes","beginDate":"2021-04-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-27","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":"7/27/21 jk created for Phase 3 CM Baseline CRF.","administrativeNotes":"Admin: 9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7643133","version":"1","preferredName":"Ancillary Study KIT Gene Mutation Other Specify","preferredDefinition":"Text different from the ones previously specified which captures the type of molecular genetic abnormality associated with the mutation of the c-kit (CD117) proto-oncogene.","longName":"7643096v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0F6783B-326C-54C1-E053-4EBD850AB455","latestVersionIndicator":"Yes","beginDate":"2021-04-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-27","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":"7/28/21 jk upd sys gen def. 4/27/21 ls created for Phase 3 CM Baseline CRF.","administrativeNotes":"Admin: 9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7643965","version":"1","preferredName":"Ancillary Study Immunohistochemical Testing Performed CPTAC Indicator","preferredDefinition":"A response to indicate whether or not any immunohistochemical tests were provided as part of a secondary study data.","longName":"7643964v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C0F82357-AB59-0B69-E053-4EBD850A598D","latestVersionIndicator":"Yes","beginDate":"2021-04-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-27","modifiedBy":"COLBERTM","dateModified":"2022-06-06","changeNote":"5/24/21 jk upd sys gen def.  4/27/21 ls created for Phase 3 CM Baseline CRF.","administrativeNotes":"6/6/22 mr  Released and RS updated to Qualified per CPTAC/Nicollette’s XLS review as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7643966","version":"1","preferredName":"Ancillary Study Immunohistochemical Testing Performed Text","preferredDefinition":"A textual description of the type and result of immunohistochemical tests provided as part of a secondary study data.","longName":"7643964v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0F87807-82CA-657C-E053-4EBD850A44BC","latestVersionIndicator":"Yes","beginDate":"2021-04-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-27","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":null,"administrativeNotes":"Admin: 9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7643967","version":"1","preferredName":"Melanoma Ulceration Outcome","preferredDefinition":"A finding which describes the formation of a break on the skin or on the surface of an organ which may be associated with melanoma.","longName":"3108476v1.0:7642805v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0F89087-CBE6-01A5-E053-4EBD850A2289","latestVersionIndicator":"Yes","beginDate":"2021-04-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-27","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":"7/28/21 jk upd sys gen def.","administrativeNotes":"Admin: 9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7643987","version":"1","preferredName":"Melanoma Microsatellitosis Outcome","preferredDefinition":"An evaluation to determine whether one or more discontinuous nests of melanoma cells measuring at least 0.3 mm in diameter and separated from the primary lesion by more than 0.05 mm of normal tissue are present in an atypical, neoplastic melanocytes sample.","longName":"7643986v1.0:7642805v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C0F8BF6F-7B7C-32FC-E053-4EBD850A140D","latestVersionIndicator":"Yes","beginDate":"2021-04-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-27","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":"7/28/21 jk upd sys gen def.","administrativeNotes":"Admin: 9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7649019","version":"1","preferredName":"Biospecimen Submitted to BCR Specimen Source Anatomic Site","preferredDefinition":"A textual description to identify the specimen source site for the specimen submitted to BCR.","longName":"7649011v1.0:7649016v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16C7A66-3DE7-711E-E053-4EBD850A6F5B","latestVersionIndicator":"Yes","beginDate":"2021-05-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-03","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":"5/3/21 ls created for Phase 3 CM Baseline CRF.","administrativeNotes":"Admin: 9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7649031","version":"1","preferredName":"Melanoma Tumor Infiltrating Lymphocytes Present Present Not Identified Indeterminate Outcome","preferredDefinition":"An evaluation to determine whether tumor infiltrating lymphocytes are present in an atypical, neoplastic melanocytes sample.","longName":"7649030v1.0:7642805v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16FB7DD-CAAD-01C8-E053-4EBD850A2401","latestVersionIndicator":"Yes","beginDate":"2021-05-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-03","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":"7/28/21 jk upd sys gen def. 7/27/21 jk upd DEC to match CM DEC format.  5/3/21 ls created for Phase 3 CM Baseline CRF.","administrativeNotes":"Admin: 9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7649041","version":"1","preferredName":"Melanoma Growth Phase Outcome","preferredDefinition":"A secondary study finding which documents the morphologic architectural pattern of the atypical, neoplastic melanocyte cell spread of a melanoma.","longName":"7649036v1.0:7649038v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16FC089-5728-01AE-E053-4EBD850AE771","latestVersionIndicator":"Yes","beginDate":"2021-05-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-03","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":"7/28/21 jk upd sys gen def.","administrativeNotes":"Admin: 9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7649047","version":"1","preferredName":"Biospecimen Submitted to BCR Site Distant Metastasis Specify Text","preferredDefinition":"A textual description specifying the site of distant metastasis for the specimen submitted to BCR.","longName":"7649046v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C170FC53-EC63-7213-E053-4EBD850A2832","latestVersionIndicator":"Yes","beginDate":"2021-05-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-03","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":"5/3/21 ls created for Phase 3 CM Baseline CRF.","administrativeNotes":"9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7649052","version":"1","preferredName":"Biospecimen Submitted to BCR Interferon Gamma Treatment Administered Prior to Specimen Resection CPTAC Indicator","preferredDefinition":"A response to indicate whether or not interferon gamma treatment was administered prior to the resection of the specimen submitted to the BCR.","longName":"7649051v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C1719B1E-B593-68EF-E053-4EBD850ABAD6","latestVersionIndicator":"Yes","beginDate":"2021-05-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-03","modifiedBy":"COLBERTM","dateModified":"2022-06-06","changeNote":"5/3/21 ls created for Phase 3 CM Baseline CRF.","administrativeNotes":"6/6/22 mr  Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7649057","version":"1","preferredName":"Biospecimen Submitted to BCR Interferon Gamma Treatment Administered 90 Days Prior to Specimen Resection CPTAC Indicator","preferredDefinition":"A response to indicate whether or not interferon gamma treatment was administered 90 days prior to the specimen resection submitted to the BCR.","longName":"7649056v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C1719B1E-B5F6-68EF-E053-4EBD850ABAD6","latestVersionIndicator":"Yes","beginDate":"2021-05-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-03","modifiedBy":"COLBERTM","dateModified":"2022-06-06","changeNote":"5/3/21 ls created for Phase 3 CM Baseline CRF.","administrativeNotes":"6/6/22 mr  Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7649190","version":"1","preferredName":"Tumor Mass Macroscopic Satellite Nodule Present Outcome","preferredDefinition":"A finding which describes whether macroscopic satellite nodule are present in a melanoma.","longName":"7649189v1.0:7642805v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C180F621-7834-084C-E053-4EBD850A0C16","latestVersionIndicator":"Yes","beginDate":"2021-05-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-04","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":"7/28/21 jk update DEC OC for consistency with other DECs.  5/4/21 ls created for Phase 3 CM Baseline CRF.","administrativeNotes":"9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7649221","version":"1","preferredName":"Surgical Margins Assessment Invasive Carcinoma Status","preferredDefinition":"A status to indicate whether the presence of actual or potential neoplastic tissue has been left outside the boundary of a resected specimen not confined to the epithelium, and has spread to the surrounding stroma.","longName":"7642156v1.0:7649216v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C182653C-B270-0C83-E053-4EBD850A0639","latestVersionIndicator":"Yes","beginDate":"2021-05-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-04","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":"6/22/21 jk upd sys gen def. 5/4/21 ls created for HNSCC CRF, generalized for reuse on other CRFs.","administrativeNotes":"9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7651562","version":"1","preferredName":"Tumor Mass Perineural Invasion Assessment Outcome","preferredDefinition":"A finding which documents the presence or degree of perineural invasion present in a sample.","longName":"7651561v1.0:7642805v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C183FD2D-3FB4-073E-E053-4EBD850AD3AC","latestVersionIndicator":"Yes","beginDate":"2021-05-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-04","modifiedBy":"KNABLEJ","dateModified":"2021-06-30","changeNote":"6/20/21 jk generalized HNSCC OC for use on Phase 3 HNSCC, CM, and Pancreatic CRFs.  5/6/21 created for HNSCC Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7651645","version":"1","preferredName":"Tumor Mass Extranodal Involvement Present Outcome","preferredDefinition":"A finding which documents if a malignant neoplasm extended beyond the lymph node capsule in a sample.","longName":"7651644v1.0:7642805v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1964C02-DEB7-750E-E053-4EBD850AD9A4","latestVersionIndicator":"Yes","beginDate":"2021-05-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-05","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":"7/27/21 jk created for Phase 3 CM Baseline CRF.  6/30/21 jk updated def to match other tumor types.  5/5/21 created for HNSCC Baseline CRF.","administrativeNotes":"9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7652406","version":"1","preferredName":"Tumor Mass Head and Neck Squamous Cell Carcinoma Anatomic Site","preferredDefinition":"The named locations of a benign or malignant pathologic structure involving the lip and oral cavity, nasal cavity, paranasal sinuses, pharynx, larynx, and salivary glands.","longName":"6796604v1.0:7652405v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C1AA4F76-91F2-577F-E053-4EBD850A8257","latestVersionIndicator":"Yes","beginDate":"2021-05-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-06","modifiedBy":"COLBERTM","dateModified":"2022-09-20","changeNote":"7/8/21 jk added HNSCC Path RPT CSI.  6/30/21 jk updated def to match format of other tumor types; created for HNSCC Baseline CRF.","administrativeNotes":"9/8/22 Added HNSCC Local Path CS/CSI. mr; 9/20/22 Released for HNSCC Path Review per jk. mr;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7652409","version":"1","preferredName":"Tumor Mass  Head and Neck Squamous Cell Carcinoma Histologic Type","preferredDefinition":"The type of tissue in which a carcinoma originated in any of the following anatomic sites: lip and oral cavity, nasal cavity, paranasal sinuses, pharynx, larynx, and salivary glands.","longName":"6796606v1.0:7652408v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C1A9F842-072B-1AAD-E053-4EBD850AC3B4","latestVersionIndicator":"Yes","beginDate":"2021-05-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-06","modifiedBy":"COLBERTM","dateModified":"2022-09-20","changeNote":"7/12/21 jk added HNSCC Path Rpt CSI. 6/30/21 jk updated def to match other tumor types.  5/6/21 ls created for HNSCC Baseline CRF.","administrativeNotes":"9/8/22 Added HNSCC Local Path CS/CSI. mr; 9/20/22 Released per jk. mr;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7652422","version":"1","preferredName":"Baseline Characteristic Biospecimen Histologic Grade","preferredDefinition":"The assignment of a position on a scale of quality to describe the microscopic physical features of cells gathered prior to an event or intervention.","longName":"7652421v1.0:7135768v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C1AB55A5-A342-5AD6-E053-4EBD850AC5ED","latestVersionIndicator":"Yes","beginDate":"2021-05-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-06","modifiedBy":"COLBERTM","dateModified":"2022-09-19","changeNote":"7/12/21 jk added HNSCC Path Rpt CSI. 5/19/21 jk upd def.  5/6/21 jk created for Phase 3 HNSCC, CM Baseline CRF.","administrativeNotes":"9/8/22 Added HNSCC Local Path CS/CSI. mr; 9/19/22 Released per jk. mr;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7652456","version":"1","preferredName":"Tumor Mass Lymphatic Invasion Present Outcome","preferredDefinition":"A finding which documents whether lymphatic invasion was present in a sample.","longName":"7652455v1.0:7642805v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1ABD6BB-AD00-7DF8-E053-4EBD850A200C","latestVersionIndicator":"Yes","beginDate":"2021-05-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-06","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":"6/30/21 jk updated def to match other tumor types.  5/6/21 created for HNSCC Baseline CRF.","administrativeNotes":"9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7652620","version":"1","preferredName":"Head and Neck Squamous Cell Carcinoma Lymph Node Dissection Performed CPTAC Indicator","preferredDefinition":"A response to indicate whether or not a lymph node dissection of the neck was performed during the study.","longName":"7652619v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C1BE9425-FFE7-5121-E053-4EBD850A5D8A","latestVersionIndicator":"Yes","beginDate":"2021-05-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-07","modifiedBy":"CLOHNES","dateModified":"2022-06-16","changeNote":"5/19/21 ls created for Phase 3 HNSCC Baseline CRF.","administrativeNotes":"6/6/22 mr  Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.; 6/16/22 added 2 AQTs, 2 OID, CCTG, designated to CCTG per Chad Winch cjl","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7652658","version":"1","preferredName":"Ancillary Study p53 Gene Analysis Outcome","preferredDefinition":"A secondary study finding following an analysis procedure to detect and identify mutations in the TP53 gene.","longName":"7652657v1.0:3124937v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C1C01E4C-E00E-308F-E053-4EBD850A601B","latestVersionIndicator":"Yes","beginDate":"2021-05-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-07","modifiedBy":"KNABLEJ","dateModified":"2021-07-01","changeNote":"7/1/21 jk updated def to match other tumor types.  5/7/21 ls created for HNSCC Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7652663","version":"1","preferredName":"Ancillary Study EGFR Amplification Gene Status","preferredDefinition":"A secondary study finding following a procedure used to detect and identify the status of amplification for the EGFR gene.","longName":"7652662v1.0:3124942v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C1C041D8-6A6D-5026-E053-4EBD850A15B4","latestVersionIndicator":"Yes","beginDate":"2021-05-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-07","modifiedBy":"KNABLEJ","dateModified":"2021-07-01","changeNote":"7/1/21 jk updated def to match other tumor types.  5/7/21 ls created for HNSCC Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7652669","version":"1","preferredName":"Ancillary Study HPV Status by PCR Finding Outcome","preferredDefinition":"A secondary study finding capturing the positive or negative result of the HPV status using the polymerase chain reaction (PCR) procedure.","longName":"7652668v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C1C01E4C-E04B-308F-E053-4EBD850A601B","latestVersionIndicator":"Yes","beginDate":"2021-05-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-07","modifiedBy":"KNABLEJ","dateModified":"2021-07-01","changeNote":"7/1/21 jk updated def to match other tumor types.  5/7/21 ls created for HNSCC Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7652675","version":"1","preferredName":"Ancillary Study HPV Status by ISH Outcome","preferredDefinition":"A secondary study finding capturing the positive or negative result of the HPV status using in situ hybridization (ISH) procedure.","longName":"7652674v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C1C0972D-2566-5C31-E053-4EBD850A818C","latestVersionIndicator":"Yes","beginDate":"2021-05-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-07","modifiedBy":"KNABLEJ","dateModified":"2021-07-06","changeNote":"7/1/21 jk updated def to match other tumor types.  5/7/21 ls created for HNSCC Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7652777","version":"1","preferredName":"Ancillary Study P16 Human Papillomavirus Status","preferredDefinition":"A secondary study finding capturing the P16/Human Papillomavirus status of both cell proliferation and cell cycle progression of the cyclin-dependent kinase inhibitor 2A (156 aa, ~17 kDa) encoded by the human CDKN2A gene.","longName":"7652776v1.0:7072106v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1FBA9FA-7977-6AB2-E053-4EBD850A3E68","latestVersionIndicator":"Yes","beginDate":"2021-05-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-10","modifiedBy":"SOKKERL","dateModified":"2023-09-30","changeNote":"7/1/21 jk updated def to match other tumor types.  5/10/21 ls created for HNSCC Baseline CRF.","administrativeNotes":"9/30/23Released SAR AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7653077","version":"1","preferredName":"Metastatic Diagnosis Specify Documented Distant Metastasis Anatomic Site","preferredDefinition":"A textual description to specify the anatomic location of any documented distant metastasis.","longName":"7653076v1.0:6796740v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C20D9C5C-8B16-4507-E053-4EBD850A925F","latestVersionIndicator":"Yes","beginDate":"2021-05-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-11","modifiedBy":"KNABLEJ","dateModified":"2021-07-26","changeNote":"7/26/21 jk added Phase 3 CM Baseline CSI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7653173","version":"1","preferredName":"Tumor Mass Soft Tissue Sarcoma Anatomic Site","preferredDefinition":"The named location of or within the body which identifies a malignant neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.","longName":"6796604v1.0:7653168v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C20FB8F3-8881-72F9-E053-4EBD850A5677","latestVersionIndicator":"Yes","beginDate":"2021-05-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-11","modifiedBy":"KNABLEJ","dateModified":"2021-08-10","changeNote":"8/10/21 jk upd sys gen def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7653179","version":"1","preferredName":"Tumor Mass Soft Tissue Sarcoma Histologic Type","preferredDefinition":"The type of tissue in which a carcinoma originated in any of the following anatomic sites: muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.","longName":"6796606v1.0:7653178v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C20E0F23-3E28-6CC4-E053-4EBD850A25D2","latestVersionIndicator":"Yes","beginDate":"2021-05-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-11","modifiedBy":"KNABLEJ","dateModified":"2021-06-30","changeNote":"6/30/21 jk updated def to match other tumor types.  5/11/21 ls created for SAR Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7653186","version":"1","preferredName":"Surgical Margins Assessment Soft Tissue Sarcoma Status","preferredDefinition":"A status to indicate whether the presence of actual or potential neoplastic tissue has been left outside the boundary of a resected specimen of the muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.","longName":"7642156v1.0:7653185v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C21064A6-0E67-4491-E053-4EBD850A405F","latestVersionIndicator":"Yes","beginDate":"2021-05-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-11","modifiedBy":"SOKKERL","dateModified":"2023-09-08","changeNote":"6/22/21 jk upd sys gen def. 5/4/21 ls created for SAR CRF.","administrativeNotes":"9/8/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7653578","version":"1","preferredName":"Baseline Characteristic Sarcoma by FNCLCC Grade","preferredDefinition":"The assignment of a position on a scale of quality to describe the microscopic physical features of cells according to the French Federation of Cancer Centers Sarcoma Group (FNCLCC).","longName":"7653571v1.0:7653573v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Incomplete","id":"C223AEF2-35B2-1188-E053-4EBD850A1F35","latestVersionIndicator":"Yes","beginDate":"2021-05-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-12","modifiedBy":"SOKKERL","dateModified":"2023-09-30","changeNote":"5/19/21 jk syn approved by EVS; def upd.  5/12/ls waiting on synonym approval from EVS for C9023.","administrativeNotes":"8/22/22 “Incomplete” RS is pending curation of the CPTAC SAR baseline CRF. per jk.  MR; 9/30/23 Released SAR AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7653587","version":"1","preferredName":"Baseline Characteristic GIST Histologic Grade","preferredDefinition":"The assignment of a position on a scale of quality to describe the microscopic physical features of cells based on the GIST histologic grading scale.","longName":"7653586v1.0:7653760v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C223FE72-1AB9-1122-E053-4EBD850AA4B5","latestVersionIndicator":"Yes","beginDate":"2021-05-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-12","modifiedBy":"KNABLEJ","dateModified":"2021-05-19","changeNote":"5/12/21 jk created for Phase 3 SAR Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7653676","version":"1","preferredName":"Ancillary Study Cytogenetic Studies Type","preferredDefinition":"A study that is secondary to another study._Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities._Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities._Something distinguishable as an identifiable class based on common qualities.","longName":"7653632v1.0:7653652v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C2247A9F-BFDE-5DB9-E053-4EBD850A80D2","latestVersionIndicator":"Yes","beginDate":"2021-05-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-12","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":null,"administrativeNotes":"9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7653752","version":"1","preferredName":"Ancillary Study Cytogenetic Studies Other Specify","preferredDefinition":"A study that is secondary to another study._Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities._Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.","longName":"7653632v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C225E8F4-62D9-066C-E053-4EBD850A0800","latestVersionIndicator":"Yes","beginDate":"2021-05-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-12","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":null,"administrativeNotes":"9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7658145","version":"1","preferredName":"Cause of Death Reason CPTAC Category","preferredDefinition":"The category describing the circumstance or condition of greatest rank or importance that results in the death of a living being.","longName":"5915155v1.0:7658143v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C23984C3-0ECA-121B-E053-4EBD850A48C5","latestVersionIndicator":"Yes","beginDate":"2021-05-13","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-13","modifiedBy":"KNABLEJ","dateModified":"2021-05-13","changeNote":"5/13/21 jk created for HNSCC FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7658148","version":"1","preferredName":"Cause of Death Reason Text","preferredDefinition":"A textual description of the circumstance or condition that results in the death of a living being.","longName":"5915155v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C238B843-2555-1EB4-E053-4EBD850A549C","latestVersionIndicator":"Yes","beginDate":"2021-05-13","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-13","modifiedBy":"COLBERTM","dateModified":"2022-06-08","changeNote":"5/13/21 jk added CM FU CRF.  5/13/21 jk created for HNSCC FU CRF; companion CDE to CDE 7658145.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7658882","version":"1","preferredName":"Post-operative Therapy Adjuvant Radiation Therapy Administered CPTAC Indicator","preferredDefinition":"A response to indicate whether or not adjuvant post-operative radiation therapy was administered with the intention of achieving the best possible initial first course treatment outcome.","longName":"7642944v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C23B0EBA-C2FC-2F2D-E053-4EBD850A5081","latestVersionIndicator":"Yes","beginDate":"2021-05-13","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-13","modifiedBy":"COLBERTM","dateModified":"2022-06-08","changeNote":"7/28/21 jk added Phase 3 CM FU CSI.  5/13/21 jk created for Phase 3 HNSCC FU CRF.","administrativeNotes":"6/6/22 mr  Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7658883","version":"1","preferredName":"Post-operative Therapy Adjuvant Chemotherapy Administered CPTAC Indicator","preferredDefinition":"A response to indicate whether or not adjuvant post-operative chemotherapy was administered with the intention of achieving the best possible initial first course treatment outcome.","longName":"7642979v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C23B0EBA-C32A-2F2D-E053-4EBD850A5081","latestVersionIndicator":"Yes","beginDate":"2021-05-13","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-13","modifiedBy":"COLBERTM","dateModified":"2022-06-08","changeNote":"7/28/21 jk added Phase 3 CM FU CSI.  5/13/21 jk created for Phase 3 HNSCC FU CRF.","administrativeNotes":"6/6/22 mr  Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7658911","version":"1","preferredName":"Post-operative Therapy Adjuvant Immunological Therapy Administered CPTAC Indicator","preferredDefinition":"A response to indicate whether or not adjuvant post-operative immunological therapy was administered with the intention of achieving the best possible initial first course treatment outcome.","longName":"7642983v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C23B0EBA-C366-2F2D-E053-4EBD850A5081","latestVersionIndicator":"Yes","beginDate":"2021-05-13","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-13","modifiedBy":"COLBERTM","dateModified":"2022-06-08","changeNote":"7/28/21 jk added Phase 3 CM FU CSI.  5/13/21 jk created for Phase 3 HNSCC FU CRF.","administrativeNotes":"6/6/22 mr  Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7658924","version":"1","preferredName":"Post-operative Therapy Adjuvant Targeted Molecular Therapy Administered CPTAC Indicator","preferredDefinition":"A response to indicate whether or not adjuvant post-operative targeted molecular therapy was administered with the intention of achieving the best possible initial first course treatment outcome.","longName":"7643106v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C23B0EBA-C394-2F2D-E053-4EBD850A5081","latestVersionIndicator":"Yes","beginDate":"2021-05-13","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-13","modifiedBy":"COLBERTM","dateModified":"2022-06-08","changeNote":"7/28/21 jk added Phase 3 CM FU CSI.  5/13/21 jk created for Phase 3 HNSCC FU CRF.","administrativeNotes":"6/6/22 mr Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7660695","version":"1","preferredName":"Follow-Up Performance Status Scale Timing Type","preferredDefinition":"The performance status timing scale used to indicate when a measurement of how well a patient is able to perform ordinary tasks and carry out daily activities is obtained.","longName":"7763721v1.0:7642112v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C23F7E0A-B062-6DE2-E053-4EBD850AF4F2","latestVersionIndicator":"Yes","beginDate":"2021-05-13","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-13","modifiedBy":"COLBERTM","dateModified":"2022-06-08","changeNote":"8/9/21 jk upd to reuse DEC 7763721 rather than DEC 6848785.  5/13/21 jk created for Phase 3 HNSCC FU CRF.","administrativeNotes":"6/8/22 mr Edit made to definition per CPTAC/Nicollette’s XLS review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7660696","version":"1","preferredName":"New Tumor Event HNSCC Anatomic Site","preferredDefinition":"The anatomic site of a newly discovered neoplasm in the lip and oral cavity, nasal cavity, paranasal sinuses, pharynx, larynx, or salivary glands that developed after initial treatment.","longName":"6848804v1.0:7643978v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C23FC7D9-0A58-28B8-E053-4EBD850A00CF","latestVersionIndicator":"Yes","beginDate":"2021-05-13","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-13","modifiedBy":"COLBERTM","dateModified":"2022-06-13","changeNote":"8/10/21 jk upd def for wording consistency.  5/13/21 jk created for Phase 3 HNSCC FU CRF.","administrativeNotes":"6/13/22 Edits made to definition per CPTAC/Nicollette’s XLS review.  MR","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7665049","version":"1","preferredName":"Definitive Treatment Completion Date","preferredDefinition":"The date on which the treatment plan for a disease or disorder chosen as the best one for a patient after all other choices concluded.","longName":"7665044v1.0:2018550v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C28A41A8-831A-0589-E053-4EBD850AA14D","latestVersionIndicator":"Yes","beginDate":"2021-05-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-17","modifiedBy":"COLBERTM","dateModified":"2022-06-15","changeNote":"5/17/21 jk created for Phase 3 HNSCC FU CRF.","administrativeNotes":"6/15/22 Edits made to definition per CPTAC/Nicollette’s XLS review.  MR","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7665060","version":"1","preferredName":"Definitive Treatment Method of Therapy Type","preferredDefinition":"A response to indicate the treatment plan for a disease or disorder determined to be the best one for a patient after all other choices have been considered.","longName":"7665048v1.0:7665033v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C28ADA18-47E9-4C1F-E053-4EBD850ADB94","latestVersionIndicator":"Yes","beginDate":"2021-05-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-17","modifiedBy":"COLBERTM","dateModified":"2022-06-13","changeNote":"7/20/21 jk replace DEC 3601544 with DEC 7665048 using CPTAC specific term C158801 used in VD.   5/17/21 jk created for Phase 3 HNSCC FU CRF.","administrativeNotes":"6/13/22 Edits made to definition per CPTAC/Nicollette’s XLS review.  MR","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7665070","version":"1","preferredName":"Smokeless Tobacco Cessation Not Applicable Checkbox Indicator","preferredDefinition":"A checkbox indicator to designate that a response is not applicable because the participant has not stopped using tobacco in a smokeless form such as chewing tobacco or snuff.","longName":"7662133v1.0:2185839v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C28B0928-DBF3-3C8B-E053-4EBD850AFA94","latestVersionIndicator":"Yes","beginDate":"2021-05-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-17","modifiedBy":"KNABLEJ","dateModified":"2021-05-19","changeNote":"5/17/21 jk created for Phase 3 HNSCC FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7665130","version":"1","preferredName":"Definitive Treatment Evidence of Disease Present after Completion of Therapy CPTAC Indicator","preferredDefinition":"A response to indicate whether or not evidence of disease was present after the completion of definitive therapy.","longName":"7665104v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C28CE274-6483-44F2-E053-4EBD850A6750","latestVersionIndicator":"Yes","beginDate":"2021-05-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-17","modifiedBy":"COLBERTM","dateModified":"2022-06-06","changeNote":"5/17/21 jk created for Phase 3 HNSCC FU CRF.","administrativeNotes":"6/6/22 mr Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7668161","version":"1","preferredName":"New Tumor Event Residual Tumor After Surgery Status","preferredDefinition":"The residual tumor status after surgery for a newly discovered neoplasm.","longName":"7648291v1.0:7062948v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C290DBB6-F101-404D-E053-4EBD850AA719","latestVersionIndicator":"Yes","beginDate":"2021-05-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-17","modifiedBy":"COLBERTM","dateModified":"2022-06-15","changeNote":"8/2/21 jk added Phase 3 CM FU CSI.  5/17/21 jk created for Phase 3 HNSCC FU CRF.","administrativeNotes":"6/15/22 Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.  MR","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7668162","version":"1","preferredName":"New Tumor Event Additional Radiation Therapy Indicator","preferredDefinition":"A response to indicate whether or not radiation was administered as an additional treatment for a newly discovered tumor.","longName":"7648298v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C2910A2D-B992-7D25-E053-4EBD850A9A74","latestVersionIndicator":"Yes","beginDate":"2021-05-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-17","modifiedBy":"CLOHNES","dateModified":"2023-12-18","changeNote":"8/2/21 jk added Phase 3 CM FU CSI.  5/17/21 jk created for Phase 3 HNSCC FU CRF.","administrativeNotes":"12/12/23 Added AQT CCTG ticket number CADSR0003182 cjl; 6/6/22 mr Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.  \r\n\r\nadded AQT and alt name OID for CCTG 5/31/22 CJL","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7668163","version":"1","preferredName":"New Tumor Event Additional Chemotherapy Indicator","preferredDefinition":"A response to indicate whether or not chemotherapy was administered as an additional treatment for a newly discovered tumor.","longName":"7648302v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C2910A2D-B9C0-7D25-E053-4EBD850A9A74","latestVersionIndicator":"Yes","beginDate":"2021-05-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-17","modifiedBy":"COLBERTM","dateModified":"2022-06-06","changeNote":"8/2/21 jk added Phase 3 CM FU CSI.  5/17/21 jk created for Phase 3 HNSCC FU CRF.","administrativeNotes":"6/6/22 mr Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7668164","version":"1","preferredName":"New Tumor Event Additional Immunotherapy Indicator","preferredDefinition":"A response to indicate whether or not immunotherapy was administered as an additional treatment for a newly discovered tumor.","longName":"7648306v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C2910A2D-B9F1-7D25-E053-4EBD850A9A74","latestVersionIndicator":"Yes","beginDate":"2021-05-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-17","modifiedBy":"COLBERTM","dateModified":"2022-06-06","changeNote":"8/2/21 jk added Phase 3 CM FU CSI.  5/17/21 jk created for Phase 3 HNSCC FU CRF.","administrativeNotes":"6/6/22 mr Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7668165","version":"1","preferredName":"New Tumor Event Additional Targeted Molecular Therapy Indicator","preferredDefinition":"A response to indicate whether or not targeted molecular therapy was administered as an additional treatment for a newly discovered tumor.","longName":"7648310v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C2910A2D-BA1F-7D25-E053-4EBD850A9A74","latestVersionIndicator":"Yes","beginDate":"2021-05-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-17","modifiedBy":"COLBERTM","dateModified":"2022-06-06","changeNote":"8/2/21 jk added Phase 3 CM FU CSI.  5/17/21 jk created for Phase 3 HNSCC FU CRF.","administrativeNotes":"6/6/22 mr Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7668166","version":"1","preferredName":"New Tumor Event Diagnostic Evidence of Recurrence or Relapse Reason","preferredDefinition":"A response to indicate testing or observational confirmation of  recurrence or relapse.","longName":"7648288v1.0:7648279v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C29154EF-F099-72BB-E053-4EBD850A27F1","latestVersionIndicator":"Yes","beginDate":"2021-05-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-17","modifiedBy":"COLBERTM","dateModified":"2022-06-13","changeNote":"5/17/21 jk created for Phase 3 HNSCC FU CRF.","administrativeNotes":"6/13/22 Edits made to definition per CPTAC/Nicollette’s XLS review.  MR","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7668266","version":"1","preferredName":"Gastrointestinal Stromal Tumor KIT Mutation Analysis Performed CPTAC Indicator","preferredDefinition":"A response to indicate whether or not KIT mutations were analyzed during the study.","longName":"7668265v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C29C4A10-7E79-1C48-E053-4EBD850A2F5D","latestVersionIndicator":"Yes","beginDate":"2021-05-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-18","modifiedBy":"COLBERTM","dateModified":"2022-06-06","changeNote":null,"administrativeNotes":"6/6/22 mr Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7668495","version":"1","preferredName":"Smokeless Tobacco Usage Unknown Checkbox Indicator","preferredDefinition":"A checkbox indicator to designate that use of tobacco in a smokeless form such as chewing tobacco or snuff is not known.","longName":"7662129v1.0:2185839v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C2B09FA0-3D6C-709F-E053-4EBD850A45AF","latestVersionIndicator":"Yes","beginDate":"2021-05-19","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-19","modifiedBy":"KNABLEJ","dateModified":"2021-05-19","changeNote":"5/17/21 jk created for Phase 3 HNSCC FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7669660","version":"1","preferredName":"Ancillary Study Mutational Analysis Testing Method Text","preferredDefinition":"A textual description of the specific molecular analysis method used to detect and identify mutations provided as part of the secondary study data.","longName":"7669659v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C2D80E55-1643-3B03-E053-4EBD850AF5DC","latestVersionIndicator":"Yes","beginDate":"2021-05-21","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-05-21","modifiedBy":"KNABLEJ","dateModified":"2021-05-24","changeNote":"5/24/21 jk upd sys gen def.  5/19/21 jk created for Phase 3 Baseline CRFs, AQT for gene specific questions.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7671808","version":"1","preferredName":"Gastrointestinal Stromal Tumor Immunohistochemical Testing Performed CPTAC Indicator","preferredDefinition":"A response to indicate whether or not any immunohistochemical tests were performed during the study.","longName":"7671807v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C3CAFF97-2E96-0DA6-E053-4EBD850AA19C","latestVersionIndicator":"Yes","beginDate":"2021-06-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-06-02","modifiedBy":"COLBERTM","dateModified":"2022-06-06","changeNote":null,"administrativeNotes":"6/6/22 mr Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7671821","version":"1","preferredName":"Immunohistochemical Testing Performed Kit Finding Outcome","preferredDefinition":"A question asking if any immunohistochemical tests were performed during the study._Mast/stem cell growth factor receptor Kit (976 aa, ~110 kDa) is encoded by the human KIT gene. This protein is involved in cell survival, tyrosine phosphorylation and ligand-mediated signaling._A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism._A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition._The result of an action.","longName":"7671820v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3CB9FD5-B284-08DA-E053-4EBD850A85E8","latestVersionIndicator":"Yes","beginDate":"2021-06-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-06-02","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":null,"administrativeNotes":"9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7675270","version":"1","preferredName":"Immunohistochemical Testing Performed DOG1 Finding Outcome","preferredDefinition":"A question asking if any immunohistochemical tests were performed during the study._Anoctamin-1 (986 aa, ~114 kDa) is encoded by the human ANO1 gene. This protein plays a role in calcium-dependent transport of chloride._A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism._A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition._The result of an action.","longName":"7675265v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3DCB1F8-9F62-2D11-E053-4EBD850A1CF9","latestVersionIndicator":"Yes","beginDate":"2021-06-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-06-03","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":null,"administrativeNotes":"9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7675275","version":"1","preferredName":"Immunohistochemical Testing Performed SDHB Finding Outcome","preferredDefinition":"A question asking if any immunohistochemical tests were performed during the study._Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial (280 aa, ~32 kDa) is encoded by the human SDHB gene. This protein plays a role in the mediation of redox reactions in the mitochondrial electron transport chain._A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism._A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition._The result of an action.","longName":"7675274v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3DD0ADC-04CC-695B-E053-4EBD850ACBA7","latestVersionIndicator":"Yes","beginDate":"2021-06-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-06-03","modifiedBy":"SOKKERL","dateModified":"2023-09-24","changeNote":null,"administrativeNotes":"9/23/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7675279","version":"1","preferredName":"Immunohistochemical Testing Performed SDHA Finding Outcome","preferredDefinition":"A question asking if any immunohistochemical tests were performed during the study._This gene is involved in the mitochondrial respiratory chain._A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism._A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition._The result of an action.","longName":"7675278v1.0:7050025v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3DCA26F-B316-566A-E053-4EBD850A9234","latestVersionIndicator":"Yes","beginDate":"2021-06-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-06-03","modifiedBy":"SOKKERL","dateModified":"2023-09-25","changeNote":null,"administrativeNotes":"9/24/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7675280","version":"1","preferredName":"Gastrointestinal Stromal Tumor Immunohistochemical Testing Performed Other Specify","preferredDefinition":"A stromal tumor most commonly seen in the gastrointestinal tract. Rare cases of solitary masses in the omentum or the mesentery have also been reported (extragastrointestinal gastrointestinal stromal tumor).  It is a tumor that differentiates along the lines of interstitial cells of Cajal.  Most cases contain KIT- or PDGFRA-activating mutations. Until recently, surgery has been the only effective therapy for this tumor.  However, many patients still experience recurrence.  Conventional chemotherapy and radiation therapy have been of limited value.  A KIT tyrosine kinase inhibitor, imatinib mesylate (also known as STI-571 or Gleevec), is now effective in the treatment of relapsed and unresectable cases._A question asking if any immunohistochemical tests were performed during the study._Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.","longName":"7671807v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3DD0ADC-04ED-695B-E053-4EBD850ACBA7","latestVersionIndicator":"Yes","beginDate":"2021-06-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-06-03","modifiedBy":"SOKKERL","dateModified":"2023-09-25","changeNote":null,"administrativeNotes":"9/24/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7675283","version":"1","preferredName":"Gastrointestinal Stromal Tumor Additional Testing Performed CPTAC Indicator","preferredDefinition":"A response to indicate whether or not any additional tests were performed during the study.","longName":"7675282v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C3DCB1F8-A02E-2D11-E053-4EBD850A1CF9","latestVersionIndicator":"Yes","beginDate":"2021-06-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-06-03","modifiedBy":"COLBERTM","dateModified":"2022-06-06","changeNote":null,"administrativeNotes":"6/6/22 mr Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7675284","version":"1","preferredName":"Gastrointestinal Stromal Tumor Additional Testing Performed Text","preferredDefinition":"A textual description of the specific tests performed on a gastrointestinal stromal tumor.","longName":"7675282v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C3DCB1F8-A054-2D11-E053-4EBD850A1CF9","latestVersionIndicator":"Yes","beginDate":"2021-06-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-06-03","modifiedBy":"COLBERTM","dateModified":"2022-07-11","changeNote":null,"administrativeNotes":"7/11/22 Updated definition for consistency per spreadsheet from JK. MR","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7696661","version":"1","preferredName":"Head and Neck Cutaneous Squamous Cell Carcinoma Pathologic T CPTAC Category","preferredDefinition":"Extent of the primary head and neck squamous cell carcinoma based on clinical stage information combined with operative findings, and evidence obtained from pathology review when surgery is the first definitive therapy.","longName":"7640049v1.0:7696660v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C53C5BA2-7673-0A57-E053-4EBD850A2540","latestVersionIndicator":"Yes","beginDate":"2021-06-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-06-20","modifiedBy":"COLBERTM","dateModified":"2022-08-22","changeNote":"6/20/21 jk created for Phase 3 HNSCC Baseline CRF; Incomplete pending defs for pT0, pT1a, pT1b PVs which are not part of the AJCC ed 8 response set.","administrativeNotes":"8/22/22 Changed RS from Incomplete to Application per jk. MR;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7708694","version":"1","preferredName":"Head and Neck Cutaneous Squamous Cell Carcinoma Pathologic M CPTAC Category","preferredDefinition":"Extent of the distant metastasis for head and neck cutaneous squamous cell carcinoma based on clinical stage information combined with operative findings, and evidence obtained from pathology review when surgery is the first definitive therapy.","longName":"7708693v1.0:7706784v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C570E26A-F326-547A-E053-4EBD850A46C2","latestVersionIndicator":"Yes","beginDate":"2021-06-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-06-23","modifiedBy":"KNABLEJ","dateModified":"2021-06-28","changeNote":"6/23/21 jk created for CPTAC HNSCC Baseline CRF for CPTAC specific PVs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7710844","version":"1","preferredName":"Head and Neck Cutaneous Squamous Cell Carcinoma Pathologic Stage","preferredDefinition":"Stage group based on the combination of T, N, and M categories and relevant prognostic factors for head and neck cutaneous squamous cell carcinoma.","longName":"7640057v1.0:7652632v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C5764D1B-E76D-79BD-E053-4EBD850A4793","latestVersionIndicator":"Yes","beginDate":"2021-06-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-06-23","modifiedBy":"COLBERTM","dateModified":"2022-08-22","changeNote":"6/23/21 jk created for CPTAC HNSCC Baseline CRF for CPTAC specific PVs.  Incomplete pending IVA, IVB, and IVC terms.","administrativeNotes":"8/22/22 Updated definition and ref doc for IVA, IVB, IVC PVs, and RS to Application per jk. MR;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7715659","version":"1","preferredName":"Head and Neck Cutaneous Squamous Cell Carcinoma Clinical M CPTAC Category","preferredDefinition":"Extent of the distant metastasis for head and neck cutaneous squamous cell carcinoma based on clinical stage information obtained from the date of cancer diagnosis until the start of definitive treatment, or within four months (whichever is shorter).","longName":"7640055v1.0:7715656v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C5DDAE7D-A19B-2610-E053-4EBD850A5378","latestVersionIndicator":"Yes","beginDate":"2021-06-28","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-06-28","modifiedBy":"KNABLEJ","dateModified":"2021-06-28","changeNote":"6/28/21 jk created for CPTAC HNSCC Baseline CRF for CPTAC specific PVs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7748862","version":"1","preferredName":"Metastatic Diagnosis No Pathologic Evidence of Distant Metastasis Checkbox Indicator","preferredDefinition":"A checkbox indicator to designate that there is no pathologic evidence of distant metastasis.","longName":"7748822v1.0:2185839v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C80AC512-BF85-540F-E053-4EBD850A94A5","latestVersionIndicator":"Yes","beginDate":"2021-07-26","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-26","modifiedBy":"KNABLEJ","dateModified":"2021-07-26","changeNote":"7/26/21 jk created for Phase 3 CM Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7748925","version":"1","preferredName":"Ancillary Study Serum Lactate Dehydrogenase Level Outcome","preferredDefinition":"A secondary study finding which capture the amount of lactate dehydrogenase present in a sample of serum as part of secondary study data.","longName":"7748922v1.0:7748924v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C810A0A9-E6C4-086E-E053-4EBD850A50A7","latestVersionIndicator":"Yes","beginDate":"2021-07-26","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-26","modifiedBy":"KNABLEJ","dateModified":"2021-07-28","changeNote":"7/28/21 jk upd sys gen def. 7/26/21 jk created for Phase 3 CM Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7748949","version":"1","preferredName":"Melanoma Tumor Regression Assessment Outcome","preferredDefinition":"An evaluation of the presence or degree of tumor regression present in an atypical, neoplastic melanocytes sample.","longName":"7748948v1.0:7642805v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C81C63EB-20AE-3FF7-E053-4EBD850A75FE","latestVersionIndicator":"Yes","beginDate":"2021-07-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-27","modifiedBy":"KNABLEJ","dateModified":"2021-07-30","changeNote":"7/28/21 jk upd sys gen def.  7/26/21 jk created for Phase 3 CM Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7751426","version":"1","preferredName":"Melanoma Multiple Known Primary Tumors at Initial Diagnosis CPTAC Indicator","preferredDefinition":"A response to indicate whether or not the individual has multiple known primary tumors at the initial melanoma diagnosis.","longName":"7751389v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C81DC193-621F-1B9F-E053-4EBD850AF148","latestVersionIndicator":"Yes","beginDate":"2021-07-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-27","modifiedBy":"COLBERTM","dateModified":"2022-06-06","changeNote":"7/27/21 jk created for Phase 3 CM Baseline CRF.","administrativeNotes":"6/6/22 mr Edits made to definition per CPTAC/Nicollette’s XLS review. Released and RS updated to Qualified as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7751477","version":"1","preferredName":"Melanoma Number of Known Primary Tumors at Initial Diagnosis Count","preferredDefinition":"The quantity of known primary tumors at the time of the initial melanoma diagnosis.","longName":"7751476v1.0:6272433v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C81BC49A-9A80-3B4B-E053-4EBD850ABE3E","latestVersionIndicator":"Yes","beginDate":"2021-07-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-27","modifiedBy":"KNABLEJ","dateModified":"2021-07-27","changeNote":"7/27/21 jk created for Phase 3 CM Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7751480","version":"1","preferredName":"Tumor Mass Histologic Subtype Text","preferredDefinition":"A textual description of the tissue histology subtype in which a tumor originated.","longName":"7751479v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C81D78C3-38E6-0A9B-E053-4EBD850A7062","latestVersionIndicator":"Yes","beginDate":"2021-07-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-27","modifiedBy":"JKNABLE","dateModified":"2023-07-03","changeNote":"8/17/21 jk added Phase 3 CM Path Review CSI.  7/27/21 jk created for Phase 3 CM Baseline CRF.","administrativeNotes":"7/3/23 Changed \"melanoma\" to \"tumor\" in definition to reflect semantics.  This was created for CPTAC melanoma content but could apply to other tumor types.  CDE was still draft new.  Set reuse by CTDC CMB content.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7756058","version":"1","preferredName":"New Tumor Event Present After Initial Treatment Melanoma Indicator","preferredDefinition":"A response to indicate whether or not a newly discovered tumor was present after the initial treatment of a tumor composed of atypical, neoplastic melanocytes.","longName":"6848796v1.0:7755594v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C89CF139-7623-5AB8-E053-4EBD850A542C","latestVersionIndicator":"Yes","beginDate":"2021-08-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-02","modifiedBy":"KNABLEJ","dateModified":"2021-08-02","changeNote":"8/2/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7757421","version":"1","preferredName":"Follow-Up Subsequent Known Primary Melanomas Found CPTAC Indicator","preferredDefinition":"A response to indicate whether or not subsequent known primary melanoma(s) were found during the follow-up period.","longName":"7757349v1.0:6841630v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C8AB308A-05F0-6ECA-E053-4EBD850A7602","latestVersionIndicator":"Yes","beginDate":"2021-08-03","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-03","modifiedBy":"COLBERTM","dateModified":"2022-06-06","changeNote":"8/3/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":"6/6/22 mr Released and RS updated to Qualified per CPTAC/Nicollette’s XLS review as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7763727","version":"1","preferredName":"Follow-Up Performance Status Scale Timing Melanoma Type","preferredDefinition":"The type of melanoma performance status timing scale used during the follow-up period.","longName":"7763721v1.0:7752528v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C927BFE9-D708-4735-E053-4EBD850A47DF","latestVersionIndicator":"Yes","beginDate":"2021-08-09","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-09","modifiedBy":"KNABLEJ","dateModified":"2021-08-09","changeNote":"8/9/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7763728","version":"1","preferredName":"Follow-Up Performance Status Scale Timing Other Specify","preferredDefinition":"A reason different than the one(s) previously specified describing the performance status timing scale used during the follow-up period.","longName":"7763721v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C9284F3E-00B2-0BC2-E053-4EBD850A3927","latestVersionIndicator":"Yes","beginDate":"2021-08-09","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-09","modifiedBy":"KNABLEJ","dateModified":"2021-08-09","changeNote":"8/9/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7763733","version":"1","preferredName":"New Tumor Event Number of Days from Date of Initial Pathologic Diagnosis to Date of Tumor Progression after Initial Treatment Count","preferredDefinition":"The number of days from date of the initial pathologic diagnosis to the date of tumor progression after the initial treatment.","longName":"7763732v1.0:7069460v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C928C45A-4D7F-2D90-E053-4EBD850AD1D9","latestVersionIndicator":"Yes","beginDate":"2021-08-09","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-09","modifiedBy":"KNABLEJ","dateModified":"2021-08-09","changeNote":"8/9/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7764235","version":"1","preferredName":"New Tumor Event Distant Metastasis Tumor Other Specify","preferredDefinition":"The site of a new distant metastatic tumor event which is different than the one(s) previously specified.","longName":"7763764v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C93BCB7C-A504-5E6B-E053-4EBD850A119B","latestVersionIndicator":"Yes","beginDate":"2021-08-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-10","modifiedBy":"KNABLEJ","dateModified":"2021-08-10","changeNote":"8/10/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7764236","version":"1","preferredName":"New Tumor Event New Primary Melanoma Site Other Specify","preferredDefinition":"The site of a new primary melanoma which is different than the one(s) previously specified.","longName":"7763773v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C939BD03-6B06-1399-E053-4EBD850A0360","latestVersionIndicator":"Yes","beginDate":"2021-08-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-10","modifiedBy":"KNABLEJ","dateModified":"2021-08-16","changeNote":"8/10/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7764237","version":"1","preferredName":"New Tumor Event Non-Melanoma Primary Site Other Specify","preferredDefinition":"The primary site of a new non-melanoma tumor event which is different than the one(s) previously specified.","longName":"7763789v1.0:6832577v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C93C2562-395D-0C78-E053-4EBD850A54C5","latestVersionIndicator":"Yes","beginDate":"2021-08-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-10","modifiedBy":"KNABLEJ","dateModified":"2021-08-16","changeNote":"8/10/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7764246","version":"1","preferredName":"New Tumor Event Non-Melanoma Primary Anatomic Site","preferredDefinition":"The named location of or within the body which identifies the primary site of a new non-melanoma tumor event.","longName":"7763789v1.0:7764046v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C93D23D2-4342-0D13-E053-4EBD850AFEAE","latestVersionIndicator":"Yes","beginDate":"2021-08-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-10","modifiedBy":"KNABLEJ","dateModified":"2021-08-10","changeNote":"8/10/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7764271","version":"1","preferredName":"New Tumor Event Melanoma Related Tumor Event Type","preferredDefinition":"The type of tumor event related to a newly discovered melanoma tumor.","longName":"7763739v1.0:7763736v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C94C53D7-AEB0-25B3-E053-4EBD850A4C28","latestVersionIndicator":"Yes","beginDate":"2021-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-11","modifiedBy":"KNABLEJ","dateModified":"2021-08-11","changeNote":"8/9/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7764287","version":"1","preferredName":"New Tumor Event Distant Metastasis Tumor Anatomic Site","preferredDefinition":"The named location of or within the body which identifies the site of a newly discovered distant metastatic tumor.","longName":"7763764v1.0:7763743v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C94C8FE1-B15E-7EB7-E053-4EBD850ABA43","latestVersionIndicator":"Yes","beginDate":"2021-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-11","modifiedBy":"KNABLEJ","dateModified":"2021-08-11","changeNote":"8/11/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7765090","version":"1","preferredName":"New Tumor Event New Primary Melanoma Anatomic Site","preferredDefinition":"The named location of or within the body which identifies the primary site of a of the new primary melanoma.","longName":"7763773v1.0:7763922v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C96051B6-A53F-5F02-E053-4EBD850A2876","latestVersionIndicator":"Yes","beginDate":"2021-08-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-12","modifiedBy":"KNABLEJ","dateModified":"2021-08-16","changeNote":"8/12/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7765091","version":"1","preferredName":"New Tumor Event Number of Primary Tumors in this Location Count","preferredDefinition":"The number of primary tumors in the specified location.","longName":"7763777v1.0:6272433v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C96051B6-A579-5F02-E053-4EBD850A2876","latestVersionIndicator":"Yes","beginDate":"2021-08-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-12","modifiedBy":"KNABLEJ","dateModified":"2021-08-16","changeNote":"8/12/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7765139","version":"1","preferredName":"New Tumor Event Other Site of New Primary Melanoma Text","preferredDefinition":"A textual description of the other site of a newly discovered new primary melanoma.","longName":"7763781v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C97199A8-094B-0F09-E053-4EBD850AD074","latestVersionIndicator":"Yes","beginDate":"2021-08-13","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-13","modifiedBy":"COLBERTM","dateModified":"2022-07-11","changeNote":"8/13/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":"7/11/22 Updated definition per spreadsheet from JK. MR","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7765140","version":"1","preferredName":"New Tumor Event Non-Melanoma Tumor Histological Type Text","preferredDefinition":"A textual description to identify the histological type of a newly discovered non-melanoma tumor event.","longName":"7763785v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C971497E-CE51-341E-E053-4EBD850A1B30","latestVersionIndicator":"Yes","beginDate":"2021-08-13","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-13","modifiedBy":"KNABLEJ","dateModified":"2021-08-13","changeNote":"8/13/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7765141","version":"1","preferredName":"New Tumor Event Unknown Non-Melanoma Primary Site Text","preferredDefinition":"A textual description to identify the primary site of a newly discovered non-melanoma tumor event.","longName":"7763792v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C971497E-CE7F-341E-E053-4EBD850A1B30","latestVersionIndicator":"Yes","beginDate":"2021-08-13","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-13","modifiedBy":"KNABLEJ","dateModified":"2021-08-16","changeNote":"8/13/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7765491","version":"1","preferredName":"New Tumor Event Other Site Text","preferredDefinition":"A textual description to the other site of a newly discovered new tumor event was identified in the study but is not present in the form.","longName":"7763769v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C9B0D6C4-2FB6-57BB-E053-4EBD850A7A9A","latestVersionIndicator":"Yes","beginDate":"2021-08-16","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-16","modifiedBy":"KNABLEJ","dateModified":"2021-08-16","changeNote":"8/16/21 jk created for Phase 3 CM FU CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7767207","version":"1","preferredName":"Tumor Mass Specify Site of Metastasis Text","preferredDefinition":"A textual description to specify the site of the metastasis.","longName":"7767206v1.0:6784451v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C9C1CDE6-6255-1C04-E053-4EBD850A9C0B","latestVersionIndicator":"Yes","beginDate":"2021-08-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-17","modifiedBy":"KNABLEJ","dateModified":"2021-08-17","changeNote":"8/17/21 jk created for Phase 3 CM Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7767519","version":"1","preferredName":"Tumor Segment Percent Tumor Surface Area Integer","preferredDefinition":"An integer number between 0 and 100 to capture the area of tissue surface in a sample that is tumorous tissue, expressed as a percentage.","longName":"7767513v1.0:6847952v1.0","contextName":"OCCPR","contextVersion":"1","dataElementConceptPublicId":"2013917","dataElementConceptVersion":"1","valueDomainPublicId":"3652737","valueDomainVersion":"1","origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C9D5BE24-E9E4-52F3-E053-4EBD850ABD55","latestVersionIndicator":"Yes","beginDate":"2021-08-18","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-08-18","modifiedBy":"COLBERTM","dateModified":"2022-09-20","changeNote":"8/18/21 jk created for CPTAC CM Path Review CRF.","administrativeNotes":"9/9/22 Added HNSCC Local Path CSI. mr; 9/20/22 Released for HNSCC Path Review per jk. mr;","unresolvedIssues":null,"deletedIndicator":"No"}]}